




Australian Government  
Cancer Australia



Annual Report  
2025-26

## Statement of acknowledgement

Cancer Australia acknowledges Aboriginal and Torres Strait Islander people as the Traditional Custodians of Country throughout Australia. We pay our respects to Elders, past and present.

We celebrate the ongoing connections of Aboriginal and Torres Strait Islander peoples to Country, culture, community, family and tradition and recognise these as integral to health, healing and wellbeing.

Cancer Australia acknowledges great diversity among Aboriginal and Torres Strait Islander peoples, and the contribution of the many voices, knowledge systems and experiences that guide all efforts to create a culturally safe and responsive cancer system that is equitable to all.

## About this report

The annual report is available online at [canceraustralia.gov.au/about-us/accountability-and-reporting](http://canceraustralia.gov.au/about-us/accountability-and-reporting).

### Contact us

If you have any queries about this report, please contact:

Ms Susie Dobson

Unit Lead, Media and Communications Unit, Cancer Australia

[enquiries@canceraustralia.gov.au](mailto:enquiries@canceraustralia.gov.au)

Internet: [canceraustralia.gov.au](http://canceraustralia.gov.au)

Email: [enquiries@canceraustralia.gov.au](mailto:enquiries@canceraustralia.gov.au)

Freecall: 1800 624 973, +61 2 9357 9400

ABN: 21 075 951 918

Print ISBN: 978-1-74127-027-3

Online ISBN: 978-1-74127-028-0

### Copyright statements

#### Paper-based publications

© Cancer Australia 2026

This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the *Copyright Act 1968* or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given the specific written permission from Cancer Australia to do so. Requests and inquiries concerning reproduction and rights are to be sent to the Publications and Copyright contact officer, Cancer Australia, Locked Bag 3, Strawberry Hills NSW 2012.

#### Internet sites

© Cancer Australia 2026

This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the *Copyright Act 1968* or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given the specific written permission from Cancer Australia to do so. Requests and inquiries concerning reproduction and rights are to be sent to the Publications and Copyright contact officer, Cancer Australia, Locked Bag 3, Strawberry Hills NSW 2012.

All information in this publication is correct as at 01 October 2026

# Letter of transmittal

01 October 2026



**Australian Government**

**Cancer Australia**

Dear Minister,

I am pleased to present Cancer Australia's Annual Report for the year ended 30 June 2026.

This Report has been prepared in accordance with section 46 of the *Public Governance, Performance and Accountability Act 2013*, which requires that an annual report be given to the entity's responsible Minister for presentation to the Parliament. It reflects the requirements for annual reports approved by the Joint Committee of Public Accounts and Audit under sections 63(2) and 70(2) of the *Public Service Act 1999*.

The report has also been prepared to be consistent with the requirements for annual reporting of the *Cancer Australia Act 2006*.

In compliance with section 10 of the Public Governance, Performance and Accountability Rule 2014, I certify that:

- i. a fraud risk assessment and fraud control plan has been prepared for Cancer Australia
- ii. appropriate mechanisms for preventing, detecting, investigating or otherwise dealing with and reporting of fraud that meet the needs of Cancer Australia are in place
- iii. all reasonable measures have been taken to deal appropriately with fraud relating to Cancer Australia.

Yours sincerely,

A handwritten signature in dark ink, appearing to read 'D M Keefe'.

Professor Dorothy Keefe, PSM, MD

Chief Executive Officer


Cancer Australia

# Contents

|                                                                                       |            |
|---------------------------------------------------------------------------------------|------------|
| <b>Statement of acknowledgement</b>                                                   | <b>b</b>   |
| <b>About this report</b>                                                              | <b>b</b>   |
| <b>Letter of transmittal</b>                                                          | <b>1</b>   |
| <b>Overview</b>                                                                       | <b>4</b>   |
| Chief Executive Officer's review                                                      | 6          |
| Advisory Council Chair review                                                         | 12         |
| Cancer Australia Advisory Council                                                     | 14         |
| <b>About Cancer Australia</b>                                                         | <b>16</b>  |
| About Cancer Australia                                                                | 18         |
| Purpose                                                                               | 19         |
| Functions and role                                                                    | 20         |
| Organisational structure                                                              | 21         |
| <b>Report on performance</b>                                                          | <b>22</b>  |
| 2025–26 highlights                                                                    | 24         |
| Annual performance statements                                                         | 26         |
| Financial overview                                                                    | 39         |
| <b>Management and accountability</b>                                                  | <b>40</b>  |
| Management and accountability                                                         | 42         |
| Corporate governance                                                                  | 43         |
| Management of human resources                                                         | 49         |
| <b>Appendices</b>                                                                     | <b>70</b>  |
| Appendix A: Report on financial performance                                           | 72         |
| Appendix B: Audited financial statements                                              | 74         |
| Appendix C: Acquittal audit report related to Cancer Australia fundraising activities | 108        |
| Appendix D: Mandatory reporting information                                           | 113        |
| Appendix E: Cancer Australia advisory groups                                          | 119        |
| Appendix F: List of requirements                                                      | 121        |
| <b>Glossary</b>                                                                       | <b>127</b> |
| <b>Abbreviations</b>                                                                  | <b>131</b> |
| <b>Index</b>                                                                          | <b>133</b> |

# List of tables

|             |                                                                                                                                   |     |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------|-----|
| Table 4.1:  | Significant non-compliance with the finance law                                                                                   | 43  |
| Table 4.2:  | Audit and Risk Committee Charter                                                                                                  | 44  |
| Table 4.3:  | Cancer Australia's Audit and Risk Committee                                                                                       | 45  |
| Table 4.4:  | Expenditure on reportable consultancy contracts (2025–26)                                                                         | 46  |
| Table 4.5:  | Expenditure on reportable non-consultancy contracts (2025–26)                                                                     | 46  |
| Table 4.6:  | Organisations receiving a share of reportable consultancy contract expenditure (2025–26)                                          | 47  |
| Table 4.7:  | Organisations receiving a share of reportable non-consultancy contract expenditure (2025–26)                                      | 47  |
| Table 4.8:  | All ongoing employees current report period (2025–26)                                                                             | 50  |
| Table 4.9:  | All non-ongoing employees current report period (2025–26)                                                                         | 51  |
| Table 4.10: | Australian Public Service Act ongoing employees current report period (2025–26)                                                   | 52  |
| Table 4.11: | Australian Public Service Act non-ongoing employees current report period (2025–26)                                               | 53  |
| Table 4.12: | Australian Public Service Act employees by full time and part time status current report period (2025–26)                         | 54  |
| Table 4.13: | Australian Public Service Act employment type by location current report period (2025–26)                                         | 55  |
| Table 4.14: | Australian Public Service Act Indigenous employment current report period (2025–26)                                               | 55  |
| Table 4.15: | Australian Public Service Act employment arrangements current report period (2025–26)                                             | 56  |
| Table 4.16: | Australian Public Service Act employment salary ranges by classification level (minimum/maximum) current report period (2025–26)  | 56  |
| Table 4.17: | Australian Public Service Act employment performance pay by classification level current report period (2025–26)                  | 57  |
| Table 4.18: | All ongoing employees previous report period (2024–25)                                                                            | 58  |
| Table 4.19: | All non-ongoing employees previous report period (2024–25)                                                                        | 59  |
| Table 4.20: | Australian Public Service Act ongoing employees previous report period (2024–25)                                                  | 60  |
| Table 4.21: | Australian Public Service Act non-ongoing employees previous report period (2024–25)                                              | 61  |
| Table 4.22: | Australian Public Service Act employees by full time and part time status previous report period (2024–25)                        | 62  |
| Table 4.23: | Australian Public Service Act employment type by location previous report period (2024–25)                                        | 63  |
| Table 4.24: | Australian Public Service Act Indigenous employment previous report period (2024–25)                                              | 63  |
| Table 4.25: | Australian Public Service Act employment arrangements previous report period (2024–25)                                            | 64  |
| Table 4.26: | Australian Public Service Act employment salary ranges by classification level (minimum/maximum) previous report period (2024–25) | 64  |
| Table 4.27: | Australian Public Service Act employment performance pay by classification level previous report period (2024–25)                 | 65  |
| Table 4.28: | Details of accountable authority during the reporting period (2025–26)                                                            | 66  |
| Table 4.29: | Information about remuneration for key management personnel (2025–26)                                                             | 67  |
| Table 4.30: | Information about remuneration for senior executives (2025–26)                                                                    | 68  |
| Table 4.31: | Information about remuneration for other highly paid staff (2025–26)                                                              | 69  |
| Table A.1:  | Entity Resource Statement subset current reporting period (2025–26)                                                               | 72  |
| Table A.2:  | Expenses for outcomes                                                                                                             | 73  |
| Table C.1:  | Details of aggregated gross income and total expenses of fundraising appeals                                                      | 112 |
| Table C.2:  | Comparison by monetary figures and percentages                                                                                    | 112 |
| Table D.1:  | Advertising agencies used by Cancer Australia in 2025–26                                                                          | 114 |
| Table D.2:  | Market research undertaken by Cancer Australia in 2025–26                                                                         | 114 |
| Table D.3:  | 2025–26 greenhouse gas emissions inventory – location-based method                                                                | 117 |
| Table D.4:  | 2025–26 electricity greenhouse gas emissions                                                                                      | 117 |

A decorative background consisting of a grid of small, light orange squares arranged in a 5x5 pattern on a dark blue-grey background.

1

# Overview



# Chief Executive Officer's review



## Reflecting on 2025–26

It is my privilege to present this review of Cancer Australia's achievements and outcomes for the 2025–26 reporting year. This year marked a period of consolidation, momentum and maturity in Cancer Australia's role as the national steward of cancer control reform as we continued to lead and coordinate implementation of the Australian Cancer Plan (the Plan). Building on the strong foundations established since the Plan's launch in November 2023, Cancer Australia worked in close partnership with governments, health services, researchers, clinicians, community organisations and people affected by cancer to translate ambition into action and deliver tangible system-level progress.

Throughout 2025–26, our focus remained firmly on improving cancer outcomes and experiences for all Australians, with a particular emphasis on equity for Aboriginal and Torres Strait Islander people and other priority populations who continue to experience poorer outcomes. The year was characterised by strong collaboration across the cancer control sector, a deepening of national infrastructure, and an increased emphasis on data-driven decision-making to support system improvement.

## Advancing implementation of the Australian Cancer Plan

Implementation of the Australian Cancer Plan continued to be the centrepiece of Cancer Australia's work in 2025–26. As the Plan entered its second full year of delivery, Cancer Australia progressed key foundational actions designed to enable long-term, sustained cancer system reform. This included strengthening national coordination mechanisms, embedding shared accountability and supporting partners across jurisdictions and sectors to align their activities with the Plan's strategic objectives and 10-year ambitions.

During the year, Cancer Australia undertook an evaluation of the first 2 years of the Plan, working closely with stakeholders across the cancer control sector to assess progress, identify lessons learned and inform future implementation priorities. This process reinforced the importance of collaboration and transparency in driving reform and provided a stronger evidence base to guide the next phase of delivery.

Cancer Australia maintained its convening role across the sector, facilitating ongoing engagement with governments, service providers, researchers and consumers to support coordinated action and shared ownership of implementation. Through this continued partnership with the sector, the Plan increasingly served as a unifying national framework to guide investment, innovation and reform across the cancer continuum, from prevention and early detection through to survivorship and end-of-life care.

*Implementation of the Australian Cancer Plan continued to be the centrepiece of Cancer Australia's work in 2025-26. As the Plan entered its second full year of delivery, Cancer Australia progressed key foundational actions designed to enable long-term, sustained cancer system reform.*

---

### **Strengthening networked and comprehensive cancer care**

Progress towards more integrated and networked models of cancer care remained a priority in 2025-26. Cancer Australia continued to support the growth and maturation of the Australian Comprehensive Cancer Network (ACCN), building on its establishment and early expansion in 2025. During the year, Cancer Australia worked to further develop, activate and invest in the ACCN, strengthening its role as a national platform for collaboration, knowledge sharing and system improvement; and supporting access to high-quality cancer care regardless of geographic location.

The continued promotion of networked care aligned closely with the National Optimal Care Pathways Framework, which supports consistent, evidence-based care across tumour streams and settings. By strengthening connections between comprehensive cancer centres and regional, rural and remote services, Cancer Australia contributed to reducing unwarranted variation in care and improving equity of access to expertise and innovation.

### **Enhancing national cancer data and evidence foundations**

In 2025-26, Cancer Australia continued to invest in strong and dynamic national foundations to underpin a modern cancer control system. Progression of the National Cancer Data Framework remained a key focus, supporting improved access to high-quality, nationally consistent data to inform policy, service planning, research and quality improvement.

During the year, Cancer Australia also advanced implementation of the National Framework for Genomics in Cancer Control, supporting greater integration of genomics into cancer care and research. This work is enabling more personalised, data-informed approaches to prevention, diagnosis and treatment; and strengthening Australia's capacity to harness emerging scientific and technological advances in cancer control.

These efforts complemented ongoing work to strengthen evidence generation and translation across the cancer continuum. By supporting data linkage, promoting standardisation and encouraging collaboration across data custodians, Cancer Australia contributed to a more connected national cancer data ecosystem capable of supporting better outcomes and accountability over time.

## Strengthening cancer research and innovation

Cancer Australia continued to play a key role in shaping national cancer research priorities and supporting innovation to improve outcomes.

Through the Cancer Australia Research Initiative (CARI), \$15 million has been invested, jointly funded with the National Health and Medical Research Council, targeting research to address the rise in early-onset cancers.

For 20 years, the [Support for Cancer Clinical Trials](#) (SCCT) program has been a core part of Cancer Australia's work to strengthen cancer research nationally. Through SCCT, Cancer Australia has invested around \$150 million in investigator-initiated, industry-independent clinical trial development in areas of unmet and emerging need with limited commercial interest. The program also supports the people, networks and infrastructure underpinning Australia's Multi-site Collaborative Cancer Clinical Trials Groups, sustaining a strong national clinical trials system across all cancers and stages of care. By increasing access to trials, SCCT enables more Australians to participate, regardless of who they are or where they live, improving prevention, treatment and care.

Cancer Australia continues to strengthen the program to keep it responsive, innovative and nationally impactful, while linking Australia's trials to global research efforts. Over the next 3 years, a further \$3 million will support all 14 Collaborative Cancer Clinical Trials Groups to build a shared genomics foundation for future trial protocols and early implementation of the National Framework for Genomics in Cancer Control.

On behalf of the Australian Government, Cancer Australia has invested \$5.9 million to establish the Richard Scolyer Professorial Chair in Brain Cancer Research at Chris O'Brien Lifehouse. Through this position, the late Professor Scolyer's contribution to brain cancer research and advocacy will be continued and celebrated, providing for strong leadership to accelerate brain cancer research, expand clinical trials and help translate research into better outcomes for patients.

Together, these investments are strengthening Australia's cancer research ecosystem and ensuring that emerging evidence is translated into practice to benefit people affected by cancer.

## Supporting equity and culturally safe cancer care

Achieving equity in cancer outcomes remained a fundamental measure of success in 2025–26. Cancer Australia continued to prioritise work that supports Aboriginal and Torres Strait Islander leadership, knowledge and sovereignty in cancer control, consistent with the Australian Cancer Plan and its alignment with the National Agreement on Closing the Gap.

Throughout the year, Cancer Australia progressed the continued implementation and growth of culturally safe cancer care, supported by targeted Australian Government investment. This included delivery of budget measure initiatives focused on strengthening culturally appropriate cancer services, workforce capability and system responses to better meet the needs of Aboriginal and Torres Strait Islander people.

Cancer Australia worked in partnership with Aboriginal and Torres Strait Islander organisations and communities to embed culturally safe approaches across prevention, screening, diagnosis, treatment and survivorship. This work reinforced the importance of Aboriginal Community Controlled Health Organisations and culturally responsive models of care in improving outcomes and experiences for Aboriginal and Torres Strait Islander people affected by cancer.

## Organisational capability and governance

Effective governance and organisational capability underpinned all of Cancer Australia's achievements in 2025–26. The agency continued to operate within a robust corporate, business and performance planning framework, ensuring strong alignment between strategic priorities, resource allocation and delivery of outcomes. This approach supported transparency, accountability and value for money in the use of public resources.

Cancer Australia's staff remained central to our success. Across the year, we continued to invest in a skilled, engaged and values-driven workforce capable of supporting system-wide reform through collaboration, evidence, leadership and stewardship. I extend my sincere thanks to Cancer Australia's staff, Advisory Council members, committees and partners for their commitment, expertise and shared purpose.

## Looking ahead

As Cancer Australia looks beyond 2026, the importance of sustained collaboration and shared accountability across the cancer control sector has never been clearer. While Australia continues to achieve strong cancer outcomes overall, persistent inequities demand continued focus, innovation and courage. Cancer Australia remains committed to leading national efforts to deliver world-class cancer outcomes and experiences for all Australians, guided by evidence, partnership and the voices of people affected by cancer.

For 2026–2029, Cancer Australia will focus on the following strategic priorities:

- › Drive the implementation of the Australian Cancer Plan, strengthening cross-sector partnerships and monitoring progress to improve cancer outcomes and experiences for all Australians affected by cancer.
- › Build and mature the ACCN to strengthen national collaboration across jurisdictions, enhance linkages between Comprehensive Cancer Centres and cancer services; and support the delivery of optimal cancer care across metropolitan, regional, rural and remote Australia.
- › Provide expert advice to governments on emerging cancer issues and technologies, including rising rates of early-onset cancers; developments in therapies such as chimeric antigen receptor T-cell (CAR-T) and proton beam therapy; and advances in population screening, including new targeted screening programs for lung cancer and melanoma.
- › Invest in cancer research priorities, in partnership with governments and philanthropic organisations, to support world-leading cancer control in Australia, including strengthening national capacity for high-quality cancer clinical trials through support for Multi-site Collaborative Cancer Clinical Trials Groups.
- › Advance implementation of the National Framework for Genomics in Cancer Control, including through the Cancer Genomics Clinical Trials Fund, to stimulate innovation in genomic medicine and support equitable access to genomics-enabled cancer clinical trials.
- › Embed consistent, high-quality, evidence-based cancer care through continued implementation of the National Optimal Care Pathways Framework, including developing, updating and promoting Optimal Care Pathways and supporting their integration into routine clinical practice.
- › Provide national leadership on cancer data and evidence, improving the collection, analysis, linkage, use and benchmarking of cancer data through implementation of the National Cancer Data Framework.
- › Partner with Aboriginal and Torres Strait Islander communities and organisations to co-design and deliver culturally safe approaches that improve cancer outcomes and experiences for Aboriginal and Torres Strait Islander people.
- › Strengthen international engagement in cancer control, leading Australia's collaboration with global partners, particularly in the Asia-Pacific region, and leveraging international expertise to inform national priorities.

In closing, I would like to thank the Minister for Health and Ageing, the Hon Mark Butler, for his leadership and ongoing support of Cancer Australia's work; and the Department of Health, Disability and Ageing for its close collaboration and constructive partnership throughout the year. Our shared commitment to implementing the Australian Cancer Plan has been critical to advancing national cancer reform and strengthening outcomes across the cancer continuum.

I also extend my sincere appreciation to Cancer Australia's Advisory Council members, and to its Chair, Associate Professor Chris Milross, for their strategic guidance, expertise and stewardship, which continues to inform and strengthen our work.

A handwritten signature in black ink, appearing to read 'D M Keefe'.

**Professor Dorothy Keefe, PSM, MD**



*Cancer Australia worked in partnership with Aboriginal and Torres Strait Islander organisations and communities to embed culturally safe approaches across prevention, screening, diagnosis, treatment and survivorship. This work reinforced the importance of Aboriginal Community Controlled Health Organisations and culturally responsive models of care in improving outcomes and experiences for Aboriginal and Torres Strait Islander people affected by cancer.*

---

# Advisory Council Chair review

As Chair of the Cancer Australia Advisory Council, I am pleased to reflect on the Advisory Council's role and contributions throughout 2025–26. During the year, the Advisory Council continued to provide strategic advice, expert insight and considered guidance to support Cancer Australia in fulfilling its legislative functions and advancing implementation of the Australian Cancer Plan.

The Advisory Council engaged in and provided advice across areas of focus for the agency, including:

- › implementation and evaluation of the Australian Cancer Plan, including input to 2-year actions, early evaluation findings, and priorities for future 5-year actions
- › implementation of the National Lung Cancer Screening Program
- › advancement of national frameworks to support best practice care, including the National Optimal Care Pathways Framework and comprehensive cancer care approaches
- › enhancement of national cancer data and evidence, including implementation of the National Cancer Data Framework
- › shaping national cancer research priorities, including advice on the Cancer Australia Research Initiative and future research focus areas
- › governance and effectiveness of Cancer Australia's advisory structures, including strengthening linkages across advisory groups
- › emerging and priority cancer control issues, including prostate cancer and opportunities for new expert advisory mechanisms
- › future directions for specific population and disease focused initiatives, including the Childhood, Adolescent and Young Adult Cancer Roadmap
- › consideration of emerging trends and risk factors, including analysis of early onset cancers
- › strengthening national approaches to cancer control through advice on key strategic priorities and emerging government directions.

Throughout 2025–26, I welcomed the opportunity to strengthen interactions across Cancer Australia's advisory groups, recognising the importance of enhancing visibility, engagement and collaboration to support more effective governance and strategic advice.

I was pleased to accept the co-chair role, along with Dan Repacholi MP, Special Envoy for Men's Health, for the newly formed Prostate Cancer Expert Advisory Group. This role has strengthened my commitment to advancing integrated cancer control strategies that bring diverse expertise together to guide national priorities and deliver more coordinated, evidence-informed outcomes.



*Throughout 2025–26, I welcomed the opportunity to strengthen interactions across Cancer Australia's advisory groups, recognising the importance of enhancing visibility, engagement and collaboration to support more effective governance and strategic advice.*

---

Over the past year, I also had the opportunity to attend both the Garma Festival and the World Indigenous Cancer Conference. These experiences were enriching and had a significant impact in strengthening my understanding of cultural safety and deepening connections with Aboriginal and Torres Strait Islander communities and remote health services. The experience reinforced for me the importance of relational approaches, cultural immersion for clinical leaders, and ongoing collaboration, and I deeply appreciated the opportunity to hear Indigenous voices firsthand.

In December last year, I was delighted to welcome Professor Patsy Yates and Professor John Zalcberg as new members of the Advisory Council. In April this year, we also welcomed Ms Christine Cockburn as a member of the Advisory Council.

I would like to thank all Advisory Council members for their valuable guidance, advice and insights throughout 2025–26. Their extensive knowledge and dedication have made a significant contribution to the council's work and to Cancer Australia's leadership in national cancer control.

Finally, I am pleased to acknowledge Cancer Australia's CEO, Professor Dorothy Keefe, PSM, MD, for her outstanding leadership of Cancer Australia in 2025–26. Under her stewardship, Cancer Australia has continued to progress its program of work and strengthen its role as the national leader in cancer control. I also commend the agency's executive, staff and expert advisors for their continued hard work, expertise and professionalism.

I particularly wish to recognise the Cancer Australia team for the continued advancement and implementation of the Australian Cancer Plan, which remains central to achieving world-class cancer outcomes and improving the experience of all Australians affected by cancer, regardless of their background or where they live.

The Advisory Council looks forward to continuing to work with Professor Keefe and her team in 2026–27 to support the agency in progressing its significant reform agenda, reducing the impact of cancer, addressing inequities, and improving outcomes for people affected by cancer.



**Associate Professor Christopher Milross**

MB BS MD FRANZCR  
FRACMA FAICD


# Cancer Australia Advisory Council

## Establishment and function

The Cancer Australia Advisory Council is established under the *Cancer Australia Act 2006* (Cth) to provide advice to the Chief Executive Officer on the performance of Cancer Australia's functions. During 2025–26, the Advisory Council comprised a Chair and 11 to 12 members at various points across the year, as appointed by the Minister for Health and Ageing.

The Advisory Council met 3 times during the reporting period and provided out-of-session advice as required. Council members contributed considered and timely advice on strategic priorities, emerging issues and the implementation of national cancer initiatives, supporting Cancer Australia's role as steward of the Australian Cancer Plan.

Members of the Advisory Council bring a substantial breadth and depth of expertise spanning cancer research and translation science, clinical practice (including epidemiology, radiation oncology, surgical oncology, medical oncology and primary care), health policy, health service delivery and Aboriginal and Torres Strait Islander cancer control. This diversity of expertise strengthens Cancer Australia's decision-making and ensures advice reflects the full cancer continuum and the needs of people affected by cancer.



## Members

The 2025–26 members of the Advisory Council were:

- › Associate Professor Christopher Milross (Chair)
- › Professor Alex Brown
- › Ms Christine Cockburn<sup>+</sup>
- › Professor Kwun Fong
- › Associate Professor Dion Frederick Forstner
- › Doctor Florian Xavier Honeyball
- › Associate Professor Glen Kennedy
- › Professor Anna Nowak
- › Doctor Simone Raye
- › Ms Carolyn Smith
- › Associate Professor Craig Underhill
- › Professor Patsy Yates<sup>\*</sup>
- › Professor John Zalcberg<sup>\*</sup>
- › Professor Joanne Aitken<sup>^</sup>
- › Ms Deborah Henderson<sup>^</sup>
- › Professor Shelley Dolan.<sup>^</sup>

<sup>^</sup> Membership ceased November 2025

<sup>\*</sup> Membership commenced December 2025

<sup>+</sup> Membership commenced April 2026

Advisory Council members are appointed for a term of no more than 3 years. Members' remuneration is governed by the Cancer Australia Act (section 30) and determined by the Remuneration Tribunal.

A decorative background consisting of a grid of small, solid orange squares arranged in a 5x5 pattern on a dark blue-grey background.

2

# About Cancer Australia



# About Cancer Australia

Cancer Australia is the Australian Government's national cancer control agency; it is a specialist agency within the Health, Disability and Ageing portfolio.

Cancer Australia aims to reduce the impact of cancer and improve outcomes for all people affected by cancer. Cancer Australia achieves its purpose by providing national leadership in cancer control, developing and promoting evidence-based best practice cancer care, providing consumer and health professional cancer information, funding priority cancer research, and strengthening national cancer data capacity.

It is estimated that in 2025 there were approximately 169,759 cases of cancer diagnosed in Australia, excluding non-melanoma skin cancers.<sup>1</sup> Cancer remains a leading cause of death in Australia, with 53,000 people expected to die from cancer in 2025.<sup>1</sup> Cancer is also the leading cause of disease burden in Australia, accounting for 16% of the burden of disease in 2024.<sup>2</sup>

This notwithstanding, it should be noted that more people in Australia are living longer after a diagnosis with cancer. Australia has seen the 5-year relative survival for all cancers combined increase from 50.4% in 1987–1991 to 71.6% in 2017–2021.<sup>1</sup>

Cancer Australia works collaboratively across the entire cancer control ecosystem with Australians affected by cancer, health professionals, researchers, policymakers and service providers. The agency is a respected thought leader in the sector and is uniquely positioned to provide robust, world-leading advice to the Australian Government on cancer policy priorities.

Cancer Australia works closely with Aboriginal and Torres Strait Islander people to co-design improved cancer outcomes for Aboriginal and Torres Strait Islander people. It fulfils its statutory obligations to fund cancer research by building research capability and addressing emerging priorities for cancer research and data.

Cancer Australia lends its expertise to inform international cancer control activity. Cancer Australia uses its position as a trusted collaborator to facilitate a unity of purpose across the sector in setting priorities for action for cancer control in Australia. Cancer Australia leverages its stakeholder relationships to cost-effectively harness eminent advice on any issues relating to cancer control at short notice.

1 Australian Institute of Health and Welfare 2025. Cancer data in Australia. Cat. no. CAN 122. Canberra: AIHW. Accessed June 2026; <https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/data>.

2 Australian Institute of Health and Welfare 2024. Australian Burden of Disease Study 2024. Cat. no. BOD 40. Canberra: AIHW. Accessed June 2026; <https://www.aihw.gov.au/reports/burden-of-disease/australian-burden-of-disease-study-2024/contents/about>.

The background of the entire page is a complex, light blue network pattern. It consists of a grid of small squares, with each square connected to its four immediate neighbors and also to several other squares further away, creating a dense web of lines. This pattern is visible behind the text and the central box.

# Purpose

*Cancer Australia's purpose is to minimise the impact of cancer, address disparities, and improve the health outcomes of people affected by cancer in Australia by providing national leadership in cancer control.*

---

# Functions and role

Cancer Australia was established by the *Cancer Australia Act 2006* (Cth) and is a non-corporate Commonwealth entity under the *Public Governance, Performance and Accountability Act 2013* (Cth).

Cancer Australia is subject to the *Auditor-General Act 1997* (Cth), and its staff are employees of the Australian Public Service (APS) under the *Public Service Act 1999* (Cth).

The role and functions of Cancer Australia are set out in the Cancer Australia Act, section 7:

- › to provide national leadership in cancer control
- › to guide scientific improvements to cancer prevention, treatment and care
- › to coordinate and liaise between the wide range of groups and health care providers with an interest in cancer
- › to make recommendations to the Commonwealth Government about cancer policy and priorities
- › to oversee a dedicated budget for research into cancer
- › to assist with the implementation of Commonwealth Government policies and programs in cancer control
- › to provide financial assistance, out of money appropriated by the Parliament, for research into cancer covered by the dedicated budget and for the implementation of policies and programs referred to above
- › any functions that the Minister, by writing, directs Cancer Australia to perform.

Cancer Australia's Chief Executive Officer (CEO) reports to the Minister for Health and Ageing.

# Organisational structure

Cancer Australia is led by the CEO, Professor Dorothy Keefe, PSM, MD. Professor Keefe is supported by the Deputy CEO, Ms Claire Howlett.

The Senior Executive team is as follows:

## **Clinical Policy Advice Branch**

- › Medical Director: Professor Vivienne Milch

## **Partnerships and Cancer Equity Branch**

- › Mr David Meredyth

## **Evidence, Priority Initiatives and Communications Branch**

- › Mr Adam Lambert

## **Corporate Operations Branch**

- › Mr Elmer Wiegold until January 2026. Mr Wiegold was also the agency's Chief Financial Officer.
- › Mr Steven McEwan from January 2026. Mr McEwan is also the agency's Chief Financial Officer.

At 30 June 2026, Cancer Australia had 81 employees, of whom 70 were ongoing.

Cancer Australia has structures, systems and processes in place to ensure that its governance, compliance and accountability responsibilities are met (see Part 4 of this report). Cancer Australia's head office is located in Sydney. Cancer Australia also maintains an office in Canberra.

## **Cancer Australia Advisory Council**

Cancer Australia draws on the broad diversity of expertise, skills and experience that Advisory Council members bring to the organisation. The Advisory Council consists of a Chair and up to 12 members appointed by the Minister for Health and Ageing, the Hon Mark Butler MP. The Advisory Council Chair's review is in Part 1 of this report.

## **Audit and Risk Committee**

Cancer Australia benefits from advice and counsel provided through a standing Audit and Risk Committee, whose members are Ms Gayle Ginnane (Chair), Ms Roslyn Jackson and Ms Belinda Small.

## **Advisory groups**

Cancer Australia acknowledges the significant input and valuable advice extended to the agency by strategic and project-specific advisory groups. Appendix E provides further information about the roles of these groups.

## **Outcome and program structure**

The outcome of Cancer Australia's work in the Health, Disability and Ageing Portfolio Budget Statements 2025–26 (PBS) is:

- › Minimised impacts of cancer, including through national leadership in cancer control with targeted research and clinical trials; evidence informed clinical practice; strengthened national data capacity; community and consumer information and support. (PBS, page 268)

The program attached to this outcome is Program 1.1: Improved cancer control.

The PBS is available at [www.transparency.gov.au](http://www.transparency.gov.au).

A decorative background consisting of a grid of small orange squares arranged in a 5x5 pattern on a dark blue background.

3

# Report on performance



# 2025–26 highlights



## **Publication of the National Cancer Data Framework**

The National Cancer Data Framework is a foundational implementation action of the Australian Cancer Plan. It sets the strategic direction for the collection, management, use and ongoing development of comprehensive and consistent health and cancer data. The framework was published in November 2025, after being approved by the Minister for Health and Ageing and all states and territories.



## **Publication of the Childhood, Adolescent and Young Adult Cancer Roadmap**

The Childhood, Adolescent and Young Adult Cancer Roadmap aims to deliver world-class outcomes and experiences for children, adolescents and young adults with cancer by enhancing supportive care, enabling better access to emerging technologies and therapies, and ensuring targeted investment into research and clinical trials. The roadmap was developed in consultation with clinicians, researchers, jurisdictions, advocacy groups and consumer representatives, and published in May 2026.



## **Expansion of the Australian Comprehensive Cancer Network**

The Australian Comprehensive Cancer Network continues its expansion to improve equity of access to comprehensive cancer care nationwide, growing to more than 1,500 members. A rural workshop was held in March 2026, ensuring Cancer Australia is continuously engaging with regional, rural and remote cancer organisations. Lessons learned from the workshop will be used in the national online workshop in 2026–27.



## **Establishment of the Prostate Cancer Expert Advisory Group**

The Prostate Cancer Expert Advisory Group provides advice to the Minister for Health and Ageing, through Cancer Australia, on holistic approaches to lessen the impact of prostate cancer, with an initial focus on early detection particularly for those at highest risk, minimising the risk of overtreatment and improving supportive care. The group is co-chaired by the Special Envoy for Men's Health, Dan Repacholi MP, and Associate Professor Chris Milross, Chair of Cancer Australia's Advisory Council.



### **Improving health outcomes for Aboriginal and Torres Strait Islander people**

Cancer Australia continues to partner with Aboriginal and Torres Strait Islander people to deliver improved cancer outcomes. In 2025–26, Cancer Australia partnered with an Indigenous-led not-for-profit organisation to co-design and facilitate a Grant Collaborative Community for the Partnerships for Culturally Safe Cancer Care program. Seven new grants were also established under this initiative, totalling almost \$4.5 million over 2 years, extending the reach of this key program. The agency also awarded an additional 4 postgraduate scholarships under the First Nations Cancer Scholarships program to the value of \$880,000 over 3 years, through the Aurora Education Foundation.



### **Supporting strategic research**

Cancer Australia implemented the Cancer Australia Research Initiative as a new approach to priority-driven research investment. In the first annual grant round, delivered in partnership with the National Health and Medical Research Council (NHMRC), a total of \$15 million was awarded to 7 research projects over 3 years.

The Support for Cancer Clinical Trials (SCCT) program continues to play a key role in strengthening Australia's national cancer clinical trials system. In its 20th year, the SCCT program supported Australia's 14 collaborative cancer clinical trial groups to develop grant-competitive trial concepts and protocols.

# Annual performance statements

As the accountable authority of Cancer Australia, I present the 2025–26 Annual Performance Statements of Cancer Australia, in accordance with paragraph 39(1)(a) of the *Public Governance, Performance and Accountability Act 2013* (Cth) (PGPA Act). In my opinion, these Annual Performance Statements are based on properly maintained records, accurately reflect the performance of the entity and comply with subsection 39(2) of the PGPA Act.



**Professor Dorothy Keefe, PSM, MD**

These Annual Performance Statements are presented in the context of Cancer Australia's purpose and program objectives. They demonstrate the outcomes achieved by the agency against the intended outcomes outlined in the Health, Disability and Ageing Portfolio Budget Statements 2025–26 (PBS) and the Cancer Australia 2025–26 Corporate Plan.

## Purpose

Cancer Australia's purpose is to minimise the impact of cancer, address disparities and improve the health outcomes of people affected by cancer in Australia by providing national leadership in cancer control (Outcome 1: Health Policy, Access and Support).

Cancer Australia's program of work contributes towards the achievement of the following outcome:

Minimised impacts of cancer, including through national leadership in cancer control with targeted research and clinical trials; evidence informed clinical practice; strengthened national data capacity; community and consumer information and support. (PBS 2025–26, page 268)

Cancer Australia's program objectives for 2025–26 were:

1. Provide national leadership in cancer control.
2. Develop and promote evidence-based best practice cancer care.
3. Fund cancer research and drive efforts to strengthen national data capacity in consultation with relevant agencies.
4. Provide consumer and health professional cancer information and resources.  
(PBS, page 270; Corporate Plan, page 2)

Cancer Australia's performance in relation to these program objectives, and the performance criteria associated with them, is provided in the tables below. There is a separate table for each program objective. The agency has substantially met its 2025–26 reference points or targets.

## 1. Provide national leadership in cancer control

| Performance criterion                                                                    | 2025–26 target                                                                                                                                                                                                                                                                                                                                                                                                                                            | Criterion source                                                                                          | Result                  |
|------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-------------------------|
| Evaluation of the sector's progress towards the Australian Cancer Plan's 2-year actions. | <p>Undertake evaluation of the sector's progress [including the Commonwealth, States and Territories and cancer control stakeholders] of delivering on the Plan's 2-year actions (2025–26).</p> <p>Review and progress activities to achieve priority 5-year actions in the Plan.</p> <p>Complete and Publish the National Cancer Data Framework.</p> <p>Assessment of potential gaps and required responses in implementation of the Plan as needed.</p> | <p>2025–26 Corporate Plan, page 10.</p> <p>Program 1.1 Portfolio Budget Statements 2025–26, page 271.</p> | Achieved.<br>See below. |

In 2025–26, Cancer Australia undertook the 2-year evaluation of the Australian Cancer Plan (the Plan) to assess sector-wide progress towards achieving the 2-year goals and identify where further activities are required to ensure implementation remains on track to meet the 5-year goals. The evaluation was guided by the Monitoring and Evaluation Framework for the Plan, which was published on 10 December 2024.

The evaluation was informed by a range of evidence sources, including extensive stakeholder consultation through targeted interviews and a survey. Implementation activities undertaken by the Commonwealth Government, state and territory governments and implementation partners were mapped to identify progress to date and areas of opportunity for increased effort. The digital evaluation website will be finalised in 2026–27.

Cancer Australia has continued to engage with stakeholders across the sector to promote the Plan and establish partnerships to collectively implement the Plan. As at June 2026, Cancer Australia has established 36 partnerships with stakeholders across the sector, including non-government organisations, philanthropic organisations, private health organisations and research institutions. The agency has also launched the Implementing the Plan website to monitor sector-led activities and demonstrate their alignment with the Plan's actions.

The National Cancer Data Framework was endorsed by the Minister for Health and Ageing and all state and territory health ministers prior to its publication on 12 November 2025.

In 2025–26, Cancer Australia undertook the following activities to implement the National Framework for Genomics in Cancer Control (Cancer Genomics Framework) – a 5-year Plan action:

- › designing and developing resources to support genomic health literacy in the community, including for people at high risk of inherited cancer, with a focus on priority populations, to enable better understanding and engagement with genomics-informed personalised prevention, risk reduction and management
- › working with the Australian Alliance for Indigenous Genomics (ALIGN) to support implementation of Indigenous-focused actions in the Cancer Genomics Framework
- › launching the Cancer Genomics Clinical Trials Fund, a \$3 million investment to foster innovation in clinical trial design using genomics and molecular targeting techniques, accelerating the translation of genomic medicine into clinical practice

- › Cancer Australia also developed a draft implementation plan for the Cancer Genomics Framework in consultation with the key stakeholders, including Genomics Australia. It will outline ongoing and upcoming activities to achieve the actions within the framework.

Cancer Australia continued to implement priority activities in 2025–26 under the National Optimal Care Pathways Framework, progressing the Plan’s 5-year action to integrate Optimal Care Pathways (OCPs) into routine cancer care. This included:

- › digitising OCPs to improve accessibility and functionality and to enable tailored access relevant to individual circumstances
- › working with AI CoLab to enhance sector engagement with OCPs
- › increasing priority population OCPs to address intersectionality and improve outcomes
- › updating content, including the common OCP template, to ensure currency and consistency across principles and steps
- › improving tools and information to support earlier diagnosis in primary care
- › developing a comprehensive communications strategy for health professionals to enhance OCP awareness and confidence
- › scoping national quality indicators to measure optimal care.

| Performance criterion                                                                                                            | 2025–26 target                                         | Criterion source                 | Result               |
|----------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|----------------------------------|----------------------|
| Drive the implementation of the Australian Brain Cancer Mission to improve outcomes for Australians diagnosed with brain cancer. | Implementation of the Australian Brain Cancer Mission. | 2025–26 Corporate Plan, page 11. | Achieved. See below. |

In 2025–26, Cancer Australia continued to work in partnership with the Department of Health, Disability and Ageing to deliver the Australian Brain Cancer Mission (the Mission) and drive improved outcomes for Australians diagnosed with brain cancer.

More than \$172 million has been committed into brain cancer research over 10 years of the Mission, consisting of \$50 million from the Australian Government and over \$122 million to date in funding and planned commitments from 12 funding partners (above the original commitment of \$50 million). As at 30 June 2026, \$37.8 million in Medical Research Future Fund (MRFF) funding has been invested in brain cancer research.

Funding partners include Australian Capital Territory (ACT) Health and Canberra Health Services, Carrie’s Beanies 4 Brain Cancer, Children’s Hospital Foundation Queensland, Cure Brain Cancer Foundation, Financial Markets Foundation for Children, Mark Hughes Foundation, Minderoo Foundation Collaboration Against Cancer Initiative, Neurosurgical Research Foundation, Robert Connor Dawes Foundation, The Kids’ Cancer Project, the State of New South Wales and the State of Victoria.

Cancer Australia continues to engage with funding partners to complement MRFF investment and progress implementation initiatives under the current Mission, while working closely with the broader brain cancer sector to support national efforts to sustain the Mission.

Under the Australian Cancer Research Program, the continuation of the Mission from 2027–28 will build on efforts to date by aligning brain cancer priorities with broader national cancer research objectives, strengthening coordination, and placing greater emphasis on translation, collaboration and measurable impact.

| Performance criterion                                                             | 2025–26 target                                | Criterion source                                                                                   | Result                  |
|-----------------------------------------------------------------------------------|-----------------------------------------------|----------------------------------------------------------------------------------------------------|-------------------------|
| Support the implementation of the National Lung Cancer Screening Program (NLCSP). | Deliver program-specific research activities. | 2025–26 Corporate Plan, page 11.<br><br>Program 1.1 Portfolio Budget Statements 2025–26, page 272. | Achieved.<br>See below. |

Cancer Australia continues to work in partnership with the Department of Health, Disability and Ageing and the National Aboriginal Community Controlled Health Organisation (NACCHO) to support implementation of the National Lung Cancer Screening Program (NLCSP), following its launch on 1 July 2025.

In 2025–26, Cancer Australia continued to work with the Thoracic Society of Australia and New Zealand to deliver a research program evaluating the NLCSP Nodule Management Protocol. Cancer Australia has also developed grant guidelines for the first round of a competitive research grant opportunity, expected to open later in 2026.

Additionally, Cancer Australia has continued to support health professionals in navigating the NLCSP through developing and delivering further education modules and resources, webinars and targeted awareness-raising activities, as well as presentations at conferences. Cancer Australia has also been working in partnership with the Australian Institute of Health and Welfare (AIHW) to link clinical quality registry and Australian Cancer Database data to the National Health Data Hub.

| Performance criterion                                                                                                                                     | 2025–26 target                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Criterion source                                                                                       | Result                  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|-------------------------|
| Partner with Aboriginal and Torres Strait Islander people to co-design and deliver improved cancer care for Aboriginal and Torres Strait Islander people. | First Nations cancer control initiatives led and co-designed by First Nations partners that align with the priorities of the Australian Cancer Plan and complement the strategic objectives of the Aboriginal and Torres Strait Islander Cancer Plan.<br><br>Deliver and commence ongoing evaluation for each initiative: <ul style="list-style-type: none"> <li>› Partnerships for Culturally Safe Cancer Care grant program</li> <li>› First Nations Cancer Scholarships program led by Aurora Education Foundation</li> <li>› Partnerships for Cancer Research grant program.</li> </ul> | 2025–26 Corporate Plan, pages 11–12.<br><br>Program 1.1 Portfolio Budget Statements 2025–26, page 273. | Achieved.<br>See below. |

Improving experience and outcomes for Aboriginal and Torres Strait Islander people affected by cancer is a key priority for Cancer Australia. Collaboration and engagement with Aboriginal and Torres Strait Islander health organisations, health professionals, researchers and consumers underpins Cancer Australia's work.

Throughout 2025–26, Cancer Australia continued to partner with Aboriginal and Torres Strait Islander people to deliver improved cancer care across a range of priority policy initiatives and programs. This includes activities funded through the 2023–24 Improving First Nations Cancer Outcomes budget measure to ensure mainstream cancer services are culturally safe and accessible for Aboriginal and Torres Strait Islander people, support national cancer research, and build the capacity of the Aboriginal and Torres Strait Islander research sector. It also includes implementation priorities of the Plan that embed Aboriginal and Torres Strait Islander voices into cancer policymaking, health service delivery and research.

In 2025–26, Cancer Australia awarded 7 grants through a second round of the Partnerships for Culturally Safe Cancer Care grant program, totalling almost \$4.5 million over 2 years (2025–26 to 2026–27). A total of 22 grants have now been awarded nationally through the program across 2024–25 and 2025–26, at a combined value of \$18 million. The program aims to improve culturally safe, responsive and accessible care in mainstream cancer services through partnerships with Aboriginal and Torres Strait Islander community-controlled organisations.

To foster knowledge-sharing and engagement opportunities between grant recipients, in 2025–26, Cancer Australia partnered with an Aboriginal owned and led organisation to co-design and facilitate a Grant Collaborative Community. An evaluation of the grant program also commenced, under the leadership and governance of an expert First Nations Reference Group.

In partnership with the Aurora Education Foundation (Aurora), a leading First Nations organisation, the First Nations Cancer Scholarships program awarded an additional 4 postgraduate scholarships to the value of \$880,000 over 3 years. These scholarships help to build the cohort of Aboriginal and Torres Strait Islander people who will lead future cancer control research, planning and service delivery. This brings the total to 9 scholarships awarded across 2024–25 and 2025–26, at a combined value of \$1.65 million. Aurora will continue to provide culturally appropriate mentoring, wraparound support and network building to underpin students' completion of their studies.

Cancer Australia continued to administer 5 grants awarded in 2024–25 through the Partnerships for Cancer Research grant program, which total \$10.9 million over 3 years. The program facilitates partnerships between research organisations working with community-controlled organisations to deliver Aboriginal and Torres Strait Islander-led, community-informed cancer research projects spanning the cancer continuum. Additionally, it seeks to build the capacity of the Aboriginal and Torres Strait Islander cancer research sector.

In 2025–26, Cancer Australia established a funded partnership with the College of Aboriginal and Torres Strait Islander Nurses and Midwives to co-design a program of work to build the cancer care nursing workforce. We also continued our partnership with the Australian Indigenous Doctors Association to deliver the First Nations Oncology Experience Program to promote careers in cancer to the Aboriginal and Torres Strait Islander specialist medical workforce. Cancer Australia continues to explore similar opportunities with other multidisciplinary health professional groups.

Cancer Australia continued to support Yardhura Walani, the National Centre for Aboriginal and Torres Strait Islander Wellbeing at the Australian National University, to undertake the Kulay Kalingka Study. The study provides insights into Aboriginal and Torres Strait Islander people's beliefs, awareness and experiences of cancer, participation in health promotion and cancer screening programs, and experiences of family and kin support.

The Kulay Kalingka Study continues to deliver sustained relationships with First Nations communities and organisations. The study is Aboriginal and Torres Strait Islander led, designed and governed. It upholds Indigenous data sovereignty principles through ownership at every point of the data life cycle and repatriation of data to participating communities. These outcomes support Cancer Australia's commitment to culturally safe cancer care by embedding First Nations leadership in national research, building a culturally grounded evidence base, and strengthening the foundations for culturally responsive models of care.

Cancer Australia continued to convene the Leadership Group on Aboriginal and Torres Strait Islander Cancer Control to drive a national, Indigenous-led approach to improving outcomes for Aboriginal and Torres Strait Islander people with cancer. Strategic input was also provided by Cancer Australia's Advisors on Aboriginal and Torres Strait Islander Cancer Control.

Cancer Australia continued to engage with NACCHO across 2025–26 to ensure alignment between the Australian Cancer Plan and NACCHO’s Aboriginal and Torres Strait Islander Cancer Plan. The 2 plans are complementary, especially in relation to the co-design of services, delivering place-based cancer care and partnering with Aboriginal community controlled health providers to deliver culturally safe services. Both plans are strongly aligned with the National Agreement on Closing the Gap Priority Reforms.

In 2025–26, 4 grants were awarded to Aboriginal and Torres Strait Islander organisations through the 2026 round of the Supporting People with Cancer grant program. (See page 34 below for more detail.)

| Performance criterion                                 | 2025–26 target                                                                                                                                                       | Criterion source                 | Result                  |
|-------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-------------------------|
| Provide leadership internationally in cancer control. | Engage collaboratively with international counterparts, including through the World Health Organization’s International Agency for Research on Cancer and G7 Cancer. | 2025–26 Corporate Plan, page 12. | Achieved.<br>See below. |

Cancer Australia’s international engagements deliver tangible benefits for Australians by strengthening the evidence base for national decision-making and supporting adaptation of international best practice to the Australian context. These engagements enhance our capacity to design more effective and equitable policies, particularly in areas where cancer experiences and outcomes are poorest or variation persists.

In 2025–26, Cancer Australia strengthened its international engagement through collaboration with the International Agency for Research on Cancer (IARC), the Union for International Cancer Control, the G7 Cancer initiative, and partners across the Asia-Pacific region.

Cancer Australia contributes to global knowledge in areas in which Australia is leading the way, including national cancer control planning, lung cancer screening and cervical cancer elimination, enabling others to benefit from Australia’s policy and implementation experience. In 2025–26, this included chairing the 68th session of the IARC Governing Council, co-leading G7 Cancer Working Group 3 on cancer outcome inequities, and taking a central role on the expert panel developing the IARC Handbook on Lung Cancer Screening.

Through its co-leadership of G7 Cancer Working Group 3, Cancer Australia has led the development and publication of an international report on cancer outcome inequities, identifying policy enablers and barriers to progress. This work is strongly aligned with the central equity focus of the Australian Cancer Plan. The report, and the accompanying paper published in *The Lancet Oncology*, make the research findings available to all Australian cancer control stakeholders and to the wider global cancer control community.

Cancer Australia’s international engagement also focuses on areas where Australia benefits from global expertise and shared learning. Targeted international collaboration enables Cancer Australia to access emerging evidence, international benchmarks and implementation insights in priority areas where Australia aims to accelerate progress. Activities in 2025–26 have included engagements on liver cancer control, improving access to clinical trials in areas of unmet need, and integrated approaches to non-communicable disease (NCD) prevention. Engagement in the United Nations Political Declaration on NCDs, adopted in December 2025, and in related forums alongside the 79th World Health Assembly reinforced the importance of coordinated, upstream prevention strategies and whole-of-government collaboration in designing policies to improve cancer control.

## 2. Develop and promote evidence-based best practice cancer care

| Performance criterion                                                                                                                                                            | 2025–26 target                                                                                                                                                                                                                                                                                                                     | Criterion source                 | Result               |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|----------------------|
| Lead the development, dissemination, and implementation of evidence-based models of cancer care to support improved patient outcomes and safe and sustainable clinical practice. | <p>Digitise the Optimal Care Pathways to improve accessibility and functionality, and explore integration into other platforms, including My Health Record and My Health App.</p> <p>Implement the National Optimal Care Pathways Framework, including engaging and supporting the cancer sector in implementation activities.</p> | 2025–26 Corporate Plan, page 13. | Achieved. See below. |

In 2025–26, Cancer Australia progressed projects to digitise OCPs to improve their accessibility and functionality for health professionals, health services and consumers. This work included scoping the integration of OCPs into digital health platforms, including the OCP consumer guides into My Health Record, in collaboration with the Australian Digital Health Agency.

Cancer Australia progressed the implementation of the National Optimal Care Pathways Framework in 2025–26. See the detailed update relating to the performance criterion ‘Evaluation of the sector’s progress towards the Australian Cancer Plan’s 2-year actions’ above.

During 2025–26, Cancer Australia continued to progress the development of new OCPs. This included:

- › release of the OCP for older people with cancer, in partnership with the Clinical Oncology Society of Australia
- › progress on the OCP for people with rare and less common cancers, in partnership with Rare Cancers Australia
- › commencing work on the OCP for children with cancer, in partnership with Children’s Cancer CoLab.

Cancer Australia also provided extensive support to the cancer sector in understanding how OCPs are developed and updated and how they function. This included supporting the development of new OCPs funded within the sector, including the:

- › release of the OCP for people with biliary cancer (developed by the Pancare Foundation and funded by the Department of Health, Disability and Ageing)
- › progress of the OCP for people living in rural and remote areas with cancer, which is being developed by Deakin University’s Equitable Cancer Outcomes across Rural and Remote Australia Research Group and funded by the Department of Health, Disability and Ageing
- › progress of the OCP for lesbian, gay, bisexual, transgender, queer/questioning, intersex, and asexual (LGBTQIA+) people with cancer, which is being developed by the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine and funded by the Department of Health, Disability and Ageing
- › progress of the OCP for people with disability with cancer, which is being developed by Cancer Council Australia and funded by the Department of Health, Disability and Ageing.

In 2025–26, Cancer Australia established the Prostate Cancer Expert Advisory Group at the request of Minister Butler. The group is co-chaired by the Special Envoy for Men’s Health, Dan Repacholi MP, and Associate Professor Chris Milross, Chair of Cancer Australia’s Advisory Council. The group provides advice to the Minister, through Cancer Australia, on holistic approaches to reducing the impact of prostate cancer in Australia, with an initial focus on early detection, particularly for those at highest risk, minimising the risk of overtreatment and improving supportive care.

The Prostate Cancer Expert Advisory Group met once during the financial year (in May 2026) and considered issues relating to the early detection of prostate cancer, including supporting the implementation of updated Clinical Guidelines for the Early Detection of Prostate Cancer, as well as research and data priorities.

Cancer Australia published the Childhood, Adolescent and Young Adult Cancer Roadmap in May 2026. The roadmap was informed by consultation with clinicians, researchers, jurisdictions, philanthropy and advocacy groups, and those with lived experience. The development process for the roadmap included a ministerial roundtable, an expert reference group, workshops, and broad engagement with the sector on a draft version. The roadmap sets national priorities for evidence-based, age-appropriate and culturally safe models of care for children and young people with cancer. The priorities include development of an OCP for children with cancer, which commenced in May 2026, as well as updates to the OCP for adolescents and young adults with cancer.

The Childhood, Adolescent and Young Adult Cancer Roadmap also supports more consistent implementation of best practice cancer care across the cancer continuum, including through improved access to emerging therapies and precision medicine. Its implementation will be supported through Cancer Australia's ongoing work under the National Optimal Care Pathways Framework, the National Framework for Genomics in Cancer Control, and the National Cancer Data Framework.

| Performance criterion                                   | 2025–26 target                                                                                                                                                                                                                                             | Criterion source                                           | Result       |
|---------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|--------------|
| Translate evidence to inform best practice cancer care. | Translate research into evidence-based information to assist and inform policy and cancer care.                                                                                                                                                            | 2025–26 Corporate Plan, page 13.                           | In progress. |
|                                                         | Review the evidence and implications of increasing incidence of early-onset cancers.                                                                                                                                                                       | Program 1.1 Portfolio Budget Statements 2025–26, page 274. |              |
|                                                         | Expand the Australian Comprehensive Cancer Network to bring together cancer services, and existing networks and alliances within and across states and territories to enable collaboration, sharing of expertise, and access to comprehensive cancer care. |                                                            |              |

Early-onset cancer is defined as cancer diagnosed beyond adolescence but before 50 years of age (20–49 years). The concept of early-onset cancers is relatively recent and rapidly evolving. Clinicians and researchers are yet to fully understand the risk factors contributing to the increased incidence of these cancers.

In response to this emerging issue, in 2025–26 Cancer Australia commissioned:

- › an epidemiological report on trends in increasing cancer incidence in people under 50, and an evidence review of risk factors for early-onset cancers, to better understand the reasons for the increase and identify interventions to alter the trajectory of early-onset cancer rates in Australia. The review was completed by the Cancer Elimination Collaboration at the University of Sydney in April 2026, and Cancer Australia will publish a summary in 2026.
- › a pilot project, led by the University of Melbourne, to develop evidence-based guidance for GPs around investigation of common signs, symptoms and symptom combinations associated with cancer. This project comprises the development of a symptom-based guide to support earlier diagnosis of cancer; and updates to 4 OCPs to strengthen guidance on signs and symptoms in OCP Step 2: Presentation, initial investigations and referral. Work is underway to finalise the content for publication in consultation with GP colleges. It is anticipated for release in late 2026.

In 2025–26, Cancer Australia continued to activate the Australian Comprehensive Cancer Network (ACCN), bringing together cancer services, networks and alliances across Australia to enable collaboration, sharing of expertise, and access to comprehensive cancer care.

ACCN membership grew to more than 1,500 members, including individuals and organisations from comprehensive cancer centres, metropolitan and regional cancer services, private health service providers, international agencies, universities and research organisations.

Cancer Australia co-hosted the second ACCN Innovations Showcase on 3 July 2025 with the Peter MacCallum Cancer Centre in Victoria, highlighting initiatives in networked comprehensive cancer care and supporting knowledge sharing across the sector.

Cancer Australia engaged with regional, rural and remote cancer organisations and health professionals to identify enablers and barriers to networked care and opportunities to strengthen collaboration and access to comprehensive cancer care. A workshop held in Dubbo in March 2026 explored local and national experiences and identified practical opportunities to improve equity, access and outcomes. Insights from this and further regional workshops in 2026–27 will inform a national online workshop.

Cancer Australia also established the Networking for Cancer Equity grant opportunity to support activation of the ACCN; connecting cancer services nationally to enable collaboration, sharing of expertise, and access to high-quality cancer care as close to home as safely possible. In the program’s inaugural round, 8 grants worth over \$1.75 million were awarded to support innovative, collaborative initiatives that improve access to comprehensive cancer care, with a focus on equity and sustainability.

In 2025–26, Cancer Australia also commenced activities in prostate cancer and liver cancer early detection and prevention, including an economic evaluation of prostate cancer screening and a national roundtable on liver cancer to identify priority actions for tackling the growing burden of this disease.

| Performance criterion                                                                                                                                                      | 2025–26 target                                                                                                                                                                                                                                                      | Criterion source                 | Result                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-------------------------|
| Invest in community engagement to support evidence-based information and support for people affected by cancer through the Supporting People with Cancer Grant initiative. | Award at least 4 grants (targeting 2 community organisations and 2 Aboriginal and Torres Strait Islander organisations) per annum to improve outcomes and support for people affected by cancer from priority populations or whose cancer outcomes are inequitable. | 2025–26 Corporate Plan, page 13. | Achieved.<br>See below. |

Cancer Australia awarded 9 grants through the 2026 round of the Supporting People with Cancer grant program, with a total value of \$1,047,216. Five grants were awarded to community organisations, and 4 were awarded to Aboriginal and Torres Strait Islander organisations.

In alignment with the Plan, these grants have a strong focus on improving equity in outcomes and experiences for all people affected by cancer.

Funding for Aboriginal and Torres Strait Islander organisations will support culturally safe, community-led initiatives across the cancer continuum, including support and referral pathways, prevention and early detection, and supportive care. Funded projects will improve access to culturally appropriate information, care and support for Aboriginal communities in remote Queensland, the Kimberley, Sydney and Tasmania.

Funding for community organisations will support targeted initiatives to improve equity in cancer outcomes and experiences for priority populations and groups whose outcomes are inequitable. This includes projects to strengthen palliative and end-of-life care for people experiencing homelessness, improve in-language information for multicultural communities, support children and adolescents affected by cancer, provide psychosocial support for LGBTIQ+ people, and enhance information and care coordination for people affected by sarcoma.

### 3. Fund cancer research and drive efforts to strengthen national data capacity in consultation with relevant agencies

| Performance criterion                                | 2025–26 target                                                                       | Criterion source                                                                               | Result                  |
|------------------------------------------------------|--------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|-------------------------|
| Oversee a dedicated budget for research into cancer. | Deliver at least one annual grant round to fund priority-driven research investment. | 2025–26 Corporate Plan, page 14.<br>Program 1.1 Portfolio Budget Statements 2025–26, page 275. | Achieved.<br>See below. |

In 2025–26, Cancer Australia implemented the Cancer Australia Research Initiative (CARI), replacing the previous Priority-driven Collaborative Cancer Research Scheme and establishing a new approach to priority-driven research investment.

CARI is a flexible research investment model designed to respond to emerging cancer research priorities and areas of unmet need. The initiative provides a structured and repeatable approach to identifying research priorities and delivering targeted cancer research investment.

Cancer Australia delivered the first annual grant round of CARI in partnership with the NHMRC. The grant opportunity was targeted to research into early-onset cancer, identified by Cancer Australia in consultation with the Research and Data Advisory Group, the NHMRC and sector participants as a priority area of emerging and unmet need.

Cancer Australia and the NHMRC jointly awarded \$15 million over 3 years to 7 research projects. Funded projects address key research areas across the cancer continuum, including prevention, early detection, treatment and survivorship.

The delivery of the first grant round demonstrates Cancer Australia's ability to implement an ongoing annual model that strengthens collaboration, supports research capability and contributes to improving cancer outcomes for Australians. CARI aligns funding to national research priorities under the Australian Cancer Plan and NHMRC research priorities.

| Performance criterion                                                                       | 2025–26 target                                                                                                 | Criterion source                 | Result                  |
|---------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------|-------------------------|
| Support Australia's national Multi-site Collaborative Cancer Clinical Trials Groups (CTGs). | Fund 14 CTGs as per published grant guideline timeframes.<br>Providers of national technical services engaged. | 2025–26 Corporate Plan, page 14. | Achieved.<br>See below. |

Now in its 20th year, the SCCT program continues to play a key role in strengthening Australia's national cancer clinical trials system, building on 2 decades of sustained investment. The program helps more Australians take part in high-quality cancer clinical trials, regardless of where they live, by promoting multi-site delivery that links clinical research hubs with regional and remote areas and through the use of tele-trials models.

Investigator-initiated, industry-independent trials that address important questions in treatment and care remain central to the program, particularly in areas of unmet need where there is limited commercial interest.

In 2025–26, the SCCT program supported Australia's 14 collaborative cancer clinical trial groups to develop grant-competitive trial concepts and protocols, helping maintain a high-quality nationally coordinated cancer clinical trials system. Continued investment in 2 national technical services delivered expert advice on quality of life, health economics and pharmacoeconomics for improved

trial design and readiness for funding. Work also progressed with partners to assess opportunities to increase participation among priority groups, including Aboriginal and Torres Strait Islander people, by strengthening culturally safe approaches to clinical trial design and implementation.

In 2025–26, Cancer Australia awarded the first instalment of a \$3 million investment over 3 years under the new Cancer Genomics Clinical Trials Fund. The fund will build the capacity of all 14 collaborative cancer clinical trial groups funded under the SCCT program to develop approaches or methods to set the foundation for and accelerate the incorporation of genomics into cancer clinical trial design. Importantly, the fund will drive early implementation of the National Framework for Genomics in Cancer Control and complement the National Cancer Data Framework.

| Performance criterion                                              | 2025–26 target                                                                                                                                                                                                  | Criterion source                                                                                   | Result                  |
|--------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|-------------------------|
| Provide high quality cancer data to inform national cancer control | Maintain published data analyses and insights on the National Cancer Control Indicators website.<br><br>Progress initiatives to improve the collection, access, analysis and reporting of national cancer data. | 2025–26 Corporate Plan, page 14.<br><br>Program 1.1 Portfolio Budget Statements 2025–26, page 275. | Achieved.<br>See below. |

Cancer Australia continued work to strengthen national cancer data capacity to inform national cancer control. Updated data for 10 indicators were published on the National Cancer Control Indicators (NCCI) website. The NCCI website is a dynamic national cancer resource that brings together data from 15 authoritative sources and covers 31 key indicators across the cancer care continuum.

Cancer Australia has progressed priority initiatives to improve the collection, access, analysis and reporting of national cancer data. A focus in 2025–26 was the finalisation and publication of the National Cancer Data Framework and commencing its implementation.

Cancer Australia developed the National Cancer Data Framework in partnership with Cancer Council Australia and the AIHW, with significant sector, cross-jurisdictional and public consultation. The National Cancer Data Framework was endorsed by the Minister for Health and Ageing and all state and territory health ministers prior to its publication on 12 November 2025.

Cancer Australia is leading national coordination of the implementation of the National Cancer Data Framework, in collaboration with the sector, as outlined below.

Cancer Australia, in partnership with Cancer Council Queensland (CCQ), has enhanced the national collection and reporting of data to improve knowledge of variations in outcomes for childhood cancer in Australia. Data collected and reported includes data on distribution and survival by non-stage prognostic indicators; distribution of non-stage prognostic indicators by socio-economic status and remoteness; survival by remoteness and socio-economic status; distribution and survival by cancer stage; and distribution of stage by socio-economic status and remoteness. Cancer Australia and CCQ have also progressed a data linkage project to study the late effects of childhood cancer and its treatment.

Cancer Australia and the Department of Health, Disability and Ageing partnered with Movember to design and embed patient-reported experience measures (PREMs) and patient-reported outcomes measures (PROMs) into national performance monitoring and reporting. A core outcome set of PREMs and PROMs has been developed through the Movember consortium, including lived experience and cancer sector representatives.

An electronic patient-reported measures collection platform has been developed to support health services in capturing PREMs and PROMs data. Work is underway to build a national reporting capability for patient-reported cancer data.

Work has also progressed on a pilot program, using data from the Prostate Cancer Outcomes Registry Australia New Zealand, to support national benchmarking. An education campaign is being developed through the Movember consortium to highlight the importance and use of PREMs and PROMs in patient-centred care. Work on potential approaches to data automation for clinical quality registries is underway, to increase the speed of data collection and reporting.

In June 2025, Yardhura Walani delivered a Kulay Kalingka Study report covering 2 collection periods across 2023 to 2025. Findings were published on the Our Mob and Cancer, Cancer Australia and NCCI websites. This work is informing the development of Aboriginal and Torres Strait Islander specific indicators for the NCCI, addressing persistent gaps in national data and supporting improved monitoring of cancer outcomes and experiences for First Nations people. Cancer Australia and the Department of Health, Disability and Ageing have provided an additional \$3 million to continue the study through to 2029, producing longitudinal data of this type for the first time.

In 2025–26, Cancer Australia and the AIHW are collaborating on the National Cancer Data Indicators project. This work will establish a core set of system-level pan-cancer indicators aligned to the OCPs, in collaboration with the Australian Cancer Data Alliance. This is a short-term action under the National Cancer Data Framework and will support the development of a National Cancer Control Performance Reporting Framework and more consistent national reporting. A key first step is agreeing on system-level measures to enable benchmarking across jurisdictions, population-based cancer registries, clinical quality registries, policymakers, and people with lived experience across Australia.

Cancer Australia is partnering with the AIHW to strengthen national cancer and screening data systems. Enduring data linkages are being established to support critical screening programs, improve the availability and consistency of cancer stage and metastatic data and enhance the timeliness and quality of cancer data collection. Collectively, these initiatives progress implementation of the actions in the National Cancer Data Framework.

#### 4. Provide consumer and health professional cancer information and resources

| Performance criterion                                                                                  | 2025–26 target                                                                                                                                        | Criterion source                                                                                   | Result                  |
|--------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|-------------------------|
| Provide evidence-based cancer information to cancer consumers, health professionals and the community. | Up-to-date evidence-based cancer information available on the Cancer Australia website.<br><br>>5 cancer information topics are reviewed and updated. | 2025–26 Corporate Plan, page 15.<br><br>Program 1.1 Portfolio Budget Statements 2025–26, page 274. | Achieved.<br>See below. |

Cancer Australia continued to comprehensively review, update and improve the user experience of the agency's websites over 2025–26, aligning with the goals and objectives of the Plan.

The new website launched in 2025 features the consolidation of several former Cancer Australia websites into a single platform, designed to provide a seamless user experience for anyone seeking accessible, reliable information about cancer and cancer control.

This year, Cancer Australia undertook a substantial program of content review and optimisation, updating cancer information topics to ensure clinical accuracy and relevance for both consumers and health professionals, as well as publishing statistics across 35 different tumour types. In total, 321 updates were made across the Cancer Australia website. The agency also commenced implementation of semantic search functionality to enhance usability and align with emerging artificial intelligence capabilities.

## Analysis

Cancer Australia has substantially met the performance criteria relating to its 2025–26 program objectives as outlined in its 2025–26 PBS and Corporate Plan.

The agency's 2025–26 program objectives were:

1. Provide national leadership in cancer control
2. Develop and promote evidence-based best practice cancer care
3. Fund cancer research and drive efforts to strengthen national data capacity in consultation with relevant agencies
4. Provide consumer and health professional cancer information and resources.

Cancer Australia's work was supported by its 2025–26 budget allocation. Details on Cancer Australia's financial performance are available at Appendix A.

Cancer Australia planned and prioritised its work in line with its purpose, program objectives and budget. Cancer Australia's performance reporting and monitoring framework supported effective reporting, analysis and oversight of performance in 2025–26. Together with the agency's strategic approach to business planning, this ensured efforts remained aligned with its purpose.

# Financial overview

The 2025–26 departmental expenses were \$17.268 million (GST exclusive). The 2025–26 administered expenses were \$34.367 million (GST exclusive).

Cancer Australia delivered a planned program of work in 2025–26, in line with the departmental and administered appropriations.

Further information on Cancer Australia's financial performance is available in the financial statements and accompanying notes of this annual report. Cancer Australia's audited financial statements are at Appendix B.

A decorative background consisting of a grid of small, light orange squares arranged in a regular pattern across the entire dark blue-grey background.

4

# ■ Management and accountability ■



# Management and accountability

This section outlines Cancer Australia's corporate governance arrangements, financial performance, management of human resources, ministerial and parliamentary coordination, compliance and other accountability obligations.

Cancer Australia's Corporate Operations Branch led the administration of and compliance with relevant legislation and Commonwealth policy regarding financial management, asset management, business continuity planning, fraud control, freedom of information, human resources, information technology, records management, security, and general administrative services required to support the agency's operations.

Cancer Australia's audited financial statements are at Appendix B. Other mandatory information can be found at Appendix D, which covers:

- › advertising and market research
- › disability reporting
- › ecologically sustainable development
- › freedom of information (FOI)
- › grant programs
- › work health and safety.

# Corporate governance

## Strategic and business planning

All Cancer Australia projects in 2025–26 were underpinned by a robust business planning framework which incorporated the agency’s 2025–26 Portfolio Budget Statements (PBS), 2025–26 Corporate Plan and 2025–26 Business Plan.

Cancer Australia’s 2025–26 Corporate Plan articulated the agency’s purpose and strategic outlook, as well as strategies for achieving its purpose and how success would be measured.

Cancer Australia’s 2025–26 Business Plan supported the agency’s strategic direction as outlined in its 2025–26 Corporate Plan. The Business Plan identified the agency’s project deliverables, incorporating the key performance indicators listed in both the Corporate Plan and the PBS.

Through this process of alignment, Cancer Australia ensures its resources and investments are delivering value for money and improving outcomes for people affected by cancer. Cancer Australia’s Annual Performance Statement, published in this Annual Report (see Part 3), acquits the agency’s performance against the performance measures included in the 2025–26 Corporate Plan and the agency’s deliverables and key performance indicators outlined in the PBS.

## Compliance reporting

There were no instances of significant non-compliance with finance law related to the entity in 2025–26.

**Table 4.1: Significant non-compliance with the finance law**

| Description of non-compliance | Remedial action |
|-------------------------------|-----------------|
| Nil                           | n/a             |

## Internal audit arrangements

In 2025–26, Cancer Australia’s auditors, Stewart Brown, performed the internal audit function. These audits were conducted in compliance with the risk-based internal audit plan, endorsed by the Audit and Risk Committee. See pages 44–45 for more information on Cancer Australia’s Audit and Risk Committee.

## Fraud and corruption control

Cancer Australia has in place appropriate fraud and corruption prevention, detection, investigation, monitoring and reporting mechanisms which meet the specific needs of the agency.

Cancer Australia has also taken all reasonable measures to minimise and appropriately deal with fraud and corruption relating to the agency, to comply with the Commonwealth Fraud and Corruption Control Framework 2024.

Cancer Australia staff were trained in fraud awareness and cybersecurity awareness, which included phishing scam and simulation training. All new employees are required to complete the fraud awareness module of the APS Induction Program.

Ethical standards

Cancer Australia, as an Australian Government agency, is bound by the *Public Service Act 1999* (Cth) and the Australian Public Service Commission guidelines for the management and development of its people.

During 2025–26, Cancer Australia continued to reinforce its internal guidelines and policies to ensure consistency with appropriate ethical standards. Our staff act ethically, support a collaborative culture, and take pride in their work. All new employees are required to complete the integrity, diversity and inclusion module in the APS Induction Program, as well as an online inclusion training program developed by SBS (Special Broadcasting Service) in collaboration with subject-matter experts.

Cancer Australia provided all new employees with a copy of the APS Values and Code of Conduct to ensure awareness of ethical standards and organisational expectations.

External scrutiny

No judicial or administrative tribunal decisions relating to Cancer Australia were handed down during 2025–26. There were no reports by the Auditor-General on the operations of the agency, other than the report on the financial statements at Appendix B. In 2025–26 there were no reports on the operations of Cancer Australia conducted by a parliamentary committee or the Commonwealth Ombudsman.

Ministerial and parliamentary coordination

During 2025–26, Cancer Australia provided high-quality, timely and evidence-based information to the Minister for Health and Ageing on national cancer control related issues. The agency continued to collaborate closely with the Department of Health, Disability and Ageing to support the Minister and implement Australian Government policies.

Audit and Risk Committee

Cancer Australia’s Audit and Risk Committee met 4 times during the year to provide independent advice and assistance to the Chief Executive Officer (CEO) on Cancer Australia’s risk control and compliance framework, and its external accountability responsibilities, in accordance with the [Audit and Risk Committee Charter](#).

The Cancer Australia Audit and Risk Committee Charter is available online (see Table 4.2).

Table 4.2: Audit and Risk Committee Charter

| Direct electronic address of the charter determining the functions of the audit committee |                                                                                                                                                                                                                           |
|-------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| URL                                                                                       | <a href="https://www.canceraustralia.gov.au/about-us/accountability-and-reporting#audit-risk-committee-charter">https://www.canceraustralia.gov.au/about-us/accountability-and-reporting#audit-risk-committee-charter</a> |

The 3 independent Audit and Risk Committee members were appointed from outside Cancer Australia. Members' details are outlined in Table 4.3.

**Table 4.3: Cancer Australia's Audit and Risk Committee**

| Member name                                                       | Qualifications, knowledge, skills or experience (include formal and informal as relevant)                                                                                                                                                                                                                                                      | Number of meetings attended | Total number of meetings held | Total annual remuneration (GST incl) | Additional information (including role on committee) |
|-------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-------------------------------|--------------------------------------|------------------------------------------------------|
| Ms Gayle Ginnane, FAICD, BA (Qld), BEcon (Qld), MDefStudies (NSW) | Ms Gayle Ginnane has over 30 years' experience in the public sector, including 12 years as the CEO of the Private Health Insurance Administration Council. Ms Ginnane also has 20 years' experience as a company director in the public and private sectors and on audit and risk committees.                                                  | 4                           | 4                             | \$17,600                             | Chair                                                |
| Ms Roslyn Jackson, FCA FGIA FAICD                                 | Ms Roslyn Jackson is a Fellow Chartered Accountant with over 30 years' experience in the profession, working in both the public and private sectors.                                                                                                                                                                                           | 3                           | 4                             | \$6,930                              | Member                                               |
| Ms Belinda Small, BCom, MBA                                       | Ms Belinda Small holds a Bachelor of Commerce and a Master of Business Administration. She has extensive experience leading enterprise-wide strategic initiatives and complex transformation agendas, and has a breadth of corporate and governance knowledge from working in both large government departments and small government agencies. | 3                           | 4                             | \$0                                  | Member                                               |

## Competitive tendering and contracting

All open tenders and contracts over \$10,000 (GST inclusive) awarded by Cancer Australia during 2025–26 were published on AusTender.

## Consultancy and non-consultancy contracts

Annual reports contain information about actual expenditure on reportable consultancy contracts and non-consultancy contracts. Information on the value of reportable consultancy and non-consultancy contracts is available on the AusTender website [tenders.gov.au](https://tenders.gov.au).

During 2025–26, eight (8) new reportable consultancy contracts were entered into totalling actual expenditure of \$0.315 million (GST incl). In addition, five (5) ongoing reportable consultancy contracts were active during 2025–26, involving total actual expenditure of \$0.084 million (GST incl). The total number of reportable consultancies (13) recorded in financial year 2025–26 amounted to \$0.399 million in total expenditure (GST incl).

Additionally, there were sixty-nine (69) new reportable non-consultancies entered into totalling actual expenditure of \$6.571 million (GST incl). Thirty (30) ongoing reportable non-consultancy contracts were active during 2025–26, involving total actual expenditure of \$9.025 million (GST incl). The total number of reportable non-consultancies (99) recorded in financial year 2025–26 amounted to \$15.596 million in total expenditure (GST incl).

Cancer Australia engages consultants as required to acquire specialist expertise and to undertake research and investigation of particular cancer control issues to inform and assist in the agency's decision-making.

Prior to engaging consultants, the agency takes into account the skills and resources required for the task, the skills available internally and the cost-effectiveness of engaging external expertise. The decision to engage a consultant is made in accordance with the *Public Governance, Performance and Accountability Act 2013* (Cth) and Regulations (including the Commonwealth Procurement Rules) and relevant internal policies.

Cancer Australia is a non-corporate Commonwealth entity. Cancer Australia's reportable contract data for 2025–26 is as follows.

**Table 4.4: Expenditure on reportable consultancy contracts (2025–26)**

|                                                                   | Number    | Expenditure<br>\$'000 (GST incl) |
|-------------------------------------------------------------------|-----------|----------------------------------|
| New contracts entered into during the reporting period            | 8         | 315                              |
| Ongoing contracts entered into during a previous reporting period | 5         | 84                               |
| <b>Total</b>                                                      | <b>13</b> | <b>399</b>                       |

**Table 4.5: Expenditure on reportable non-consultancy contracts (2025–26)**

|                                                                   | Number    | Expenditure<br>\$'000 (GST incl) |
|-------------------------------------------------------------------|-----------|----------------------------------|
| New contracts entered into during the reporting period            | 69        | 6,571                            |
| Ongoing contracts entered into during a previous reporting period | 30        | 9,025                            |
| <b>Total</b>                                                      | <b>99</b> | <b>15,596</b>                    |

**Table 4.6: Organisations receiving a share of reportable consultancy contract expenditure (2025–26)**

| Name of organisation            | Organisation ABN | Expenditure<br>\$'000 (GST incl) |
|---------------------------------|------------------|----------------------------------|
| Jacinta Elston Pty Ltd          | 98 657 253 220   | \$187                            |
| Australian Government Solicitor | 69 405 937 639   | \$72                             |
| Sax Institute                   | 68 095 542 886   | \$31                             |
| Deloitte Touche Tohmatsu        | 74 490 121 060   | \$27                             |
| Concur Consulting               | 90 261 120 291   | \$17                             |

**Note:** This table provides information on those organisations that received the 5 largest shares of Cancer Australia's expenditure on such contracts, and those organisations that received 5% or more of expenditure on such contracts.

**Table 4.7: Organisations receiving a share of reportable non-consultancy contract expenditure (2025–26)**

| Name of organisation                       | Organisation ABN | Expenditure<br>\$'000 (GST incl) |
|--------------------------------------------|------------------|----------------------------------|
| Aurora Education Foundation Limited        | 28 158 391 363   | \$2,097                          |
| The Movember Foundation                    | 48 894 537 905   | \$1,643                          |
| Evolve FM                                  | 52 605 472 580   | \$1,618                          |
| Australian National University             | 52 234 063 906   | \$1,460                          |
| Australian Institute of Health and Welfare | 16 515 245 497   | \$1,030                          |
| University of Technology Sydney            | 77 257 686 961   | \$883                            |

**Note:** This table provides information on those organisations that received the 5 largest shares of Cancer Australia's expenditure on such contracts, and those organisations that received 5% or more of expenditure on such contracts.

## Strategic Commissioning Framework

Cancer Australia operates in line with the Strategic Commissioning Framework. Core work is done in-house in most cases, and any outsourcing of core work is minimal and aligns with the limited circumstances permitted under the framework.

## Australian National Audit Office Access

All Cancer Australia contracts contain provisions allowing access by the Auditor-General.

## Purchasing

In 2025–26, Cancer Australia sourced goods and services in accordance with the principles set out in the Commonwealth Procurement Rules.

The agency continued to reinforce procurement policies and procedures reflecting the need for compliance with these guidelines, focusing on:

- › value for money
- › encouraging competition
- › efficient, effective, ethical and economical use of Australian Government resources
- › accountability and transparency
- › compliance with other Australian Government policies.

The agency also provides training and education, and support for staff in procurement and grants.

All procurement and grant activity within the agency is reviewed to ensure compliance with legislative requirements and to maximise best practice.

## Indigenous Procurement Policy

Cancer Australia continues to support diversity in its supplier base through the ongoing promotion and application of the Indigenous Procurement Policy, providing greater opportunities for Indigenous-owned businesses to contribute to the Australian economy and create more jobs for local communities.

## Small business

Cancer Australia supports small business participation in the Commonwealth Government procurement market. Small and medium enterprise (SME) and small enterprise participation statistics are available on the Department of Finance's website: <https://www.finance.gov.au/government/procurement/statistics-australian-government-procurement-contracts>.

To ensure SMEs can engage in fair competition for Australian Government business, Cancer Australia's procurement practices include use of:

- › the Commonwealth Contracting Suite for low-risk procurements valued under \$200,000
- › electronic systems and other processes to facilitate on-time payment performance, including payment cards.

## Exempt contracts

There were no contracts in excess of \$10,000 entered into by Cancer Australia during 2025–26 that were exempt from being published on AusTender due to FOI reasons.

# Management of human resources

At 30 June 2026, Cancer Australia had 81 employees, of whom 70 were ongoing and 11 were non-ongoing. Most staff were located in Sydney and Canberra. The workforce was predominantly female (86%).

Cancer Australia continues to place great value on reinforcing a productive and inclusive workplace by attracting and retaining high-calibre, talented and engaged staff. Cancer Australia staff have a diverse range of skill sets, with expertise in areas including epidemiology, clinical practice, research, data analysis, population health, public health, public policy, communications, project management, human resources management and financial management.

## Employment arrangements

Cancer Australia staff at non-Senior Executive Service (non-SES) level are employed under the terms and conditions of the Cancer Australia Enterprise Agreement 2024–2027.

As of 30 June 2026, Cancer Australia had 78 non-SES staff, and 3 SES staff (excluding Cancer Australia's CEO and Advisory Council members). Fifteen staff receive individual flexibility arrangements under clauses 32–37 of the Enterprise Agreement.

## Training and development

Cancer Australia supports staff to develop their capabilities in line with business needs and career aspirations. Each year the agency implements a professional development plan to help staff to realise their full potential. In addition to formal training and other development opportunities, the professional development plan incorporates financial assistance and study leave for staff to undertake relevant tertiary education. Study leave allowances were expanded under the Cancer Australia Enterprise Agreement 2024–2027, delivering improved benefit to staff.

During 2025–26, training and education was delivered to staff in line with Cancer Australia's strategy and individual development needs (as identified through the Performance Development Program). In 2025–26, Cancer Australia's training was delivered through face-to-face, virtual and e-learning programs provided by accredited training organisations.

The agency also provided training for some or all staff in integrity, privacy awareness, records management, fraud awareness, cybersecurity, appropriate workplace behaviour, diversity and inclusion, and work health and safety.

## Cancer Australia staffing statistics

Tables 4.8 to 4.17 provide information relating to the distribution and classification of Cancer Australia staff as at 30 June 2026 for the 2025–26 financial year.

**Table 4.8: All ongoing employees current report period (2025–26)**

|                      | Man/male  |           |           | Woman/female |           |           | Non-binary |           |          | Prefers not to answer |           |          | Uses a different term |           |          | Total     |
|----------------------|-----------|-----------|-----------|--------------|-----------|-----------|------------|-----------|----------|-----------------------|-----------|----------|-----------------------|-----------|----------|-----------|
|                      | Full time | Part time | Total     | Full time    | Part time | Total     | Full time  | Part time | Total    | Full time             | Part time | Total    | Full time             | Part time | Total    |           |
| NSW                  | 3         | 1         | 4         | 30           | 8         | 38        | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 42        |
| Qld                  | 0         | 0         | 0         | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| SA                   | 0         | 0         | 0         | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| Tas                  | 0         | 0         | 0         | 1            | 0         | 1         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 1         |
| Vic                  | 0         | 0         | 0         | 1            | 1         | 2         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 2         |
| WA                   | 0         | 0         | 0         | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| ACT                  | 7         | 0         | 7         | 13           | 4         | 17        | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 24        |
| NT                   | 0         | 0         | 0         | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| External territories | 0         | 0         | 0         | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| Overseas             | 0         | 0         | 0         | 1            | 0         | 1         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 1         |
| <b>Total</b>         | <b>10</b> | <b>1</b>  | <b>11</b> | <b>46</b>    | <b>13</b> | <b>59</b> | <b>0</b>   | <b>0</b>  | <b>0</b> | <b>0</b>              | <b>0</b>  | <b>0</b> | <b>0</b>              | <b>0</b>  | <b>0</b> | <b>70</b> |

### Notes:

The figures in Table 4.8 include:

1. headcount figures of Cancer Australia staff as at 30 June 2026
  2. staff on leave and secondment
  3. staff acting at a higher level, for any period as at 30 June 2026 (that is, these staff are listed against their higher duties classification).
- They exclude the Cancer Australia CEO and Advisory Council members and chair, who are appointed under the *Cancer Australia Act 2006* (Cth).

**Table 4.9: All non-ongoing employees current report period (2025–26)**

|                      | Man/male  |           |          | Woman/female |           |           | Non-binary |           |          | Prefers not to answer |           |          | Uses a different term |           |          | Total     |
|----------------------|-----------|-----------|----------|--------------|-----------|-----------|------------|-----------|----------|-----------------------|-----------|----------|-----------------------|-----------|----------|-----------|
|                      | Full time | Part time | Total    | Full time    | Part time | Total     | Full time  | Part time | Total    | Full time             | Part time | Total    | Full time             | Part time | Total    |           |
| NSW                  | 0         | 0         | 0        | 6            | 0         | 6         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 6         |
| Qld                  | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| SA                   | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| Tas                  | 0         | 0         | 0        | 0            | 1         | 1         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 1         |
| Vic                  | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| WA                   | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| ACT                  | 0         | 0         | 0        | 4            | 0         | 4         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 4         |
| NT                   | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| External territories | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| Overseas             | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| <b>Total</b>         | <b>0</b>  | <b>0</b>  | <b>0</b> | <b>10</b>    | <b>1</b>  | <b>11</b> | <b>0</b>   | <b>0</b>  | <b>0</b> | <b>0</b>              | <b>0</b>  | <b>0</b> | <b>0</b>              | <b>0</b>  | <b>0</b> | <b>11</b> |

**Notes:**

The figures in Table 4.9 include:

1. headcount figures of Cancer Australia staff as at 30 June 2026
2. staff on leave and secondment
3. staff acting at a higher level, for any period as at 30 June 2026 (that is, these staff are listed against their higher duties classification).

They exclude the Cancer Australia CEO and Advisory Council members and chair, who are appointed under the Cancer Australia Act.

**Table 4.10: Australian Public Service Act ongoing employees current report period (2025–26)**

|              | Man/male  |           |           | Woman/female |           |           | Non-binary |           |          | Prefers not to answer |           |          | Uses a different term |           |          | Total     |
|--------------|-----------|-----------|-----------|--------------|-----------|-----------|------------|-----------|----------|-----------------------|-----------|----------|-----------------------|-----------|----------|-----------|
|              | Full time | Part time | Total     | Full time    | Part time | Total     | Full time  | Part time | Total    | Full time             | Part time | Total    | Full time             | Part time | Total    |           |
| SES 3        | 0         | 0         | 0         | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| SES 2        | 0         | 0         | 0         | 1            | 0         | 1         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 1         |
| SES 1        | 2         | 0         | 2         | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 2         |
| EL 2         | 2         | 0         | 2         | 6            | 0         | 6         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 8         |
| EL 1         | 4         | 0         | 4         | 13           | 8         | 21        | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 25        |
| APS 6        | 2         | 0         | 2         | 18           | 4         | 22        | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 24        |
| APS 5        | 0         | 1         | 1         | 6            | 1         | 7         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 8         |
| APS 4        | 0         | 0         | 0         | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| APS 3        | 0         | 0         | 0         | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| APS 2        | 0         | 0         | 0         | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| APS 1        | 0         | 0         | 0         | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| Other        | 0         | 0         | 0         | 2            | 0         | 2         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 2         |
| <b>Total</b> | <b>10</b> | <b>1</b>  | <b>11</b> | <b>46</b>    | <b>13</b> | <b>59</b> | <b>0</b>   | <b>0</b>  | <b>0</b> | <b>0</b>              | <b>0</b>  | <b>0</b> | <b>0</b>              | <b>0</b>  | <b>0</b> | <b>70</b> |

Notes:

The figures in Table 4.10 include:

1. headcount figures of Cancer Australia staff as at 30 June 2026
2. staff on leave and secondment
3. staff acting at a higher level, for any period as at 30 June 2026 (that is, these staff are listed against their higher duties classification).

They exclude the Cancer Australia CEO and Advisory Council members and chair, who are appointed under the Cancer Australia Act.

**Table 4.11: Australian Public Service Act non-ongoing employees current report period (2025–26)**

|              | Man/male  |           |          | Woman/female |           |           | Non-binary |           |          | Prefers not to answer |           |          | Uses a different term |           |          | Total     |
|--------------|-----------|-----------|----------|--------------|-----------|-----------|------------|-----------|----------|-----------------------|-----------|----------|-----------------------|-----------|----------|-----------|
|              | Full time | Part time | Total    | Full time    | Part time | Total     | Full time  | Part time | Total    | Full time             | Part time | Total    | Full time             | Part time | Total    |           |
| SES 3        | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| SES 2        | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| SES 1        | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| EL 2         | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| EL 1         | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| APS 6        | 0         | 0         | 0        | 9            | 1         | 10        | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 10        |
| APS 5        | 0         | 0         | 0        | 1            | 0         | 1         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 1         |
| APS 4        | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| APS 3        | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| APS 2        | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| APS 1        | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| Other        | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| <b>Total</b> | <b>0</b>  | <b>0</b>  | <b>0</b> | <b>10</b>    | <b>1</b>  | <b>11</b> | <b>0</b>   | <b>0</b>  | <b>0</b> | <b>0</b>              | <b>0</b>  | <b>0</b> | <b>0</b>              | <b>0</b>  | <b>0</b> | <b>11</b> |

**Notes:**

The figures in Table 4.11 include:

1. headcount figures of Cancer Australia staff as at 30 June 2026
2. staff on leave and secondment
3. staff acting at a higher level, for any period as at 30 June 2026 (that is, these staff are listed against their higher duties classification).

They exclude the Cancer Australia CEO and Advisory Council members and chair, who are appointed under the Cancer Australia Act.

**Table 4.12: Australian Public Service Act employees by full time and part time status current report period (2025–26)**

|              | Ongoing   |           |               | Non-ongoing |           |                   | Total     |
|--------------|-----------|-----------|---------------|-------------|-----------|-------------------|-----------|
|              | Full time | Part time | Total ongoing | Full time   | Part time | Total non-ongoing |           |
| SES 3        | 0         | 0         | 0             | 0           | 0         | 0                 | 0         |
| SES 2        | 1         | 0         | 1             | 0           | 0         | 0                 | 1         |
| SES 1        | 2         | 0         | 2             | 0           | 0         | 0                 | 2         |
| EL 2         | 8         | 0         | 8             | 0           | 0         | 0                 | 8         |
| EL 1         | 17        | 8         | 25            | 0           | 0         | 0                 | 25        |
| APS 6        | 20        | 4         | 24            | 9           | 1         | 10                | 34        |
| APS 5        | 6         | 2         | 8             | 1           | 0         | 1                 | 9         |
| APS 4        | 0         | 0         | 0             | 0           | 0         | 0                 | 0         |
| APS 3        | 0         | 0         | 0             | 0           | 0         | 0                 | 0         |
| APS 2        | 0         | 0         | 0             | 0           | 0         | 0                 | 0         |
| APS 1        | 0         | 0         | 0             | 0           | 0         | 0                 | 0         |
| Other        | 2         | 0         | 2             | 0           | 0         | 0                 | 2         |
| <b>Total</b> | <b>56</b> | <b>14</b> | <b>70</b>     | <b>10</b>   | <b>1</b>  | <b>11</b>         | <b>81</b> |

**Notes:**

The figures in Table 4.12 include:

1. headcount figures of Cancer Australia staff as at 30 June 2026
2. staff on leave and secondment
3. staff acting at a higher level, for any period as at 30 June 2026 (that is, these staff are listed against their higher duties classification).

They exclude the Cancer Australia CEO and Advisory Council members and chair, who are appointed under the Cancer Australia Act.

**Table 4.13: Australian Public Service Act employment type by location current report period (2025–26)**

|                      | Ongoing   | Non-ongoing | Total     |
|----------------------|-----------|-------------|-----------|
| NSW                  | 42        | 6           | 48        |
| Qld                  | 0         | 0           | 0         |
| SA                   | 0         | 0           | 0         |
| Tas                  | 1         | 1           | 2         |
| Vic                  | 2         | 0           | 2         |
| WA                   | 0         | 0           | 0         |
| ACT                  | 24        | 4           | 28        |
| NT                   | 0         | 0           | 0         |
| External territories | 0         | 0           | 0         |
| Overseas             | 1         | 0           | 1         |
| <b>Total</b>         | <b>70</b> | <b>11</b>   | <b>81</b> |

**Notes:**

The figures in Table 4.13 include:

1. headcount figures of Cancer Australia staff as at 30 June 2026
2. staff on leave and secondment
3. staff acting at a higher level, for any period as at 30 June 2026 (that is, these staff are listed against their higher duties classification).

They exclude the Cancer Australia CEO and Advisory Council members and chair, who are appointed under the Cancer Australia Act.

**Table 4.14: Australian Public Service Act Indigenous employment current report period (2025–26)**

|              | Total    |
|--------------|----------|
| Ongoing      | 1        |
| Non-ongoing  | 0        |
| <b>Total</b> | <b>1</b> |

**Notes:**

The figures in Table 4.14 include:

1. headcount figures of Cancer Australia staff as at 30 June 2026
2. staff on leave and secondment.
3. staff acting at a higher level, for any period as at 30 June 2026 (that is, these staff are listed against their higher duties classification).

They exclude the Cancer Australia CEO and Advisory Council members and chair, who are appointed under the Cancer Australia Act.

**Table 4.15: Australian Public Service Act employment arrangements current report period (2025–26)**

|                                                 | SES      | Non-SES   | Total     |
|-------------------------------------------------|----------|-----------|-----------|
| Cancer Australia Enterprise Agreement 2024–2027 | 0        | 78        | 78        |
| SES determination                               | 3        | 0         | 3         |
| <b>Total</b>                                    | <b>3</b> | <b>78</b> | <b>81</b> |

**Table 4.16: Australian Public Service Act employment salary ranges by classification level (minimum/maximum) current report period (2025–26)**

|                              | Minimum salary  | Maximum salary   |
|------------------------------|-----------------|------------------|
| SES 3                        | \$0             | \$0              |
| SES 2                        | \$275,337       | \$330,543        |
| SES 1                        | \$228,205       | \$243,746        |
| EL 2                         | \$145,858       | \$172,685        |
| EL 1                         | \$122,250       | \$139,430        |
| APS 6                        | \$99,733        | \$112,233        |
| APS 5                        | \$90,178        | \$96,829         |
| APS 4                        | \$82,909        | \$87,604         |
| APS 3                        | \$73,180        | \$81,115         |
| APS 2                        | \$63,324        | \$69,103         |
| APS 1                        | \$57,497        | \$60,947         |
| Other                        | \$133,947       | \$149,887        |
| <b>Minimum/maximum range</b> | <b>\$57,497</b> | <b>\$330,543</b> |

**Table 4.17:** Australian Public Service Act employment performance pay by classification level  
current report period (2025–26)

|              | Number of<br>employees<br>receiving<br>performance pay | Aggregated<br>(sum total) of<br>all payments<br>made | Average of<br>all payments<br>made | Minimum<br>payment<br>made to<br>employees | Maximum<br>payment<br>made to<br>employees |
|--------------|--------------------------------------------------------|------------------------------------------------------|------------------------------------|--------------------------------------------|--------------------------------------------|
| SES 3        | 0                                                      | 0                                                    | 0                                  | 0                                          | 0                                          |
| SES 2        | 0                                                      | 0                                                    | 0                                  | 0                                          | 0                                          |
| SES 1        | 0                                                      | 0                                                    | 0                                  | 0                                          | 0                                          |
| EL 2         | 0                                                      | 0                                                    | 0                                  | 0                                          | 0                                          |
| EL 1         | 0                                                      | 0                                                    | 0                                  | 0                                          | 0                                          |
| APS 6        | 0                                                      | 0                                                    | 0                                  | 0                                          | 0                                          |
| APS 5        | 0                                                      | 0                                                    | 0                                  | 0                                          | 0                                          |
| APS 4        | 0                                                      | 0                                                    | 0                                  | 0                                          | 0                                          |
| APS 3        | 0                                                      | 0                                                    | 0                                  | 0                                          | 0                                          |
| APS 2        | 0                                                      | 0                                                    | 0                                  | 0                                          | 0                                          |
| APS 1        | 0                                                      | 0                                                    | 0                                  | 0                                          | 0                                          |
| Other        | 0                                                      | 0                                                    | 0                                  | 0                                          | 0                                          |
| <b>Total</b> | <b>0</b>                                               | <b>0</b>                                             | <b>0</b>                           | <b>0</b>                                   | <b>0</b>                                   |

**Performance pay:** No member of Cancer Australia’s staff was employed under performance-based remuneration conditions in 2025–26.

Tables 4.18 to 4.27 provide information relating to the distribution and classification of Cancer Australia staff as at 30 June 2025 for the 2024–25 financial year.

**Table 4.18: All ongoing employees previous report period (2024–25)**

|                      | Man/male  |           |           | Woman/female |           |           | Non-binary |           |          | Prefers not to answer |           |          | Uses a different term |           |          | Total     |
|----------------------|-----------|-----------|-----------|--------------|-----------|-----------|------------|-----------|----------|-----------------------|-----------|----------|-----------------------|-----------|----------|-----------|
|                      | Full time | Part time | Total     | Full time    | Part time | Total     | Full time  | Part time | Total    | Full time             | Part time | Total    | Full time             | Part time | Total    |           |
| NSW                  | 8         | 1         | 9         | 36           | 6         | 42        | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 51        |
| Qld                  | 0         | 0         | 0         | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| SA                   | 0         | 0         | 0         | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| Tas                  | 0         | 0         | 0         | 1            | 0         | 1         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 1         |
| Vic                  | 0         | 0         | 0         | 2            | 0         | 2         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 2         |
| WA                   | 0         | 0         | 0         | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| ACT                  | 5         | 1         | 6         | 7            | 4         | 11        | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 17        |
| NT                   | 0         | 0         | 0         | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| External territories | 0         | 0         | 0         | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| Overseas             | 0         | 0         | 0         | 1            | 1         | 2         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 2         |
| <b>Total</b>         | <b>13</b> | <b>2</b>  | <b>15</b> | <b>47</b>    | <b>11</b> | <b>58</b> | <b>0</b>   | <b>0</b>  | <b>0</b> | <b>0</b>              | <b>0</b>  | <b>0</b> | <b>0</b>              | <b>0</b>  | <b>0</b> | <b>73</b> |

**Notes:**

The figures in Table 4.18 include:

1. headcount figures of Cancer Australia staff as at 30 June 2025
  2. staff on leave and secondment
  3. staff acting at a higher level, for any period as at 30 June 2025 (that is, these staff are listed against their higher duties classification).
- They exclude the Cancer Australia CEO and Advisory Council members and chair, who are appointed under the Cancer Australia Act.

**Table 4.19: All non-ongoing employees previous report period (2024–25)**

|                      | Man/male  |           |          | Woman/female |           |           | Non-binary |           |          | Prefers not to answer |           |          | Uses a different term |           |          | Total     |
|----------------------|-----------|-----------|----------|--------------|-----------|-----------|------------|-----------|----------|-----------------------|-----------|----------|-----------------------|-----------|----------|-----------|
|                      | Full time | Part time | Total    | Full time    | Part time | Total     | Full time  | Part time | Total    | Full time             | Part time | Total    | Full time             | Part time | Total    |           |
| NSW                  | 0         | 0         | 0        | 3            | 1         | 4         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 4         |
| Qld                  | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| SA                   | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| Tas                  | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| Vic                  | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| WA                   | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| ACT                  | 1         | 0         | 1        | 4            | 2         | 6         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 7         |
| NT                   | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| External territories | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| Overseas             | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| <b>Total</b>         | <b>1</b>  | <b>0</b>  | <b>1</b> | <b>7</b>     | <b>3</b>  | <b>10</b> | <b>0</b>   | <b>0</b>  | <b>0</b> | <b>0</b>              | <b>0</b>  | <b>0</b> | <b>0</b>              | <b>0</b>  | <b>0</b> | <b>11</b> |

**Notes:**

The figures in Table 4.19 include:

1. headcount figures of Cancer Australia staff as at 30 June 2025
  2. staff on leave and secondment
  3. staff acting at a higher level, for any period as at 30 June 2025 (that is, these staff are listed against their higher duties classification).
- They exclude the Cancer Australia CEO and Advisory Council members and chair, who are appointed under the Cancer Australia Act.

**Table 4.20: Australian Public Service Act ongoing employees previous report period (2024–25)**

|              | Man/male  |           |           | Woman/female |           |           | Non-binary |           |          | Prefers not to answer |           |          | Uses a different term |           |          | Total     |
|--------------|-----------|-----------|-----------|--------------|-----------|-----------|------------|-----------|----------|-----------------------|-----------|----------|-----------------------|-----------|----------|-----------|
|              | Full time | Part time | Total     | Full time    | Part time | Total     | Full time  | Part time | Total    | Full time             | Part time | Total    | Full time             | Part time | Total    |           |
| SES 3        | 0         | 0         | 0         | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| SES 2        | 0         | 0         | 0         | 1            | 0         | 1         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 1         |
| SES 1        | 2         | 0         | 2         | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 2         |
| EL 2         | 2         | 0         | 2         | 8            | 0         | 8         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 10        |
| EL 1         | 5         | 1         | 6         | 14           | 4         | 18        | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 24        |
| APS 6        | 3         | 0         | 3         | 20           | 5         | 25        | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 28        |
| APS 5        | 1         | 1         | 2         | 2            | 1         | 3         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 5         |
| APS 4        | 0         | 0         | 0         | 1            | 0         | 1         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 1         |
| APS 3        | 0         | 0         | 0         | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| APS 2        | 0         | 0         | 0         | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| APS 1        | 0         | 0         | 0         | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| Other        | 0         | 0         | 0         | 1            | 1         | 2         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 2         |
| <b>Total</b> | <b>13</b> | <b>2</b>  | <b>15</b> | <b>47</b>    | <b>11</b> | <b>58</b> | <b>0</b>   | <b>0</b>  | <b>0</b> | <b>0</b>              | <b>0</b>  | <b>0</b> | <b>0</b>              | <b>0</b>  | <b>0</b> | <b>73</b> |

**Notes:**

The figures in Table 4.20 include:

1. headcount figures of Cancer Australia staff as at 30 June 2025
2. staff on leave and secondment
3. staff acting at a higher level, for any period as at 30 June 2025 (that is, these staff are listed against their higher duties classification).

They exclude the Cancer Australia CEO and Advisory Council members and chair, who are appointed under the Cancer Australia Act.

**Table 4.21: Australian Public Service Act non-ongoing employees previous report period (2024–25)**

|              | Man/male  |           |          | Woman/female |           |           | Non-binary |           |          | Prefers not to answer |           |          | Uses a different term |           |          | Total     |
|--------------|-----------|-----------|----------|--------------|-----------|-----------|------------|-----------|----------|-----------------------|-----------|----------|-----------------------|-----------|----------|-----------|
|              | Full time | Part time | Total    | Full time    | Part time | Total     | Full time  | Part time | Total    | Full time             | Part time | Total    | Full time             | Part time | Total    |           |
| SES 3        | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| SES 2        | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| SES 1        | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| EL 2         | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| EL 1         | 0         | 0         | 0        | 1            | 1         | 2         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 2         |
| APS 6        | 1         | 0         | 1        | 3            | 1         | 4         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 5         |
| APS 5        | 0         | 0         | 0        | 3            | 1         | 4         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 4         |
| APS 4        | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| APS 3        | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| APS 2        | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| APS 1        | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| Other        | 0         | 0         | 0        | 0            | 0         | 0         | 0          | 0         | 0        | 0                     | 0         | 0        | 0                     | 0         | 0        | 0         |
| <b>Total</b> | <b>1</b>  | <b>0</b>  | <b>1</b> | <b>7</b>     | <b>3</b>  | <b>10</b> | <b>0</b>   | <b>0</b>  | <b>0</b> | <b>0</b>              | <b>0</b>  | <b>0</b> | <b>0</b>              | <b>0</b>  | <b>0</b> | <b>11</b> |

**Notes:**

The figures in Table 4.21 include:

1. headcount figures of Cancer Australia staff as at 30 June 2025
2. staff on leave and secondment
3. staff acting at a higher level, for any period as at 30 June 2025 (that is, these staff are listed against their higher duties classification).

They exclude the Cancer Australia CEO and Advisory Council members and chair, who are appointed under the Cancer Australia Act.

**Table 4.22: Australian Public Service Act employees by full time and part time status previous report period (2024–25)**

|              | Ongoing   |           |               | Non-ongoing |           |                   | Total     |
|--------------|-----------|-----------|---------------|-------------|-----------|-------------------|-----------|
|              | Full time | Part time | Total ongoing | Full time   | Part time | Total non-ongoing |           |
| SES 3        | 0         | 0         | 0             | 0           | 0         | 0                 | 0         |
| SES 2        | 1         | 0         | 1             | 0           | 0         | 0                 | 1         |
| SES 1        | 2         | 0         | 2             | 0           | 0         | 0                 | 2         |
| EL 2         | 10        | 0         | 10            | 0           | 0         | 0                 | 10        |
| EL 1         | 19        | 5         | 24            | 1           | 1         | 2                 | 26        |
| APS 6        | 23        | 5         | 28            | 4           | 1         | 5                 | 33        |
| APS 5        | 3         | 2         | 5             | 3           | 1         | 4                 | 9         |
| APS 4        | 1         | 0         | 1             | 0           | 0         | 0                 | 1         |
| APS 3        | 0         | 0         | 0             | 0           | 0         | 0                 | 0         |
| APS 2        | 0         | 0         | 0             | 0           | 0         | 0                 | 0         |
| APS 1        | 0         | 0         | 0             | 0           | 0         | 0                 | 0         |
| Other        | 1         | 1         | 2             | 0           | 0         | 0                 | 2         |
| <b>Total</b> | <b>60</b> | <b>13</b> | <b>73</b>     | <b>8</b>    | <b>3</b>  | <b>11</b>         | <b>84</b> |

**Notes:**

The figures in Table 4.22 include:

1. headcount figures of Cancer Australia staff as at 30 June 2025
2. staff on leave and secondment
3. staff acting at a higher level, for any period as at 30 June 2025 (that is, these staff are listed against their higher duties classification).

They exclude the Cancer Australia CEO and Advisory Council members and chair, who are appointed under the Cancer Australia Act.

**Table 4.23: Australian Public Service Act employment type by location previous report period (2024–25)**

|                      | Ongoing   | Non-ongoing | Total     |
|----------------------|-----------|-------------|-----------|
| NSW                  | 51        | 4           | 55        |
| Qld                  | 0         | 0           | 0         |
| SA                   | 0         | 0           | 0         |
| Tas                  | 1         | 0           | 1         |
| Vic                  | 2         | 0           | 2         |
| WA                   | 0         | 0           | 0         |
| ACT                  | 17        | 7           | 24        |
| NT                   | 0         | 0           | 0         |
| External territories | 0         | 0           | 0         |
| Overseas             | 2         | 0           | 2         |
| <b>Total</b>         | <b>73</b> | <b>11</b>   | <b>84</b> |

**Notes:**

The figures in Table 4.23 include:

1. headcount figures of Cancer Australia staff as at 30 June 2025
2. staff on leave and secondment
3. staff acting at a higher level, for any period as at 30 June 2025 (that is, these staff are listed against their higher duties classification).

They exclude the Cancer Australia CEO and Advisory Council members and chair, who are appointed under the Cancer Australia Act.

**Table 4.24: Australian Public Service Act Indigenous employment previous report period (2024–25)**

|              | Total    |
|--------------|----------|
| Ongoing      | 0        |
| Non-ongoing  | 1        |
| <b>Total</b> | <b>1</b> |

**Notes:**

The figures in Table 4.24 include:

1. headcount figures of Cancer Australia staff as at 30 June 2025
2. staff on leave and secondment
3. staff acting at a higher level, for any period as at 30 June 2025 (that is, these staff are listed against their higher duties classification).

They exclude the Cancer Australia CEO and Advisory Council members and chair, who are appointed under the Cancer Australia Act.

**Table 4.25:** Australian Public Service Act employment arrangements previous report period (2024–25)

|                                                 | SES      | Non-SES   | Total     |
|-------------------------------------------------|----------|-----------|-----------|
| Cancer Australia Enterprise Agreement 2024–2027 | 0        | 81        | 81        |
| SES determination                               | 3        | 0         | 3         |
| <b>Total</b>                                    | <b>3</b> | <b>81</b> | <b>84</b> |

**Table 4.26:** Australian Public Service Act employment salary ranges by classification level (minimum/maximum) previous report period (2024–25)

|                              | Minimum salary  | Maximum salary   |
|------------------------------|-----------------|------------------|
| SES 3                        | \$0             | \$0              |
| SES 2                        | \$265,257       | \$310,198        |
| SES 1                        | \$219,851       | \$234,823        |
| EL 2                         | \$141,062       | \$167,007        |
| EL 1                         | \$118,230       | \$134,845        |
| APS 6                        | \$96,211        | \$108,543        |
| APS 5                        | \$87,213        | \$92,051         |
| APS 4                        | \$80,183        | \$84,723         |
| APS 3                        | \$70,774        | \$78,448         |
| APS 2                        | \$61,242        | \$66,831         |
| APS 1                        | \$54,516        | \$58,849         |
| Other                        | \$129,543       | \$144,958        |
| <b>Minimum/maximum range</b> | <b>\$54,516</b> | <b>\$310,198</b> |

**Table 4.27:** Australian Public Service Act employment performance pay by classification level previous report period (2024–25)

|              | Number of employees receiving performance pay | Aggregated (sum total) of all payments made | Average of all payments made | Minimum payment made to employees | Maximum payment made to employees |
|--------------|-----------------------------------------------|---------------------------------------------|------------------------------|-----------------------------------|-----------------------------------|
| SES 3        | 0                                             | 0                                           | 0                            | 0                                 | 0                                 |
| SES 2        | 0                                             | 0                                           | 0                            | 0                                 | 0                                 |
| SES 1        | 0                                             | 0                                           | 0                            | 0                                 | 0                                 |
| EL 2         | 0                                             | 0                                           | 0                            | 0                                 | 0                                 |
| EL 1         | 0                                             | 0                                           | 0                            | 0                                 | 0                                 |
| APS 6        | 0                                             | 0                                           | 0                            | 0                                 | 0                                 |
| APS 5        | 0                                             | 0                                           | 0                            | 0                                 | 0                                 |
| APS 4        | 0                                             | 0                                           | 0                            | 0                                 | 0                                 |
| APS 3        | 0                                             | 0                                           | 0                            | 0                                 | 0                                 |
| APS 2        | 0                                             | 0                                           | 0                            | 0                                 | 0                                 |
| APS 1        | 0                                             | 0                                           | 0                            | 0                                 | 0                                 |
| Other        | 0                                             | 0                                           | 0                            | 0                                 | 0                                 |
| <b>Total</b> | <b>0</b>                                      | <b>0</b>                                    | <b>0</b>                     | <b>0</b>                          | <b>0</b>                          |

**Performance pay:** No member of Cancer Australia's staff was employed under performance-based remuneration conditions in 2024–25.

Remuneration for Senior Executive Service officers

The CEO is a full-time public office holder, as defined in the *Remuneration Tribunal Act 1973* (Cth). The position’s remuneration is set by the Minister for Health and Ageing within the salary determination set by the Remuneration Tribunal.

SES officers employed under the Public Service Act have conditions set out in the Cancer Australia SES Handbook. Remuneration is determined by the CEO, in accordance with remuneration guidelines promulgated by the Department of Health, Disability and Ageing.

Key management personnel are those people who have authority and responsibility for planning, directing, and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity.

Cancer Australia has determined the key management personnel to be the CEO, Deputy CEO, SES officers, Chief Operating Officer (COO) and Chief Financial Officer (CFO), and Medical Director.

**Table 4.28: Details of accountable authority during the reporting period (2025–26)**

|                                  |                               | Period as the accountable authority or member within the reporting period |                                   |
|----------------------------------|-------------------------------|---------------------------------------------------------------------------|-----------------------------------|
| Name                             | Position title/position held  | Start date (1 July 2025 or after)                                         | End date (30 June 2026 or before) |
| Professor Dorothy Keefe, PSM, MD | Chief Executive Officer (CEO) | 1 July 2025                                                               | 30 June 2026                      |

**Table 4.29: Information about remuneration for key management personnel (2025–26)**

| Name            | Position title                                         | Short-term benefits |         |                               | Post-employment benefits | Other long-term benefits     |                    | Termination benefits     | Total remuneration |
|-----------------|--------------------------------------------------------|---------------------|---------|-------------------------------|--------------------------|------------------------------|--------------------|--------------------------|--------------------|
|                 |                                                        | Base salary         | Bonuses | Other benefits and allowances |                          | Superannuation contributions | Long service leave | Other long-term benefits |                    |
| Keefe, Dorothy  | Chief Executive Officer                                | 464,675             | –       | 36,086                        | 54,343                   | –                            | 10,783             | –                        | 565,887            |
| Howlett, Claire | Deputy CEO                                             | 342,935             | –       | –                             | 60,636                   | –                            | 7,955              | –                        | 411,526            |
| McEwan, Steven  | Head Corporate Operations/COO/CFO                      | 96,695              | –       | –                             | 12,204                   | –                            | 1,799              | –                        | 110,698            |
| Milch, Vivienne | Medical Director                                       | 237,266             | –       | 25,179                        | 35,884                   | –                            | 5,866              | –                        | 304,195            |
| Meredyth, David | Head, Partnerships and Cancer Equity                   | 220,992             | –       | 23,173                        | 44,062                   | –                            | 5,676              | –                        | 293,903            |
| Lambert, Adam   | Head Evidence, Priority Initiatives and Communications | 234,772             | –       | 21,566                        | 40,308                   | –                            | 5,492              | –                        | 302,138            |
| Cox, Raylene    | Acting Head, Partnerships and Cancer Equity            | 41,802              | –       | 1,860                         | 4,325                    | –                            | 741                | –                        | 48,728             |
| Wiegold, Elmer  | Head Corporate Operations/COO/CFO                      | 130,739             | –       | –                             | 24,645                   | –                            | 3,141              | –                        | 158,525            |

**Table 4.30: Information about remuneration for senior executives (2025–26)**

| Total remuneration bands | Number of senior executives | Short-term benefits |                 |                                       | Post-employment benefits             |                            | Other long-term benefits         |                              | Termination benefits | Total remuneration |
|--------------------------|-----------------------------|---------------------|-----------------|---------------------------------------|--------------------------------------|----------------------------|----------------------------------|------------------------------|----------------------|--------------------|
|                          |                             | Average base salary | Average bonuses | Average other benefits and allowances | Average superannuation contributions | Average long service leave | Average other long-term benefits | Average termination benefits |                      |                    |
| \$0 – \$220,000          | 0                           | 0                   | 0               | 0                                     | 0                                    | 0                          | 0                                | 0                            | 0                    | 0                  |
| \$220,001 – \$245,000    | 0                           | 0                   | 0               | 0                                     | 0                                    | 0                          | 0                                | 0                            | 0                    | 0                  |
| \$245,001 – \$270,000    | 0                           | 0                   | 0               | 0                                     | 0                                    | 0                          | 0                                | 0                            | 0                    | 0                  |
| \$270,001 – \$295,000    | 0                           | 0                   | 0               | 0                                     | 0                                    | 0                          | 0                                | 0                            | 0                    | 0                  |
| \$295,001 – \$320,000    | 0                           | 0                   | 0               | 0                                     | 0                                    | 0                          | 0                                | 0                            | 0                    | 0                  |
| \$320,001 – \$345,000    | 0                           | 0                   | 0               | 0                                     | 0                                    | 0                          | 0                                | 0                            | 0                    | 0                  |
| \$345,001 – \$370,000    | 0                           | 0                   | 0               | 0                                     | 0                                    | 0                          | 0                                | 0                            | 0                    | 0                  |
| \$370,001 – \$395,000    | 0                           | 0                   | 0               | 0                                     | 0                                    | 0                          | 0                                | 0                            | 0                    | 0                  |
| \$395,001 – \$420,000    | 0                           | 0                   | 0               | 0                                     | 0                                    | 0                          | 0                                | 0                            | 0                    | 0                  |
| \$420,001 – \$445,000    | 0                           | 0                   | 0               | 0                                     | 0                                    | 0                          | 0                                | 0                            | 0                    | 0                  |
| \$445,001 – \$470,000    | 0                           | 0                   | 0               | 0                                     | 0                                    | 0                          | 0                                | 0                            | 0                    | 0                  |
| \$470,001 – \$495,000    | 0                           | 0                   | 0               | 0                                     | 0                                    | 0                          | 0                                | 0                            | 0                    | 0                  |

**Table 4.31: Information about remuneration for other highly paid staff (2025–26)**

| Total remuneration bands | Number of other highly paid staff | Short-term benefits |                 |                                       | Post-employment benefits             | Other long-term benefits   |                                  | Termination benefits         | Total remuneration         |
|--------------------------|-----------------------------------|---------------------|-----------------|---------------------------------------|--------------------------------------|----------------------------|----------------------------------|------------------------------|----------------------------|
|                          |                                   | Average base salary | Average bonuses | Average other benefits and allowances | Average superannuation contributions | Average long service leave | Average other long-term benefits | Average termination benefits | Average total remuneration |
| \$260,000 – \$270,000    | 0                                 | 0                   | 0               | 0                                     | 0                                    | 0                          | 0                                | 0                            | 0                          |
| \$270,001 – \$295,000    | 0                                 | 0                   | 0               | 0                                     | 0                                    | 0                          | 0                                | 0                            | 0                          |
| \$295,001 – \$320,000    | 0                                 | 0                   | 0               | 0                                     | 0                                    | 0                          | 0                                | 0                            | 0                          |
| \$320,001 – \$345,000    | 0                                 | 0                   | 0               | 0                                     | 0                                    | 0                          | 0                                | 0                            | 0                          |
| \$345,001 – \$370,000    | 0                                 | 0                   | 0               | 0                                     | 0                                    | 0                          | 0                                | 0                            | 0                          |
| \$370,001 – \$395,000    | 0                                 | 0                   | 0               | 0                                     | 0                                    | 0                          | 0                                | 0                            | 0                          |
| \$395,001 – \$420,000    | 0                                 | 0                   | 0               | 0                                     | 0                                    | 0                          | 0                                | 0                            | 0                          |
| \$420,001 – \$445,000    | 0                                 | 0                   | 0               | 0                                     | 0                                    | 0                          | 0                                | 0                            | 0                          |
| \$445,001 – \$470,000    | 0                                 | 0                   | 0               | 0                                     | 0                                    | 0                          | 0                                | 0                            | 0                          |
| \$470,001 – \$495,000    | 0                                 | 0                   | 0               | 0                                     | 0                                    | 0                          | 0                                | 0                            | 0                          |
| \$495,001 – \$520,000    | 0                                 | 0                   | 0               | 0                                     | 0                                    | 0                          | 0                                | 0                            | 0                          |
| \$520,001 – \$545,000    | 0                                 | 0                   | 0               | 0                                     | 0                                    | 0                          | 0                                | 0                            | 0                          |

A decorative background consisting of a grid of small orange squares arranged in 5 rows and 5 columns on a dark blue-grey background.

5

# Appendices



# Appendix A: Report on financial performance

**Table A.1: Entity Resource Statement subset current reporting period (2025–26)**

|                                                                 | Current<br>available<br>appropriation<br>(a) | Payments<br>made<br>(b) | Balance<br>remaining<br>(a)-(b) |
|-----------------------------------------------------------------|----------------------------------------------|-------------------------|---------------------------------|
|                                                                 | \$'000                                       | \$'000                  | \$'000                          |
| <b>Departmental</b>                                             |                                              |                         |                                 |
| Annual appropriations – ordinary annual services                | 13,223                                       | 9,697                   | 3,526                           |
| Prior year appropriations available – ordinary annual services  | 4,213                                        | 4,213                   | 0                               |
| Departmental capital budget                                     | 85                                           | 85                      | 0                               |
| s74 retained revenue receipts                                   | 3,713                                        | 3,555                   | 158                             |
| <b>Total departmental annual appropriations</b>                 | <b>21,234</b>                                | <b>17,550</b>           | <b>3,684</b>                    |
| <b>Total departmental resourcing (A)</b>                        | <b>21,234</b>                                | <b>17,550</b>           | <b>3,684</b>                    |
| <b>Administered</b>                                             |                                              |                         |                                 |
| Annual appropriations – ordinary annual services                | 34,379                                       | 32,910                  | 1,469                           |
| Prior year appropriations available – ordinary annual services  | 4,936                                        | 4,936                   | 0                               |
| Total administered annual appropriations                        | 39,315                                       | 37,846                  | 1,469                           |
| <b>Total administered resourcing (B)</b>                        | <b>39,315</b>                                | <b>37,846</b>           | <b>1,469</b>                    |
| <b>Total resourcing and payments for Cancer Australia (A+B)</b> | <b>60,549</b>                                | <b>55,396</b>           | <b>5,153</b>                    |

**Table A.2: Expenses for outcomes**

|                                                                      | Budget*<br>2025–26<br>\$'000 | Actual<br>expenses<br>2025–26<br>\$'000 | Variation<br>2025–26<br>\$'000 |
|----------------------------------------------------------------------|------------------------------|-----------------------------------------|--------------------------------|
| Outcome 1: Improved Cancer Control                                   | (a)                          | (b)                                     | (a) – (b)                      |
| <b>Program 1.1: Improved Cancer Control</b>                          |                              |                                         |                                |
| <b>Administered expenses</b>                                         |                              |                                         |                                |
| Ordinary annual services (Appropriation Act Nos. 1)                  | 34,379                       | 34,367                                  | 12                             |
| Other services (Appropriation Act Nos. 2, 4 and 6)                   | –                            | –                                       | –                              |
| s74 External Revenue <sup>1</sup>                                    | –                            | –                                       | –                              |
| Payments to corporate entities                                       | –                            | –                                       | –                              |
| Expenses not requiring appropriation in the Budget year <sup>2</sup> | –                            | –                                       | –                              |
| <b>Administered total</b>                                            | <b>34,379</b>                | <b>34,367</b>                           | <b>12</b>                      |
| <b>Departmental expenses</b>                                         |                              |                                         |                                |
| Departmental appropriation                                           | 13,223                       | 13,223                                  | 0                              |
| s74 External Revenue <sup>1</sup>                                    | 2,286                        | 2,892                                   | (606)                          |
| Expenses not requiring appropriation in the Budget year <sup>2</sup> | 1,568                        | 1,153                                   | 415                            |
| <b>Departmental total</b>                                            | <b>17,077</b>                | <b>17,268</b>                           | <b>(191)</b>                   |
| <b>Total expenses for Program 1.1</b>                                | <b>51,456</b>                | <b>51,635</b>                           | <b>(179)</b>                   |
|                                                                      |                              |                                         |                                |
|                                                                      |                              | <b>2025–26</b>                          | <b>2024–25</b>                 |
| <b>Average Staffing level (number)</b>                               |                              | <b>75</b>                               | <b>78</b>                      |

\* Full-year budget, including any subsequent adjustment made to the 2025–26 budget at Additional Estimates.

1. Estimated expenses incurred in relation to receipts retained under section 74 of the PGPA Act 2013.
2. Expenses not requiring appropriation in the Budget year are made up of depreciation expenses, amortisation expenses, make good expenses and audit fees.

# Appendix B: Audited financial statements

## Independent auditor's report



### INDEPENDENT AUDITOR'S REPORT

#### To the Minister for Health and Ageing

#### Opinion

In my opinion, the financial statements of Cancer Australia (the Entity) for the year ended 30 June 2026:

- (a) comply with Australian Accounting Standards – Simplified Disclosures and the *Public Governance, Performance and Accountability (Financial Reporting) Rule 2015*; and
- (b) present fairly the financial positions of the Entity as at 30 June 2026 and their financial performance and cash flows for the year then ended.

The financial statements of the Entity, which I have audited, comprise the following as at 30 June 2026 and for the year then ended:

- Statement by the Accountable Authority and Chief Financial Officer;
- Statement of Comprehensive Income;
- Statement of Financial Position;
- Statement of Changes in Equity;
- Cash Flow Statement;
- Administered Schedule of Comprehensive Income;
- Administered Schedule of Assets and Liabilities;
- Administered Reconciliation Schedule;
- Administered Cash Flow Statement; and
- Notes to and forming part of the financial statements, comprising material accounting policy information and other explanatory information.

#### Basis for opinion

I conducted my audit in accordance with the Australian National Audit Office Auditing Standards, which incorporate the Australian Auditing Standards. My responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of my report. I am independent of the Entity in accordance with the relevant ethical requirements for financial statement audits conducted by the Auditor-General and their delegates. These include the relevant independence requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) to the extent that they are not in conflict with the *Auditor-General Act 1997*. I have also fulfilled my other responsibilities in accordance with the Code. I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my opinion.

#### Accountable Authority's responsibility for the financial statements

As the Accountable Authority of the Entity, the Chief Executive Officer is responsible under the *Public Governance, Performance and Accountability Act 2013* (the Act) for the preparation and fair presentation of annual financial statements that comply with Australian Accounting Standards – Simplified Disclosures and the rules made under the Act. The Chief Executive Officer is also responsible for such internal control as the Chief Executive Officer determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Chief Executive Officer is responsible for assessing the ability of the Entity to continue as a going concern, taking into account whether the entities' operations will cease as a result of an administrative restructure or for any other reason. The Chief Executive Officer is also responsible for

GPO Box 707, Canberra ACT 2601  
38 Sydney Avenue, Forrest ACT 2603  
Phone (02) 6203 7300

disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the assessment indicates that it is not appropriate.

#### **Auditor's responsibilities for the audit of the financial statements**

My objective is to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes my opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian National Audit Office Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit in accordance with the Australian National Audit Office Auditing Standards, I exercise professional judgement and maintain professional scepticism throughout the audit. I also:

- identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for my opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control;
- evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Accountable Authority;
- conclude on the appropriateness of the Accountable Authority's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If I conclude that a material uncertainty exists, I am required to draw attention in my auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify my opinion. My conclusions are based on the audit evidence obtained up to the date of my auditor's report. However, future events or conditions may cause the Entity to cease to continue as a going concern; and
- evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

I communicate with the Accountable Authority regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that I identify during my audit.

Australian National Audit Office



Michael Bryant

Senior Director

Delegate of the Auditor-General

Canberra

3 September 2026

**Financial statements table of contents**


|                                                       |    |
|-------------------------------------------------------|----|
| Independent auditor’s report                          | 74 |
| Statement of Comprehensive Income                     | 78 |
| Statement of Financial Position                       | 79 |
| Statement of Changes in Equity                        | 81 |
| Cash Flow Statement                                   | 82 |
| Administered Schedule of Comprehensive Income         | 84 |
| Administered Schedule of Assets and Liabilities       | 85 |
| Administered Reconciliation Schedule                  | 86 |
| Administered Cash Flow Statement                      | 87 |
| Notes to and forming part of the financial statements | 88 |

**Statement by the Accountable Authority and Chief Financial Officer**  
for the period ended 30 June 2026

In our opinion, the attached financial statements for the year ended 30 June 2026 comply with subsection 42(2) of the *Public Governance, Performance and Accountability Act 2013* (PGPA Act), and are based on properly maintained financial records as per subsection 41(2) of the PGPA Act.

In our opinion, at the date of this statement, there are reasonable grounds to believe that Cancer Australia will be able to pay its debts as and when they fall due.


Signed.....



Professor Dorothy Keefe PSM  
Accountable Authority / CEO

2 September 2026

Signed.....



Steven McEwan  
Chief Financial Officer

2 September 2026

# Statement of Comprehensive Income

for the period ended 30 June 2026

|                                                                          | Notes | 2026<br>\$        | 2025<br>\$        | Original Budget <sup>1</sup><br>\$ |
|--------------------------------------------------------------------------|-------|-------------------|-------------------|------------------------------------|
| <b>NET COST OF SERVICES</b>                                              |       |                   |                   |                                    |
| <b>Expenses</b>                                                          |       |                   |                   |                                    |
| Employee benefits                                                        | 3A    | 12,181,090        | 11,953,205        | 11,077,000                         |
| Suppliers                                                                | 3B    | 2,389,422         | 2,755,293         | 2,355,000                          |
| Grants                                                                   | 3C    | 1,583,597         | 1,548,750         | 1,584,000                          |
| Depreciation and amortisation                                            | 7     | 1,091,785         | 1,031,342         | 995,000                            |
| Finance costs                                                            |       | 4,176             | 4,117             | 4,000                              |
| Interest on right-of-use asset                                           |       | 16,582            | 24,382            | 17,000                             |
| Losses from asset disposals                                              |       | 1,443             | -                 | -                                  |
| <b>Total expenses</b>                                                    |       | <b>17,268,095</b> | <b>17,317,089</b> | <b>16,032,000</b>                  |
| <b>Own-source income</b>                                                 |       |                   |                   |                                    |
| <b>Own-source revenue</b>                                                |       |                   |                   |                                    |
| Rendering of services                                                    | 4A    | 3,466,178         | 3,583,526         | 2,512,000                          |
| Other revenue                                                            | 4B    | 63,774            | 127,072           | 73,000                             |
| <b>Total own-source revenue</b>                                          |       | <b>3,529,952</b>  | <b>3,710,598</b>  | <b>2,585,000</b>                   |
| <b>Total own-source income</b>                                           |       | <b>3,529,952</b>  | <b>3,710,598</b>  | <b>2,585,000</b>                   |
| <b>Net cost of services</b>                                              |       | <b>13,738,143</b> | <b>13,606,491</b> | <b>13,447,000</b>                  |
| Revenue from Government                                                  | 4C    | 13,223,000        | 14,109,000        | 13,371,000                         |
| <b>Surplus/(Deficit) on continuing operations</b>                        |       | <b>(515,143)</b>  | <b>502,509</b>    | <b>(76,000)</b>                    |
| <b>OTHER COMPREHENSIVE INCOME</b>                                        |       |                   |                   |                                    |
| Items not subject to subsequent reclassification to net cost of services |       |                   |                   |                                    |
| Changes in asset revaluation reserve                                     |       | 111,527           | -                 | -                                  |
| <b>Total other comprehensive income</b>                                  |       | <b>111,527</b>    | <b>-</b>          | <b>-</b>                           |
| <b>Total comprehensive income/(loss)</b>                                 |       | <b>(403,616)</b>  | <b>502,509</b>    | <b>(76,000)</b>                    |

The above statement should be read in conjunction with the accompanying notes.

<sup>1</sup> Budget reported in the 2025-26 Portfolio Budget Statements published in May 2025.

## Budget Variance Commentary

Explanations are only provided where the variance is greater than 10% of the Original Budget. If the variance is greater than 10%, but small in the overall context of the financial statements, judgement was used to determine if an explanation would be useful in analysing Cancer Australia's performance.

### Rendering of services

Rendering of services revenue was \$0.96M higher than budget because of additional Memorandum of Understanding (MOU) funding received including: 1. Kulay Kalingka Study \$0.5M. 2. Contract variation for the Engagement of Medical Officer by the Department \$0.1M and 3. Prostate Cancer Screening Economic Evaluation \$0.3M. Additionally an amount was received from the Cancer Institute of NSW for the Cancer Institute eviQ Program \$0.1M. The MOUs or extensions were executed after the 25-26 PBS figures were finalised.

### Other Revenue

The variance relates to lower than expected fundraising revenue.

### Total Comprehensive Loss

The comprehensive loss for the period ending June 2026 was \$0.5M. Since the 25-26 PBS figures were finalised the agency received approval for an operating loss totalling \$0.5M relating to unspent MOU funds received late in the 2024-25 financial year for the Kulay Kalingka Study.

## Statement of Financial Position

as at 30 June 2026

|                                           | Notes | 2026<br>\$       | 2025<br>\$       | Original Budget <sup>1</sup><br>\$ |
|-------------------------------------------|-------|------------------|------------------|------------------------------------|
| <b>ASSETS</b>                             |       |                  |                  |                                    |
| <b>Financial assets</b>                   |       |                  |                  |                                    |
| Cash and cash equivalents                 |       | 122,627          | 124,933          | 167,000                            |
| Trade and other receivables               | 6     | 3,913,382        | 4,287,761        | 3,063,000                          |
| <b>Total financial assets</b>             |       | <b>4,036,009</b> | <b>4,412,694</b> | <b>3,230,000</b>                   |
| <b>Non-financial assets</b>               |       |                  |                  |                                    |
| Property, plant and equipment             | 7     | 1,561,173        | 2,233,418        | 1,633,000                          |
| Intangibles                               | 7     | 1,582            | 7,544            | 12,000                             |
| Prepayments                               |       | 203,231          | 168,782          | 182,000                            |
| <b>Total non-financial assets</b>         |       | <b>1,765,986</b> | <b>2,409,744</b> | <b>1,827,000</b>                   |
| <b>Total assets</b>                       |       | <b>5,801,995</b> | <b>6,822,438</b> | <b>5,057,000</b>                   |
| <b>LIABILITIES</b>                        |       |                  |                  |                                    |
| <b>Payables</b>                           |       |                  |                  |                                    |
| Suppliers                                 | 8A    | 224,216          | 213,983          | 428,000                            |
| Other payables                            | 8B    | 473,816          | 398,186          | 15,000                             |
| <b>Total payables</b>                     |       | <b>698,032</b>   | <b>612,169</b>   | <b>443,000</b>                     |
| <b>Interest bearing liabilities</b>       |       |                  |                  |                                    |
| Leases                                    | 9     | 1,207,719        | 2,127,195        | 1,208,000                          |
| <b>Total interest bearing liabilities</b> |       | <b>1,207,719</b> | <b>2,127,195</b> | <b>1,208,000</b>                   |
| <b>Provisions</b>                         |       |                  |                  |                                    |
| Employee provisions                       | 10A   | 2,893,671        | 2,766,064        | 2,651,000                          |
| Other provisions                          | 10B   | 280,894          | 276,715          | 281,000                            |
| <b>Total provisions</b>                   |       | <b>3,174,565</b> | <b>3,042,779</b> | <b>2,932,000</b>                   |
| <b>Total liabilities</b>                  |       | <b>5,080,316</b> | <b>5,782,143</b> | <b>4,583,000</b>                   |
| <b>Net assets</b>                         |       | <b>721,679</b>   | <b>1,040,295</b> | <b>474,000</b>                     |
| <b>EQUITY</b>                             |       |                  |                  |                                    |
| Contributed equity                        |       | 1,895,160        | 1,810,160        | 1,895,000                          |
| Reserves                                  |       | 214,684          | 103,157          | 103,000                            |
| (Accumulated deficit)                     |       | (1,388,165)      | (873,022)        | (1,524,000)                        |
| <b>Total equity</b>                       |       | <b>721,679</b>   | <b>1,040,295</b> | <b>474,000</b>                     |

The above statement should be read in conjunction with the accompanying notes.

<sup>1</sup> Budget reported in the 2025-26 Portfolio Budget Statements published in May 2025.

### Budget Variance Commentary

#### Cash and Cash Equivalents

The cash and cash equivalent balance fluctuates during the year as funds are drawn down to settle suppliers.

#### Trade and other receivables

The YTD receivables balance is comprised of appropriation receivable \$3.56M and debtors \$0.27M. Debtors include staff leave liability transfers.

#### Prepayments

The budget variance relates to additional IT licences.

**Budget Variance Commentary (continued)****Suppliers and other payables**

The budget variance for suppliers relates to the timing of supplier payments. Other payables includes an accrual of \$0.4M which represents unpaid salaries and superannuation for the period from the last payroll on 17 June 2026 until the reporting date.

**Reserves**

The budget variance is due to the outcome of the asset revaluation conducted during 2025-26.

# Statement of Changes in Equity

for the period ended 30 June 2026

|                                              | 2026               | 2025               | Original Budget <sup>1</sup> |
|----------------------------------------------|--------------------|--------------------|------------------------------|
|                                              | \$                 | \$                 | \$                           |
| <b>CONTRIBUTED EQUITY</b>                    |                    |                    |                              |
| <b>Opening balance</b>                       |                    |                    |                              |
| Balance carried forward from previous period | <u>1,810,160</u>   | <u>1,725,160</u>   | <u>1,810,000</u>             |
| <b>Opening balance</b>                       | <u>1,810,160</u>   | <u>1,725,160</u>   | <u>1,810,000</u>             |
| <b>Transactions with owners</b>              |                    |                    |                              |
| <b>Contributions by owners</b>               |                    |                    |                              |
| Departmental capital budget                  | <u>85,000</u>      | <u>85,000</u>      | <u>85,000</u>                |
| <b>Total transactions with owners</b>        | <u>85,000</u>      | <u>85,000</u>      | <u>85,000</u>                |
| <b>Closing balance as at 30 June</b>         | <u>1,895,160</u>   | <u>1,810,160</u>   | <u>1,895,000</u>             |
| <b>RETAINED EARNINGS</b>                     |                    |                    |                              |
| <b>Opening balance</b>                       |                    |                    |                              |
| Balance carried forward from previous period | <u>(873,022)</u>   | <u>(1,375,531)</u> | <u>(1,448,000)</u>           |
| <b>Adjusted opening balance</b>              | <u>(873,022)</u>   | <u>(1,375,531)</u> | <u>(1,448,000)</u>           |
| <b>Comprehensive income</b>                  |                    |                    |                              |
| Surplus/(Deficit) for the period             | <u>(515,143)</u>   | <u>502,509</u>     | <u>(76,000)</u>              |
| <b>Total comprehensive income</b>            | <u>(515,143)</u>   | <u>502,509</u>     | <u>(76,000)</u>              |
| <b>Closing balance as at 30 June</b>         | <u>(1,388,165)</u> | <u>(873,022)</u>   | <u>(1,524,000)</u>           |
| <b>Asset Revaluation Reserve</b>             |                    |                    |                              |
| <b>Opening balance</b>                       |                    |                    |                              |
| Balance carried forward from previous period | <u>103,157</u>     | <u>103,157</u>     | <u>103,000</u>               |
| Other comprehensive income                   | <u>111,527</u>     | <u>-</u>           | <u>-</u>                     |
| <b>Closing balance as at 30 June</b>         | <u>214,684</u>     | <u>103,157</u>     | <u>103,000</u>               |
| <b>TOTAL EQUITY</b>                          | <u>721,679</u>     | <u>1,040,295</u>   | <u>474,000</u>               |

The above statement should be read in conjunction with the accompanying notes.

<sup>1</sup> Budget reported in the 2025-26 Portfolio Budget Statements published in May 2025.

|                                                                                                                                                                                                            |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Accounting Policy</b>                                                                                                                                                                                   |
| <b>Equity injections</b>                                                                                                                                                                                   |
| Amounts appropriated which are designated as 'equity injections' for a year (less any formal reduction) and Departmental Capital Budgets (DCB) are recognised directly in contributed equity in that year. |
| <b>Budget Variance Commentary</b>                                                                                                                                                                          |
| <b>Deficit for the period</b>                                                                                                                                                                              |
| The variance reflects the approved operating loss relating to unspent MOU funds from 2024-25.                                                                                                              |

# Cash Flow Statement

for the period ended 30 June 2026

|                                                                     | Notes | 2026<br>\$          | 2025<br>\$          | Original Budget <sup>1</sup><br>\$ |
|---------------------------------------------------------------------|-------|---------------------|---------------------|------------------------------------|
| <b>OPERATING ACTIVITIES</b>                                         |       |                     |                     |                                    |
| <b>Cash received</b>                                                |       |                     |                     |                                    |
| Appropriations                                                      |       | 13,750,000          | 12,964,973          | 13,568,000                         |
| Rendering of services                                               |       | 3,332,279           | 3,622,439           | 2,512,000                          |
| Net GST received                                                    |       | 383,990             | 615,770             | 186,000                            |
| Fundraising                                                         |       | 319                 | 56,358              | -                                  |
| <b>Total cash received</b>                                          |       | <b>17,466,588</b>   | <b>17,259,540</b>   | <b>16,266,000</b>                  |
| <b>Cash used</b>                                                    |       |                     |                     |                                    |
| Employees                                                           |       | (12,015,727)        | (11,757,516)        | (11,077,000)                       |
| Suppliers                                                           |       | (2,712,767)         | (3,120,926)         | (2,286,000)                        |
| Interest payments on lease liability                                |       | (16,582)            | (24,382)            | (17,000)                           |
| Grants                                                              |       | (1,583,597)         | (1,548,750)         | (1,584,000)                        |
| Net GST paid                                                        |       | -                   | -                   | (186,000)                          |
| <b>Total cash used</b>                                              |       | <b>(16,328,673)</b> | <b>(16,451,574)</b> | <b>(15,150,000)</b>                |
| <b>Net cash from operating activities</b>                           |       | <b>1,137,915</b>    | <b>807,966</b>      | <b>1,116,000</b>                   |
| <b>INVESTING ACTIVITIES</b>                                         |       |                     |                     |                                    |
| <b>Cash used</b>                                                    |       |                     |                     |                                    |
| Purchase of property, plant and equipment                           |       | (305,745)           | (58,434)            | (282,000)                          |
| Purchase of intangible assets                                       |       | -                   | (3,040)             | -                                  |
| <b>Total cash used</b>                                              |       | <b>(305,745)</b>    | <b>(61,474)</b>     | <b>(282,000)</b>                   |
| <b>Net cash used by investing activities</b>                        |       | <b>(305,745)</b>    | <b>(61,474)</b>     | <b>(282,000)</b>                   |
| <b>FINANCING ACTIVITIES</b>                                         |       |                     |                     |                                    |
| <b>Cash received</b>                                                |       |                     |                     |                                    |
| Departmental capital budget                                         |       | 85,000              | 85,000              | 85,000                             |
| <b>Total cash received</b>                                          |       | <b>85,000</b>       | <b>85,000</b>       | <b>85,000</b>                      |
| <b>Cash used</b>                                                    |       |                     |                     |                                    |
| Lease principal repayments                                          |       | (919,476)           | (873,591)           | (919,000)                          |
| <b>Total cash used</b>                                              |       | <b>(919,476)</b>    | <b>(873,591)</b>    | <b>(919,000)</b>                   |
| <b>Net cash used by financing activities</b>                        |       | <b>(834,476)</b>    | <b>(788,591)</b>    | <b>(834,000)</b>                   |
| <b>Net decrease in cash held</b>                                    |       | <b>(2,306)</b>      | <b>(42,099)</b>     | <b>-</b>                           |
| Cash and cash equivalents at the beginning of the reporting period  |       | 124,933             | 167,032             | 167,000                            |
| <b>Cash and cash equivalents at the end of the reporting period</b> |       | <b>122,627</b>      | <b>124,933</b>      | <b>167,000</b>                     |

The above statement should be read in conjunction with the accompanying notes.

<sup>1</sup> Budget reported in the 2025-26 Portfolio Budget Statements published in May 2025.

**Budget Variance Commentary****Rendering of Services and section 74 receipts transferred to OPA**

Rendering of services is higher than budget due to additional MOU funding agreed since the 2025-26 Portfolio Budget Statements were finalised. Refer variance comments in Statement of Comprehensive Income for further details.

**Net GST received and paid**

Cancer Australia is required to make Goods and Services Tax (GST) payments on eligible goods and services. The net GST received represents the refund of those amounts from the Australian Taxation Office. GST estimates are based on prior years' trends and fluctuate from year to year based on the payments for goods and services. The net GST received was used to settle commitments, rather than drawing on additional funding.

**Suppliers**

Expenditure is higher than budget due to expenditure associated with the additional MOU funding.

## Administered Schedule of Comprehensive Income

for the period ended 30 June 2026

|                                         | Notes | 2026<br>\$          | 2025<br>\$   | Original Budget <sup>1</sup><br>\$ |
|-----------------------------------------|-------|---------------------|--------------|------------------------------------|
| <b>NET COST OF SERVICES</b>             |       |                     |              |                                    |
| <b>Expenses</b>                         |       |                     |              |                                    |
| Suppliers                               | 15A   | <b>13,316,574</b>   | 17,040,937   | 10,024,000                         |
| Grants and service delivery contracts   | 15B   | <b>21,049,941</b>   | 17,284,335   | 23,175,000                         |
| <b>Total expenses</b>                   |       | <b>34,366,515</b>   | 34,325,272   | 33,199,000                         |
| <b>Income</b>                           |       |                     |              |                                    |
| <b>Revenue</b>                          |       |                     |              |                                    |
| <b>Non-taxation revenue</b>             |       |                     |              |                                    |
| Return of grant monies                  |       | <b>22,092</b>       | 56,556       | -                                  |
| <b>Total non-taxation revenue</b>       |       | <b>22,092</b>       | 56,556       | -                                  |
| <b>Total revenue</b>                    |       | <b>22,092</b>       | 56,556       | -                                  |
| <b>Net cost of services</b>             |       | <b>(34,344,423)</b> | (34,268,716) | (33,199,000)                       |
| <b>Deficit on continuing operations</b> |       | <b>(34,344,423)</b> | (34,268,716) | (33,199,000)                       |
| <b>Total comprehensive loss</b>         |       | <b>(34,344,423)</b> | (34,268,716) | (33,199,000)                       |

The above schedule should be read in conjunction with the accompanying notes.

<sup>1</sup> Budget reported in the 2025-26 Portfolio Budget Statements published in May 2025.

### Budget Variance Commentary

#### Suppliers

Supplier payments vary from year to year depending upon contracts awarded.

#### Return of grant monies

Grant funding paid from prior years administered appropriations were returned to Cancer Australia by grant recipients in accordance with the grant acquittal and funding agreements. This is dependent upon supplier initiated returns.

## Administered Schedule of Assets and Liabilities

as at 30 June 2026

|                                                               | Notes | 2026<br>\$       | 2025<br>\$  | Original Budget <sup>1</sup><br>\$ |
|---------------------------------------------------------------|-------|------------------|-------------|------------------------------------|
| <b>ASSETS</b>                                                 |       |                  |             |                                    |
| <b>Financial assets</b>                                       |       |                  |             |                                    |
| Cash and cash equivalents                                     | 16A   | <b>32,648</b>    | 33,550      | 30,000                             |
| Trade and other receivables                                   | 16B   | <b>1,236,075</b> | 1,523,883   | 840,000                            |
| <b>Total financial assets</b>                                 |       | <b>1,268,723</b> | 1,557,433   | 870,000                            |
| <b>Non-financial assets</b>                                   |       |                  |             |                                    |
| Prepayments                                                   |       | <b>197,950</b>   | 252,381     | 112,000                            |
| <b>Total non-financial assets</b>                             |       | <b>197,950</b>   | 252,381     | 112,000                            |
| <b>Total assets administered on behalf of Government</b>      |       | <b>1,466,673</b> | 1,809,814   | 982,000                            |
| <b>LIABILITIES</b>                                            |       |                  |             |                                    |
| <b>Payables</b>                                               |       |                  |             |                                    |
| Suppliers                                                     | 17A   | <b>1,006,036</b> | 2,084,685   | 561,000                            |
| Grants                                                        | 17B   | <b>481,460</b>   | 3,011,073   | 587,000                            |
| <b>Total payables</b>                                         |       | <b>1,487,496</b> | 5,095,758   | 1,148,000                          |
| <b>Total liabilities administered on behalf of Government</b> |       | <b>1,487,496</b> | 5,095,758   | 1,148,000                          |
| <b>Net liabilities</b>                                        |       | <b>(20,823)</b>  | (3,285,944) | (166,000)                          |

The above schedule should be read in conjunction with the accompanying notes.

<sup>1</sup> Budget reported in the 2025-26 Portfolio Budget Statements published in May 2025.

### Budget Variance Commentary

#### Trade and other receivables

Trade and other receivables are mainly GST receivable from the Australian Taxation Office.

#### Prepayments

Prepayments relate to venue hire fees for future events, IT website costs and licences.

#### Suppliers payables

Suppliers payable vary year to year being dependent on the timing of work delivered by suppliers and the payment terms of contracts.

#### Grants

Grants payable vary each year due to the timing of grant milestones and associated payments.

## Administered Reconciliation Schedule

as at 30 June 2026

|                                                                      | 2026               | 2025         |
|----------------------------------------------------------------------|--------------------|--------------|
|                                                                      | \$                 | \$           |
| <b>Opening assets less liabilities as at 1 July</b>                  | <b>(3,285,944)</b> | (166,321)    |
| <b>Net cost of services</b>                                          |                    |              |
| Income                                                               | 22,092             | 56,556       |
| Expenses                                                             |                    |              |
| Payments to entities other than Commonwealth entities                | (25,774,859)       | (25,122,686) |
| Payments to Commonwealth entities                                    | (8,591,656)        | (9,202,586)  |
| <b>Transfers from/(to) the Australian Government</b>                 |                    |              |
| Appropriation transfers from Official Public Account                 |                    |              |
| Payments to entities other than Commonwealth entities                | 37,631,636         | 31,205,649   |
| Appropriation transfers to Official Public Account                   |                    |              |
| Receipts from entities other than Commonwealth entities <sup>1</sup> | (22,092)           | (56,556)     |
| <b>Closing assets less liabilities as at 30 June</b>                 | <b>(20,823)</b>    | (3,285,944)  |

The above schedule should be read in conjunction with the accompanying notes.

<sup>1</sup> In 2025-26, \$0.022m of grant funding paid from prior years administered appropriations and in previous financial years were returned to Cancer Australia by grant recipients in accordance with the grant acquittal and funding agreements. The unspent funds from various funding agreements have been returned to the Consolidated Revenue Fund in accordance with the appropriation Acts and guidelines.

### Accounting Policy

#### Administered cash transfers to and from the Official Public Account

Administered revenues are collected by Cancer Australia on behalf of the Government with parties outside the Government. Collections are transferred to the OPA maintained by the Department of Finance. Conversely, cash is drawn from the OPA to make payments under Parliamentary appropriation on behalf of Government. These transfers to and from the OPA are adjustments to the administered cash held by the entity on behalf of the Government and reported as such in the schedule of administered cash flows and in the administered reconciliation schedule.

## Administered Cash Flow Statement

for the period ended 30 June 2026

|                                                                                | Notes | 2026<br>\$          | 2025<br>\$          |
|--------------------------------------------------------------------------------|-------|---------------------|---------------------|
| <b>OPERATING ACTIVITIES</b>                                                    |       |                     |                     |
| <b>Cash received</b>                                                           |       |                     |                     |
| Net GST received                                                               |       | 3,206,321           | 1,654,350           |
| Other                                                                          |       | 22,092              | 56,556              |
| <b>Total cash received</b>                                                     |       | <b>3,228,413</b>    | <b>1,710,906</b>    |
| <b>Cash used</b>                                                               |       |                     |                     |
| Grants                                                                         |       | (20,827,918)        | (14,859,937)        |
| Suppliers                                                                      |       | (20,010,942)        | (17,945,636)        |
| <b>Total cash used</b>                                                         |       | <b>(40,838,860)</b> | <b>(32,805,573)</b> |
| <b>Net cash used by operating activities</b>                                   |       | <b>(37,610,447)</b> | <b>(31,094,667)</b> |
| Cash and cash equivalents at the beginning of the reporting period             |       | 33,550              | 29,873              |
| <b>Cash from Official Public Account</b>                                       |       |                     |                     |
| Appropriations                                                                 |       | 37,631,637          | 31,205,649          |
| <b>Cash to Official Public Account</b>                                         |       |                     |                     |
| Administered receipts                                                          |       | (22,092)            | (107,305)           |
| <b>Cash and cash equivalents at the end of the reporting period</b>            | 16A   | <b>32,648</b>       | <b>33,550</b>       |
| The above statement should be read in conjunction with the accompanying notes. |       |                     |                     |

## Notes to and forming part of the financial statements

|                                                                     |     |
|---------------------------------------------------------------------|-----|
| Note 1: Overview                                                    | 89  |
| Note 2: Events After the Reporting Period                           | 89  |
| Note 3: Expenses                                                    | 90  |
| Note 4: Own-Source Income                                           | 92  |
| Note 5: Fair Value Measurements                                     | 93  |
| Note 6: Financial Assets                                            | 94  |
| Note 7: Non-Financial Assets                                        | 95  |
| Note 8: Payables                                                    | 98  |
| Note 9: Interest Bearing Liabilities                                | 98  |
| Note 10: Provisions                                                 | 99  |
| Note 11: Contingent Assets and Liabilities                          | 99  |
| Note 12: Key Management Personnel Remuneration                      | 100 |
| Note 13: Related Party Disclosure                                   | 100 |
| Note 14: Financial Instruments                                      | 101 |
| Note 15: Administered – Expenses                                    | 102 |
| Note 16: Administered – Financial Assets                            | 103 |
| Note 17: Administered – Payables                                    | 103 |
| Note 18: Administered – Contingent Assets and Liabilities           | 103 |
| Note 19: Administered – Financial Instruments                       | 104 |
| Note 20: Appropriations                                             | 105 |
| Note 21: Current/non-current distinction for Assets and Liabilities | 107 |

## Notes to and forming part of the financial statements

### Note 1: Overview

The entity conducts the following administered activities on behalf of the Government: provide national leadership in cancer control, guide scientific improvements to cancer prevention, treatment and care; coordinate and liaise between the wide range of groups and health care providers with an interest in cancer care and provide advice and make recommendations to the Australian Government on cancer policy and priorities.

Cancer Australia is an Australian Government controlled entity. It is a non-corporate Commonwealth entity and a not-for-profit entity, with registered office at Level 14, 300 Elizabeth Street, Surry Hills NSW.

The continued existence of the entity in its present form and with its present programs is dependent on Government policy and on continuing funding by Parliament for the entity's administration and programs.

#### 1.1 Basis of Preparation of the Financial Statements

The financial statements are required by section 42 of the *Public Governance, Performance and Accountability Act 2013* (the PGPA Act).

The financial statements have been prepared in accordance with:

- *Public Governance, Performance and Accountability (Financial Reporting) Rule 2015* (FRR); and
- Australian Accounting Standards and Interpretations – including simplified disclosures for Tier 2 Entities under AASB 1060 issued by the Australian Accounting Standards Board (AASB) that apply for the reporting period.

The financial statements have been prepared on an accrual basis and in accordance with the historical cost convention, except for certain assets and liabilities at fair value. Except where stated, no allowance is made for the effect of changing prices on the results or the financial position. The financial statements are presented in Australian dollars.

#### 1.2 New Accounting Standards

New or revised standards, interpretations and amending standards that were issued prior to the sign-off date and are applicable in the current reporting period did not have a material effect, and are not expected to have a future material impact, on Cancer Australia's financial statements.

No accounting standard has been adopted earlier than the application date as stated in the standard.

#### 1.3 Significant Accounting Judgements and Estimates

In the process of applying the accounting policies listed in this note, Cancer Australia has made judgements that would have a significant impact on the amounts recorded in the financial statements.

No accounting assumptions or estimates have been identified that have a significant risk of causing a material adjustment to carrying amounts of assets and liabilities within the next accounting period.

In accordance with AASB 13 *Fair Value Measurement* Cancer Australia has applied estimations of assets at fair value. Estimations of employee long service leave entitlements have also been applied in accordance with AASB 119 *Employee Benefits*. Cancer Australia uses the short-hand method to calculate employee long service leave entitlements, discounted using the government bond rate issued by the Department of Finance.

#### 1.4 Taxation

Cancer Australia is exempt from all forms of taxation except Fringe Benefits Tax (FBT) and the Goods and Services Tax (GST).

#### 1.5 Reporting of Administered Activities

Administered revenues, expenses, assets, liabilities and cash flows are disclosed in the administered schedules and related notes.

Except where otherwise stated, administered items are accounted for on the same basis and using the same policies as for Departmental items, including the application of Australian Accounting Standards.

### Note 2: Events After the Reporting Period

Cancer Australia is not aware of any events occurring after 30 June 2026 that have the potential to significantly affect the on-going structure or activities of either Cancer Australia's Administered or Departmental functions.

## Notes to and forming part of the financial statements

### Note 3: Expenses

|                                   | 2026              | 2025       |
|-----------------------------------|-------------------|------------|
|                                   | \$                | \$         |
| <b>Note 3A: Employee Benefits</b> |                   |            |
| Wages and salaries                | <b>9,067,393</b>  | 8,921,502  |
| Superannuation                    |                   |            |
| Defined contribution plans        | <b>1,310,919</b>  | 1,320,611  |
| Defined benefit plans             | <b>275,332</b>    | 258,091    |
| Leave and other entitlements      | <b>1,398,758</b>  | 1,453,001  |
| Separation and redundancies       | <b>128,688</b>    | -          |
| <b>Total employee benefits</b>    | <b>12,181,090</b> | 11,953,205 |

### Accounting Policy

Liabilities for 'short-term' employee benefits and termination benefits expected within twelve months of the end of reporting period are measured at their nominal amounts.

Other long-term employee benefits are measured as net total of the present value of the defined benefit obligation at the end of the reporting period minus the fair value at the end of the reporting period of plan assets (if any) out of which the obligations are to be settled directly.

#### Leave and entitlements

The liability for employee benefits includes provision for annual leave and long service leave.

The leave liabilities are calculated on the basis of employee's remuneration at the estimated salary rates that will be applied at the time the leave is taken, including Cancer Australia's superannuation contribution rates to the extent that the leave is likely to be taken during service rather than paid out on termination.

The estimate of the present value of the liability takes into account attrition rates and pay increases through promotion and inflation.

#### Superannuation

Cancer Australia's staff are members of the Commonwealth Superannuation Scheme (CSS), the Public Sector Superannuation Scheme (PSS), or the PSS accumulation plan (PSSap), or other superannuation funds held outside the Australian Government.

The CSS and PSS are defined benefit schemes for the Australian Government. The PSSap is a defined contribution scheme.

The liability for defined benefits is recognised in the financial statements of the Australian Government and is settled by the Australian Government in due course. This liability is reported in the Department of Finance's administered schedules and notes.

Cancer Australia makes employer contributions to the employees' defined benefit superannuation scheme at rates determined by an actuary to be sufficient to meet the current cost to the Government. Cancer Australia accounts for the contributions as if they were contributions to defined contribution plans.

The liability for superannuation recognised as at 30 June represents outstanding contributions for the final fortnight of the year.

## Notes to and forming part of the financial statements

### Note 3: Expenses

|                                                      | 2026             | 2025             |
|------------------------------------------------------|------------------|------------------|
|                                                      | \$               | \$               |
| <b>Note 3B: Suppliers</b>                            |                  |                  |
| <b>Goods and services supplied or rendered</b>       |                  |                  |
| Learning and development                             | 23,457           | 34,972           |
| Travel                                               | 149,616          | 135,193          |
| Consultants                                          | 226,087          | 212,851          |
| Contractors                                          | 308,546          | 600,687          |
| Property and office                                  | 416,960          | 432,664          |
| Information technology and licenses                  | 852,197          | 785,628          |
| Other                                                | 364,968          | 504,097          |
| <b>Total goods and services supplied or rendered</b> | <b>2,341,831</b> | <b>2,706,092</b> |
| <br>Goods supplied                                   | <br>6,041        | <br>12,143       |
| Services rendered                                    | 2,335,790        | 2,693,949        |
| <b>Total goods and services supplied or rendered</b> | <b>2,341,831</b> | <b>2,706,092</b> |
| <br><b>Other suppliers</b>                           |                  |                  |
| Workers compensation expenses                        | 47,591           | 49,201           |
| <b>Total other suppliers</b>                         | <b>47,591</b>    | <b>49,201</b>    |
| <b>Total suppliers</b>                               | <b>2,389,422</b> | <b>2,755,293</b> |
| <br><b>Note 3C: Grants</b>                           |                  |                  |
| Private sector:                                      |                  |                  |
| Non-profit organisations                             | 1,583,597        | 1,548,750        |
| <b>Total grants</b>                                  | <b>1,583,597</b> | <b>1,548,750</b> |

### Accounting Policy

#### Grants

Cancer Australia administers a number of grant schemes. Grant liabilities are recognised to the extent that (i) the services required to be performed by the grantee have been performed or (ii) the grant eligibility criteria have been satisfied, but payments due have not been made. When the Government enters into an agreement to make these grants and services but services have not been performed or criteria satisfied, this is considered a commitment.

## Notes to and forming part of the financial statements

### Note 4: Own-Source Income

|  | 2026 | 2025 |
|--|------|------|
|  | \$   | \$   |

#### Note 4A: Rendering of services

|                                    |                  |                  |
|------------------------------------|------------------|------------------|
| Rendering of services              | 3,466,178        | 3,583,526        |
| <b>Total rendering of services</b> | <b>3,466,178</b> | <b>3,583,526</b> |

#### Disaggregation of revenue from contracts with customers

Type of customer:

|                                                  |                  |                  |
|--------------------------------------------------|------------------|------------------|
| Australian Government entities (related parties) | 3,373,678        | 3,583,526        |
| Non-government entities                          | 92,500           | -                |
|                                                  | <b>3,466,178</b> | <b>3,583,526</b> |

### Accounting Policy

#### Rendering of services

Revenue from the sale of goods is recognised when control has been transferred to the buyer. In relation to AASB 1058, Cancer Australia recognises the revenue when control of the cash is obtained.

Receivables for goods and services, which have 30 day terms (2024-25: 30 days), are recognised at the nominal amounts due less any impairment allowance account. Collectability of debts is reviewed at the end of the reporting period. Allowances are made when collectability of the debt is no longer probable.

#### Note 4B: Other revenue

|                                                              |               |                |
|--------------------------------------------------------------|---------------|----------------|
| Fundraising                                                  | 319           | 56,358         |
| Resources received free of charge - Remuneration of auditors | 61,000        | 61,000         |
| Other revenue                                                | 2,455         | 9,714          |
| <b>Total other revenue</b>                                   | <b>63,774</b> | <b>127,072</b> |

### Accounting Policy

#### Resources received free of charge

Resources received free of charge are recognised as revenue when, and only when, a fair value can be reliably determined and the services would have been purchased if they had not been donated. Use of those resources is recognised as an expense.

#### Fundraising revenue

Fundraising revenue is recognised when Cancer Australia obtains control over the funds.

#### Note 4C: Revenue from Government

##### Appropriations:

|                                      |                   |                   |
|--------------------------------------|-------------------|-------------------|
| Departmental appropriations          | 13,223,000        | 14,109,000        |
| <b>Total revenue from Government</b> | <b>13,223,000</b> | <b>14,109,000</b> |

### Accounting Policy

#### Revenue from Government

Amounts appropriated for Departmental appropriations for the year (adjusted for any formal additions and reductions) are recognised as Revenue from Government when Cancer Australia gains control of the Appropriation, except for certain amounts that relate to activities that are reciprocal in nature, in which case revenue is recognised only when it has been earned.

Appropriations receivable are recognised at their nominal amounts.

# Notes to and forming part of the financial statements

| Note 5: Fair Value Measurements |                                                            |         |
|---------------------------------|------------------------------------------------------------|---------|
|                                 | Fair value measurements at the end of the reporting period |         |
|                                 | 2026                                                       | 2025    |
|                                 | \$                                                         | \$      |
| <b>Non-financial assets</b>     |                                                            |         |
| Buildings                       | 424,556                                                    | 473,637 |
| Property, plant and equipment   | 205,645                                                    | 93,166  |

Notes:

1. There has been no change to valuation techniques.
2. Cancer Australia's assets are held for operational purposes and not held for the purposes of deriving a profit. The current use of all controlled assets is considered their highest and best use.
3. The remaining assets reported by Cancer Australia are not measured at fair value in the Statement of Financial Position.

**Accounting Policy**

Cancer Australia performs an internal management review of the fair value of its fixed assets at least once every 12 months. If a particular asset class experiences significant and volatile changes in fair value (i.e. where indicators suggest that the value of the class has changed materially since the previous reporting period), that class is subject to specific valuation in the reporting period, where practicable, regardless of the timing of the last review. The nature of Cancer Australia's assets are predominantly low value assets with a useful life of between 3 to 10 years.

## Notes to and forming part of the financial statements

### Note 6: Financial Assets

|                                                    | 2026             | 2025      |
|----------------------------------------------------|------------------|-----------|
|                                                    | \$               | \$        |
| <b>Note 6: Trade and other receivables</b>         |                  |           |
| Goods and services                                 | <b>268,568</b>   | 124,369   |
| <b>Total goods and services receivables</b>        | <b>268,568</b>   | 124,369   |
| <b>Appropriation receivable</b>                    |                  |           |
| Appropriation receivable                           | <b>3,560,965</b> | 4,087,965 |
| <b>Total appropriation receivable</b>              | <b>3,560,965</b> | 4,087,965 |
| <b>Other receivables</b>                           |                  |           |
| GST receivable from the Australian Taxation Office | <b>83,849</b>    | 75,427    |
| <b>Total other receivables</b>                     | <b>83,849</b>    | 75,427    |
| <b>Total trade and other receivables (net)</b>     | <b>3,913,382</b> | 4,287,761 |

Credit terms for goods and services were within 30 days (2024-25: 30 days).

No allowance for impairment was required at reporting date (2024-25: nil).

### Accounting Policy

#### Trade and other receivables

Trade and other receivables that are held for the purpose of collecting the contractual cash flows where the cash flows are solely payments of principal and interest, that are not provided at below-market interest rates, are subsequently measured at amortised cost using the effective interest method adjusted for any loss allowance.

## Notes to and forming part of the financial statements

### Note 7: Non-Financial Assets

#### Reconciliation of the opening and closing balances of Property, Plant and Equipment and Intangibles for 2026

|                                                       | Buildings        | Plant & Equipment | Intangibles  | Total            |
|-------------------------------------------------------|------------------|-------------------|--------------|------------------|
|                                                       | \$               | \$                | \$           | \$               |
| <b>As at 1 July 2025</b>                              |                  |                   |              |                  |
| Gross book value                                      | 5,521,489        | 944,813           | 1,254,264    | 7,720,566        |
| Accumulated depreciation and amortisation             | (3,381,237)      | (851,646)         | (1,246,721)  | (5,479,604)      |
| <b>Total as at 1 July 2025</b>                        | <b>2,140,252</b> | <b>93,167</b>     | <b>7,543</b> | <b>2,240,962</b> |
| Additions                                             | 153,387          | 152,358           | -            | 305,745          |
| Revaluations recognised in other comprehensive income | 64,220           | 47,308            | -            | 111,528          |
| Revaluations recognised in net cost of services       | -                | (1,486)           | -            | (1,486)          |
| Depreciation and amortisation                         | (266,688)        | (83,492)          | (5,961)      | (356,142)        |
| Loss on Disposals                                     | -                | (1,443)           | -            | (1,443)          |
| Other Movements                                       | -                | (766)             | -            | (766)            |
| Depreciation on right-of-use assets                   | (735,644)        | -                 | -            | (735,644)        |
| <b>Total as at 30 June 2026</b>                       | <b>1,355,527</b> | <b>205,646</b>    | <b>1,582</b> | <b>1,562,755</b> |
| <b>Total as at 30 June 2026 represented by:</b>       |                  |                   |              |                  |
| Gross book value                                      | 5,739,095        | 1,140,784         | 1,254,264    | 8,134,143        |
| Accumulated depreciation and amortisation             | (4,383,568)      | (935,138)         | (1,252,682)  | (6,571,388)      |
| <b>Total as at 30 June 2026:</b>                      | <b>1,355,527</b> | <b>205,646</b>    | <b>1,582</b> | <b>1,562,755</b> |
| <b>Carrying amount of right-of-use assets</b>         | <b>930,972</b>   | <b>-</b>          | <b>-</b>     | <b>930,972</b>   |

Notes to and forming part of the financial statements

**Note 7: Non-Financial Assets (cont'd)**

**Accounting Policy**

Assets are recorded at cost on acquisition except as stated below. The cost of acquisition includes the fair value of assets transferred in exchange for consideration and liabilities undertaken. Financial assets are initially measured at their fair value plus transaction costs where appropriate.

Assets acquired at no cost, or for nominal consideration, are initially recognised as assets and income at their fair value at the date of acquisition, unless acquired as a consequence of restructuring of administrative arrangements. In the latter case, assets are initially recognised as contributions by owners at the amounts at which they were recognised in the transferor's accounts immediately prior to the restructuring.

**Asset recognition threshold**

Purchases of property, plant and equipment are recognised initially at cost in the Statement of Financial Position, except for purchases costing less than \$2,000, which are expensed in the year of acquisition (other than where they form part of a group of similar items which are significant in total).

**Leased right-of-use (ROU) assets**

Leased ROU assets are capitalised at the commencement date of the lease and comprise of the initial lease liability amount, initial direct costs incurred when entering into the lease less any lease incentives received. These assets are accounted for by Commonwealth lessees as separate asset classes to corresponding assets owned outright, but included in the same column as where the corresponding underlying assets would be presented if they were owned.

An impairment review is undertaken for any right-of-use lease asset that shows indicators of impairment and an impairment loss is recognised against any right of use lease asset that is impaired. Leased ROU assets continue to be measured at cost after initial recognition in Commonwealth agency, GGS and Whole of Government financial statements.

**Revaluations**

Following initial recognition at cost, property, plant and equipment (excluding ROU assets) are carried at fair value less subsequent accumulated depreciation and accumulated impairment losses. Valuation reviews are conducted with sufficient frequency to ensure that the carrying amounts of assets did not differ materially from the assets' fair values as at the reporting date. The regularity of independent valuations depends upon the nature of the assets and volatility of movements in market values for the relevant assets.

A full revaluation was undertaken by B&A Valuers at 28 February 2026 including an assessment of useful lives. A materiality assessment was also undertaken by B&A Valuers as at 30 June 2026 comparing the carrying value of assets to the reported fair values.

Revaluation adjustments are made on a class basis. Any revaluation increment is credited to equity under the heading of asset revaluation reserve except to the extent that it reversed a previous revaluation decrement of the same asset class that was previously recognised in the surplus/deficit. Revaluation decrements for a class of assets are recognised directly in the surplus/deficit except to the extent that they reversed a previous revaluation increment for that class.

**Depreciation**

Depreciable property, plant and equipment assets are written-off to their estimated residual values over their estimated useful lives to Cancer Australia using, in all cases, the straight-line method of depreciation.

Depreciation rates (useful lives), residual values and methods are reviewed at each reporting date and necessary adjustments are recognised in the current, or current and future reporting periods, as appropriate.

Depreciation rates applying to each class of depreciable asset are based on the following useful lives:

| 2026          | 2025          |
|---------------|---------------|
| 3 to 10 years | 3 to 10 years |

The depreciation rates for ROU assets are based on the commencement date to the earlier of the end of the useful life of the ROU asset or the end of the lease term.

## Notes to and forming part of the financial statements

### **Impairment**

All assets were assessed for impairment at 30 June 2026. Where indications of impairment exist, the asset's recoverable amount is estimated and an impairment adjustment made if the asset's recoverable amount is less than its carrying amount. No indicators of impairment were identified.

The recoverable amount of an asset is the higher of its fair value less costs of disposal and its value in use. Value in use is the present value of the future cash flows expected to be derived from the asset. Where the future economic benefit of an asset is not primarily dependent on the asset's ability to generate future cash flows, and the asset would be replaced if Cancer Australia were deprived of the asset, its value in use is taken to be its depreciated replacement cost.

### **Derecognition**

An item of property, plant and equipment is derecognised upon disposal or when no further future economic benefits are expected from its use or disposal.

### **Intangibles**

Cancer Australia's intangibles comprise purchased software and website costs. These assets are carried at cost less accumulated amortisation and accumulated impairment losses.

Software and website costs are amortised on a straight-line basis over its anticipated useful life. The anticipated useful life of Cancer Australia's intangibles is three years (2024-25: three years).

All software and website assets were assessed for indications of impairment as at 30 June 2026. No indicators of impairment were identified.

## Notes to and forming part of the financial statements

### Note 8: Payables

|  | 2026 | 2025 |
|--|------|------|
|  | \$   | \$   |

#### Note 8A: Suppliers

|                              |                |                |
|------------------------------|----------------|----------------|
| Trade creditors and accruals | 224,216        | 213,983        |
| <b>Total suppliers</b>       | <b>224,216</b> | <b>213,983</b> |

Settlement is usually made within 30 days (2024-25: 30 days).

#### Note 8B: Other payables

|                             |                |                |
|-----------------------------|----------------|----------------|
| Salaries and wages          | 345,252        | 313,183        |
| Superannuation              | 54,256         | 49,520         |
| Other                       | 74,308         | 35,483         |
| <b>Total other payables</b> | <b>473,816</b> | <b>398,186</b> |

### Note 9: Interest Bearing Liabilities

|  | 2026 | 2025 |
|--|------|------|
|  | \$   | \$   |

#### Leases

|                     |                  |                  |
|---------------------|------------------|------------------|
| Lease liabilities   | 1,207,719        | 2,127,195        |
| <b>Total leases</b> | <b>1,207,719</b> | <b>2,127,195</b> |

Total cash outflow for leases for the year ended 30 June 2026 was \$919,476 (2024-25: \$873,591).

#### Maturity analysis - contractual undiscounted cash flows

|                      |                  |                  |
|----------------------|------------------|------------------|
| Within 1 year        | 975,633          | 936,059          |
| Between 1 to 5 years | 241,268          | 1,216,901        |
| More than 5 years    | -                | -                |
| <b>Total leases</b>  | <b>1,216,901</b> | <b>2,152,960</b> |

Cancer Australia, in its capacity as lessee has entered into a lease agreement for Sydney office in 2020-21 with a seven (7) year lease term without extension options. Similarly, Cancer Australia also entered another agreement for Canberra Lease during 2022-23 with a five (5) year Lease term without extension options.

The above lease disclosures should be read in conjunction with the accompanying notes 3B and 7.

### Accounting Policy

#### Leases

For all new contracts entered into, Cancer Australia considers whether the contract is, or contains a lease. A lease is defined as a contract, or part of a contract, that conveys the right to use an asset (the underlying asset) for a period of time in exchange for consideration.

Once it has been determined that a contract is, or contains a lease, the lease liability is initially measured at the present value of the lease payments unpaid at the commencement date, discounted using the interest rate implicit in the lease, if that rate is readily determinable, or the department's incremental borrowing rate.

Subsequent to initial measurement, the liability will be reduced for payments made and increased for interest. It is remeasured to reflect any reassessment or modification to the lease. When the lease liability is remeasured, the corresponding adjustment is reflected in the right-of-use asset or profit and loss depending on the nature of the reassessment or modification.

## Notes to and forming part of the financial statements

### Note 10: Provisions

|                                                  | 2026                               | 2025                       |
|--------------------------------------------------|------------------------------------|----------------------------|
|                                                  | \$                                 | \$                         |
| <b>Note 10A: Employee provisions</b>             |                                    |                            |
| Leave                                            | <b>2,893,671</b>                   | 2,766,064                  |
| <b>Total employee provisions</b>                 | <b>2,893,671</b>                   | 2,766,064                  |
| <b>Note 10B: Other provisions</b>                |                                    |                            |
|                                                  | <b>Provision for<br/>make good</b> | Provision for<br>make good |
|                                                  | \$                                 | \$                         |
| <b>As at 1 July 2025</b>                         | <b>276,715</b>                     | 272,598                    |
| Additional provisions made                       | -                                  | -                          |
| Amounts used                                     | -                                  | -                          |
| Unwinding of discount or change in discount rate | <b>4,179</b>                       | 4,117                      |
| <b>Total as at 30 June 2026</b>                  | <b>280,894</b>                     | 276,715                    |

Cancer Australia, in its capacity as a lessee, has entered into two lease agreements (FY2023 Canberra office, FY2021 Sydney office). The Sydney lease agreement includes a provision requiring Cancer Australia to restore the premises to their original condition at the conclusion of the lease. Cancer Australia recognises a provision for make good to reflect the present value of the obligation.

### Note 11: Contingent Assets and Liabilities

Cancer Australia has not identified any quantifiable, unquantifiable or significant remote contingent assets or liabilities as at 30 June 2026 (2024-25: Nil).

### Accounting Policy

Contingent liabilities and contingent assets are not recognised in the Statement of Financial Position but are reported in the notes. They may arise from uncertainty as to the existence of a liability or asset or represent an asset or liability in respect of which the amount cannot be reliably measured. Contingent assets are disclosed when settlement is probable but not virtually certain and contingent liabilities are disclosed when settlement is greater than remote.

## Notes to and forming part of the financial statements

### Note 12: Key Management Personnel Remuneration

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity. Cancer Australia has determined the key management personnel to be the Chief Executive Officer, Deputy Chief Executive Officer, Senior Executive Service Officers, Chief Operating Officer and Chief Financial Officer and Ministers. Key management personnel remuneration is reported in the table below:

|                                                                          | 2026             | 2025             |
|--------------------------------------------------------------------------|------------------|------------------|
|                                                                          | \$               | \$               |
| Short-term employee benefits                                             | 1,877,740        | 1,877,139        |
| Post-employment benefits                                                 | 276,407          | 272,579          |
| Other long-term employee benefits                                        | 41,453           | 42,999           |
| <b>Total key management personnel remuneration expenses <sup>1</sup></b> | <b>2,195,600</b> | <b>2,192,717</b> |

The total number of key management personnel included in the above table are eight (2024-25: seven).

<sup>1</sup> The above key management personnel remuneration excludes the remuneration and other benefits of the Ministers. The Ministers' remuneration and other benefits are set by the Remuneration Tribunal and are not paid by Cancer Australia.

### Note 13 : Related Party Disclosures

#### Related party relationships

Cancer Australia is an Australian Government controlled entity. Related parties to this entity are Key Management Personnel, including the Ministers and Executive, and other Australian Government entities.

#### Transactions with related parties:

Given the breadth of Government activities, related parties may transact with the government sector in the same capacity as ordinary citizens. Such transactions include the payment or refund of taxes, receipt of a Medicare rebate or higher education loans. These transactions have not been separately disclosed in this note.

Significant transactions with related parties can include:

- the payments of grants or loans;
- purchases of goods and services;
- asset purchases, sales transfers or leases;
- debts forgiven; and
- guarantees.

Giving consideration to relationships with related entities, and transactions entered into during the reporting period by Cancer Australia, it has been determined that there are no related party transactions to be separately disclosed.

## Notes to and forming part of the financial statements

### Note 14: Financial Instruments

|  | 2026 | 2025 |
|--|------|------|
|  | \$   | \$   |

#### Note 14: Financial instruments

##### Financial assets measured at amortised cost

|                                                          |                |                |
|----------------------------------------------------------|----------------|----------------|
| Cash and cash equivalents                                | 122,627        | 124,933        |
| Trade receivables                                        | 268,568        | 124,369        |
| <b>Total financial assets measured at amortised cost</b> | <b>391,195</b> | <b>249,302</b> |
| <b>Total financial assets</b>                            | <b>391,195</b> | <b>249,302</b> |

##### Financial liabilities

##### Financial liabilities measured at amortised cost

|                                                         |                |                |
|---------------------------------------------------------|----------------|----------------|
| Trade creditors and accruals                            | 224,216        | 213,983        |
| <b>Financial liabilities measured at amortised cost</b> | <b>224,216</b> | <b>213,983</b> |
| <b>Total financial liabilities</b>                      | <b>224,216</b> | <b>213,983</b> |

### Accounting Policy

#### Financial assets

Cancer Australia is a non-financial entity whose financial assets are limited to trade receivables and bank deposits. Cancer Australia's trade receivables relate to services provided and do not arise as a result of their primary business objectives. Accordingly, the receivables are more aligned to a basic lending arrangement whereby cash flows will be generated through the collection of the amounts outstanding.

Cancer Australia's business model is to hold financial assets to collect the contractual cash flows and the cash flows relate solely to payments of interest and principal amounts.

Based on the above, Cancer Australia's financial assets should subsequently be measured at amortised cost.

Amortised cost is determined using the effective interest method.

#### Effective interest method

Income is recognised on an effective interest rate basis for financial assets that are recognised at amortised cost.

#### Impairment of financial assets

Financial assets are assessed for impairment at the end of each reporting period based on Expected Credit Losses, using the general approach which measures the loss allowance based on an amount equal to lifetime expected credit losses where risk has significantly increased, or an amount equal to 12-month expected credit losses if risk has not increased.

The simplified approach for trade, contract and lease receivables is used. This approach always measures the loss allowance as the amount equal to the lifetime expected credit losses.

A write-off constitutes a derecognition event where the write-off directly reduces the gross carrying amount of the financial asset.

#### Financial Liabilities

Financial liabilities are classified as other financial liabilities. Financial liabilities are recognised and derecognised upon 'trade date'.

#### Financial liabilities at amortised cost

Financial liabilities are initially measured at fair value, net of transaction costs. These liabilities are subsequently measured at amortised cost using the effective interest method, with interest expense recognised on an effective interest basis.

Supplier and other payables are recognised at amortised cost. Liabilities are recognised to the extent that the goods or services have been received (and irrespective of having been invoiced).

## Notes to and forming part of the financial statements

### Note 15: Administered - Expenses

|                                                        | 2026              | 2025              |
|--------------------------------------------------------|-------------------|-------------------|
|                                                        | \$                | \$                |
| <b>Note 15A: Suppliers</b>                             |                   |                   |
| <b>Goods and services supplied or rendered</b>         |                   |                   |
| Sponsorship                                            | 127,090           | 226,211           |
| Media and Other Promotional                            | 163,821           | 210,943           |
| Consultants                                            | 297,771           | 684,536           |
| Sitting and advisory fees                              | 401,354           | 416,381           |
| IT Website Costs                                       | 438,716           | 371,060           |
| Travel                                                 | 540,797           | 431,797           |
| Contractors                                            | 11,076,278        | 14,389,307        |
| Other                                                  | 270,748           | 310,701           |
| <b>Total goods and services supplied or rendered</b>   | <b>13,316,574</b> | <b>17,040,937</b> |
| <b>Goods and services are made up of:</b>              |                   |                   |
| Goods supplied                                         | 27,652            | 48,564            |
| Services rendered                                      | 13,288,922        | 16,992,373        |
| <b>Total goods and services supplied or rendered</b>   | <b>13,316,574</b> | <b>17,040,937</b> |
| <b>Total suppliers</b>                                 | <b>13,316,574</b> | <b>17,040,937</b> |
| <b>Note 15B: Grants and service delivery contracts</b> |                   |                   |
| Public sector                                          |                   |                   |
| State and Territory Governments                        | 7,279,198         | 6,337,723         |
| Private sector                                         |                   |                   |
| Not-for-profit organisations                           | 13,770,743        | 10,946,612        |
| <b>Total grants and service delivery contracts</b>     | <b>21,049,941</b> | <b>17,284,335</b> |

### Accounting Policy

#### Grants

Cancer Australia administers a number of grants on behalf of the Government. Grant liabilities are recognised to the extent that (i) the services required to be performed by the grantee have been performed or (ii) the grant eligibility criteria have been satisfied, but payments due have not been made. When the Government enters into an agreement to make these grants and services, but services have not been performed or criteria satisfied, this is considered a commitment.

## Notes to and forming part of the financial statements

### Note 16: Administered - Financial Assets

|  | 2026 | 2025 |
|--|------|------|
|  | \$   | \$   |

#### Note 16A: Cash and cash equivalents

|                                        |               |               |
|----------------------------------------|---------------|---------------|
| Cash on hand or on deposit             | 32,648        | 33,550        |
| <b>Total cash and cash equivalents</b> | <b>32,648</b> | <b>33,550</b> |

#### Note 16B: Trade and other receivables

|                                                    |                  |                  |
|----------------------------------------------------|------------------|------------------|
| Net GST receivable from Australian Taxation Office | 1,235,553        | 1,512,307        |
| Other receivables                                  | 522              | 11,576           |
| <b>Total trade and other receivables</b>           | <b>1,236,075</b> | <b>1,523,883</b> |

Credit terms for goods and services were within 30 days (2024-25: 30 days).

No allowance for impairment was required at reporting date (2024-25: nil).

### Accounting Policy

#### Cash

Cash is recognised at its nominal amount. Cash and cash equivalents includes:

- a) cash on hand;
- b) demand deposits in bank accounts with an original maturity of 3 months or less that are readily convertible to known amounts of cash and subject to insignificant risk of changes in value; and
- c) cash in special accounts.

#### Trade and other receivables

Trade and other receivables that are held for the purpose of collecting the contractual cash flows where the cash flows are solely payments of principal and interest, that are not provided at below-market interest rates, are subsequently measured at amortised cost using the effective interest method adjusted for any loss allowance.

### Note 17: Administered - Payables

|  | 2026 | 2025 |
|--|------|------|
|  | \$   | \$   |

#### Note 17A: Suppliers

|                              |                  |                  |
|------------------------------|------------------|------------------|
| Trade creditors and accruals | 1,006,036        | 2,084,685        |
| <b>Total suppliers</b>       | <b>1,006,036</b> | <b>2,084,685</b> |

Settlement is usually made within 30 days (2024-25: 30 days).

#### Note 17B: Grants

|                                     |                |                  |
|-------------------------------------|----------------|------------------|
| Non-profit and profit organisations | 481,460        | 3,011,073        |
| <b>Total grants</b>                 | <b>481,460</b> | <b>3,011,073</b> |

Settlement is usually made according to the terms and conditions of each grant. This is usually within 30 days of performance or eligibility (2024-25: 30 days).

### Note 18: Administered - Contingent Assets and Liabilities

Cancer Australia has not identified any quantifiable, unquantifiable or significant remote contingencies as at 30 June 2026 (2024-25: Nil).

## Notes to and forming part of the financial statements

### Note 19: Administered - Financial Instruments

|                                                          | 2026             | 2025             |
|----------------------------------------------------------|------------------|------------------|
|                                                          | \$               | \$               |
| <b>Financial assets measured at amortised cost</b>       |                  |                  |
| Cash on hand or on deposit                               | 32,648           | 33,550           |
| Trade and Other Receivables                              |                  |                  |
| Other receivables                                        | 522              | 11,575           |
| Trade and Other Receivables                              | 522              | 11,575           |
| <b>Total financial assets measured at amortised cost</b> | <b>33,170</b>    | <b>45,125</b>    |
| <b>Total financial assets</b>                            | <b>33,170</b>    | <b>45,125</b>    |
| <b>Financial liabilities</b>                             |                  |                  |
| <b>Financial liabilities measured at amortised cost</b>  |                  |                  |
| Trade creditors                                          | 1,006,036        | 2,084,685        |
| Grants payable                                           | 481,460          | 3,011,073        |
| <b>Financial liabilities measured at amortised cost</b>  | <b>1,487,496</b> | <b>5,095,758</b> |
| <b>Total financial liabilities</b>                       | <b>1,487,496</b> | <b>5,095,758</b> |

## Notes to and forming part of the financial statements

### Note 20: Appropriations

**Table A: Annual Appropriations ('Recoverable GST exclusive')**

#### Annual Appropriations for 2025-26

|                             | Annual<br>Appropriation <sup>1</sup> | Adjustments to<br>Appropriation <sup>2</sup> | Total<br>Appropriation | Appropriation<br>Applied in 2026<br>(current and<br>prior years) | Variance <sup>3</sup> |
|-----------------------------|--------------------------------------|----------------------------------------------|------------------------|------------------------------------------------------------------|-----------------------|
|                             | \$                                   | \$                                           | \$                     | \$                                                               | \$                    |
| <b>Departmental</b>         |                                      |                                              |                        |                                                                  |                       |
| Ordinary annual services    | 13,223,000                           | 3,713,437                                    | 16,936,437             | 17,393,018                                                       | (456,581)             |
| Capital Budget <sup>4</sup> | 85,000                               | -                                            | 85,000                 | 157,724                                                          | (72,724)              |
| <b>Total departmental</b>   | <b>13,308,000</b>                    | <b>3,713,437</b>                             | <b>17,021,437</b>      | <b>17,550,742</b>                                                | <b>(529,305)</b>      |
| <b>Administered</b>         |                                      |                                              |                        |                                                                  |                       |
| Ordinary annual services    |                                      |                                              |                        |                                                                  |                       |
| Administered items          | 34,379,000                           | -                                            | 34,379,000             | 37,845,974                                                       | (3,466,974)           |
| <b>Total administered</b>   | <b>34,379,000</b>                    | <b>-</b>                                     | <b>34,379,000</b>      | <b>37,845,974</b>                                                | <b>(3,466,974)</b>    |

Notes:

<sup>1</sup> There were no amounts quarantined from 2026 Administered or Departmental Appropriations.

<sup>2</sup> Adjustments to Appropriation including PGPA Act Section 74 receipts.

<sup>3</sup> The departmental variance primarily represents the timing difference of payments to suppliers and employees and section 74 receipts. The administered variance is mainly due to the timing difference of payments to suppliers.

<sup>4</sup> Departmental Capital Budgets are appropriated through Appropriation Acts (No.1). They form part of ordinary annual services, and are not separately identified in the annual Appropriation Acts.

#### Annual Appropriations for 2024-25

|                             | Annual<br>Appropriation <sup>1</sup> | Adjustments to<br>Appropriation <sup>2</sup> | Total<br>Appropriation | Appropriation<br>Applied in 2025<br>(current and prior<br>years) | Variance <sup>3</sup> |
|-----------------------------|--------------------------------------|----------------------------------------------|------------------------|------------------------------------------------------------------|-----------------------|
|                             | \$                                   | \$                                           | \$                     | \$                                                               | \$                    |
| <b>Departmental</b>         |                                      |                                              |                        |                                                                  |                       |
| Ordinary annual services    | 14,109,000                           | 3,823,354                                    | 17,932,354             | 16,852,986                                                       | 1,079,368             |
| Capital Budget <sup>4</sup> | 85,000                               | -                                            | 85,000                 | 62,441                                                           | 22,559                |
| <b>Total departmental</b>   | <b>14,194,000</b>                    | <b>3,823,354</b>                             | <b>18,017,354</b>      | <b>16,915,427</b>                                                | <b>1,101,927</b>      |
| <b>Administered</b>         |                                      |                                              |                        |                                                                  |                       |
| Ordinary annual services    |                                      |                                              |                        |                                                                  |                       |
| Administered items          | 34,362,000                           | -                                            | 34,362,000             | 30,476,731                                                       | 3,885,269             |
| <b>Total administered</b>   | <b>34,362,000</b>                    | <b>-</b>                                     | <b>34,362,000</b>      | <b>30,476,731</b>                                                | <b>3,885,269</b>      |

Notes:

<sup>1</sup> There were no amounts quarantined from 2025 Administered or Departmental Appropriations.

<sup>2</sup> Adjustments to Appropriation including PGPA Act Section 74 receipts.

<sup>3</sup> The departmental variance primarily represents the timing difference of payments to suppliers and employees and section 74 receipts. The administered variance is mainly due to the timing difference of payments to suppliers.

<sup>4</sup> Departmental Capital Budgets are appropriated through Appropriation Acts (No.1). They form part of ordinary annual services, and are not separately identified in the annual Appropriation Acts.

## Notes to and forming part of the financial statements

**Table B: Unspent Annual Appropriations ('Recoverable GST exclusive')**

|                                               | 2026<br>\$       | 2025<br>\$ |
|-----------------------------------------------|------------------|------------|
| <b>Departmental</b>                           |                  |            |
| Appropriation Act (No.1) 2024-25              | -                | 4,212,897  |
| Appropriation Act (No.1) 2025-26 <sup>1</sup> | <b>3,683,592</b> | -          |
| <b>Total departmental</b>                     | <b>3,683,592</b> | 4,212,897  |
| <b>Administered</b>                           |                  |            |
| Appropriation Act (No.1) 2024-25              | -                | 4,935,886  |
| Appropriation Act (No.1) 2025-26 <sup>1</sup> | <b>1,468,912</b> | -          |
| <b>Total administered</b>                     | <b>1,468,912</b> | 4,935,886  |

<sup>1</sup> Appropriation Act (No.1) 2025-26 includes cash and cash equivalents at 30 June 2026.

**Table C: Net Cash Appropriation Arrangements**

|                                                                                                                                                            | 2026<br>\$       | 2025<br>\$ |
|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|------------|
| <b>Total comprehensive income/(loss) - as per the Statement of Comprehensive Income</b>                                                                    | <b>(403,616)</b> | 502,509    |
| <b>Plus:</b> depreciation/amortisation of assets funded through appropriations (departmental capital budget funding and/or equity injections) <sup>1</sup> | <b>356,142</b>   | 295,698    |
| <b>Plus:</b> depreciation of right-of-use assets <sup>2</sup>                                                                                              | <b>735,644</b>   | 735,644    |
| <b>Less:</b> lease principal repayments <sup>2</sup>                                                                                                       | <b>(919,476)</b> | (873,591)  |
| <b>Net Cash Operating Surplus/ (Deficit)</b>                                                                                                               | <b>(231,307)</b> | 660,260    |

<sup>1</sup> From 2010-11, the Government introduced net cash appropriation arrangements where revenue appropriations for depreciation/amortisation expenses of non-corporate Commonwealth entities and selected corporate Commonwealth entities were replaced with a separate capital budget provided through equity appropriations. Capital budgets are to be appropriated in the period when cash payment for capital expenditure is required.

<sup>2</sup> The inclusion of depreciation/amortisation expenses related to right-of-use leased assets and the lease liability principal repayment amount reflects the impact of AASB 16 Leases, which does not directly reflect a change in appropriation arrangements.

## Notes to and forming part of the financial statements

### 21. Current/non-current distinction for assets and liabilities

#### 21A: Current/non-current distinction for assets and liabilities

|                                               | 2026             | 2025             |
|-----------------------------------------------|------------------|------------------|
|                                               | \$               | \$               |
| <b>Assets expected to be recovered in:</b>    |                  |                  |
| <b>No more than 12 months</b>                 |                  |                  |
| Cash and cash equivalents                     | 122,627          | 124,933          |
| Trade and other receivables                   | 3,913,382        | 4,287,761        |
| Prepayments                                   | 203,231          | 168,782          |
| <b>Total no more than 12 months</b>           | <b>4,239,240</b> | <b>4,581,476</b> |
| <b>More than 12 months</b>                    |                  |                  |
| Property, plant and equipment                 | 1,561,173        | 2,233,418        |
| Intangibles                                   | 1,582            | 7,544            |
| <b>Total more than 12 months</b>              | <b>1,562,755</b> | <b>2,240,962</b> |
| <b>Total assets</b>                           | <b>5,801,995</b> | <b>6,822,438</b> |
| <b>Liabilities expected to be settled in:</b> |                  |                  |
| <b>No more than 12 months</b>                 |                  |                  |
| Suppliers                                     | 224,216          | 213,982          |
| Other payables                                | 473,816          | 398,186          |
| Leases                                        | 967,416          | 919,476          |
| Employee provisions                           | 841,123          | 791,721          |
| Other provisions                              | 280,894          | 276,715          |
| <b>Total No more than 12 months</b>           | <b>2,787,465</b> | <b>2,600,080</b> |
| <b>More than 12 months</b>                    |                  |                  |
| Leases                                        | 240,303          | 1,207,718        |
| Employee provisions                           | 2,052,548        | 1,974,345        |
| <b>Total more than 12 months</b>              | <b>2,292,851</b> | <b>3,182,063</b> |
| <b>Total liabilities</b>                      | <b>5,080,316</b> | <b>5,782,143</b> |

#### 21B: Administered - Current/non-current distinction for assets and liabilities

|                                               | 2026             | 2025             |
|-----------------------------------------------|------------------|------------------|
|                                               | \$               | \$               |
| <b>Assets expected to be recovered in:</b>    |                  |                  |
| <b>No more than 12 months</b>                 |                  |                  |
| Cash and cash equivalents                     | 32,648           | 33,550           |
| Trade and other receivables                   | 1,236,075        | 1,523,883        |
| Prepayments                                   | 197,950          | 252,381          |
| <b>Total no more than 12 months</b>           | <b>1,466,673</b> | <b>1,809,814</b> |
| <b>More than 12 months</b>                    | -                | -                |
| <b>Total more than 12 months</b>              | -                | -                |
| <b>Total assets</b>                           | <b>1,466,673</b> | <b>1,809,814</b> |
| <b>Liabilities expected to be settled in:</b> |                  |                  |
| <b>No more than 12 months</b>                 |                  |                  |
| Suppliers                                     | 1,006,036        | 2,084,685        |
| Grants                                        | 481,460          | 3,011,073        |
| <b>Total no more than 12 months</b>           | <b>1,487,496</b> | <b>5,095,758</b> |
| <b>More than 12 months</b>                    | -                | -                |
| <b>Total more than 12 months</b>              | -                | -                |
| <b>Total liabilities</b>                      | <b>1,487,496</b> | <b>5,095,758</b> |

# Appendix C: Acquittal audit report related to Cancer Australia fundraising activities

# Independent Auditor's report – Cancer Australia fundraising activities



+61 2 9412 3033    info@stewartbrown.com.au  
PO Box 5515, Chatswood NSW 2057, Australia  
Level 2, Tower 1, 495 Victoria Avenue, Chatswood NSW 2067  
www.stewartbrown.com.au

## CANCER AUSTRALIA

ABN: 21 075 951 918

### ACQUITTAL AUDIT REPORT FOR THE YEAR ENDED 30 JUNE 2026

### INDEPENDENT AUDITOR'S REPORT TO THE EXECUTIVES OF CANCER AUSTRALIA

Independent audit report in relation to Cancer Australia's statement of income and expenditure of the fundraising activities relating to the donation from Hume Bank.

We have audited:

- a) the accompanying statement of income and expenditure of Cancer Australia for the year ended 30 June 2026, a summary of significant accounting policies, other explanatory information, and management's attestation statement; and
- b) Cancer Australia's compliance with the *Charitable Fundraising Act 1991* for the year ended 30 June 2026.

#### **Management's responsibility**

Management is responsible for:

- a) the preparation and fair presentation of the financial statement in accordance with the *Corporations Act 2001* and Australian Accounting Standards;
- b) such internal control as management determines is necessary to enable the preparation of the financial statement that is free from material misstatement, whether due to fraud or error.

#### **Auditor's responsibility**

Our responsibility is to express an opinion, based on our audit, on the statement of income & expenditure of the Project.

We conducted our audit of the financial statement in accordance with *Corporations Act 2001* and Australian Accounting Standards. The applicable Standards require that we comply with relevant ethical requirements and plan and perform our work to:

- a) obtain reasonable assurance about whether the financial statement is free from material misstatement.
- b) Complying with Accounting Standards, *Corporations Regulations 2001*, *Charitable Fundraising Act 1991* and other mandatory professional reporting requirements.

ABN 63 271 338 023

Liability limited by a scheme approved under Professional Standards Legislation

**CANCER AUSTRALIA**

**ABN: 21 075 951 918**

**ACQUITTAL AUDIT REPORT**  
**FOR THE YEAR ENDED 30 JUNE 2026**

**INDEPENDENT AUDITOR'S REPORT**  
**TO THE EXECUTIVES OF CANCER AUSTRALIA**

**Auditor's responsibility (continued)**

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statement. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statement, whether due to fraud or error.

In making those risk assessments, the auditor considers internal control relevant to the fundraising recipient's preparation and fair presentation of the financial statement, in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the fundraising recipient's internal control. An audit also includes evaluating the appropriateness of accounting policies used by management, as well as evaluating the overall presentation of the financial statement.

***Charitable Fundraising Act 1991***

We have a responsibility under section 24 of the New South Wales *Charitable Fundraising Act 1991* to report to the entity's members whether, in our opinion the annual financial report of the entity complies with the *Charitable Fundraising Act 1991*, including:

- a) whether the accounts show a true and fair view of the financial results of fundraising appeals for the year to which they relate; and
- b) whether the accounts and associated records have been properly kept during that year in accordance with this Act and the regulations; and
- c) whether money received as a result of fundraising appeals conducted during the year has been properly accounted for and applied in accordance with this Act and the regulations; and
- d) the solvency of the organisation.

We must also report to members if we are satisfied that

- a) There has been a contravention of this Act or the regulations; and
- b) the circumstances are such that, in the auditor's opinion, the matter has not been or will not be adequately dealt with by comment in the auditor's report on the accounts or by bringing the matter to the notice of the person concerned or of the trustees or members of the governing body of the organisation concerned.

---

ABN 63 271 338 023

Liability limited by a scheme approved under Professional Standards Legislation

**CANCER AUSTRALIA**  
**ABN: 21 075 951 918**

**ACQUITTAL AUDIT REPORT**  
**FOR THE YEAR ENDED 30 JUNE 2026**

**INDEPENDENT AUDITOR'S REPORT**  
**TO THE EXECUTIVES OF CANCER AUSTRALIA**

**Opinion**

Pursuant to the requirements of section 24(2) of the New South Wales *Charitable Fundraising Act 1991*, in our opinion:


- a) the financial report gives a true and fair view of the financial result of fundraising appeal activities for the financial year ended 30 June 2026; and
- b) the financial report has been properly drawn up, and the associated records have been properly kept for the year ended 30 June 2026, in accordance with the New South Wales *Charitable Fundraising Act 1991*; and
- c) money received as a result of fundraising appeal activities conducted during the year ended 30 June 2026 have been properly accounted for and applied in accordance with the New South Wales *Charitable Fundraising Act 1991*; and
- d) at the date of this report there are reasonable grounds to believe that entity will be able to pay its debts as and when they become due and payable.

**Use of Report**

This report has been prepared for Cancer Australia in accordance with the Accounting Standards, *Corporations Regulations 2001*, *Charitable Fundraising Act 1991*, and other mandatory professional reporting requirements. We disclaim any assumption of responsibility for any reliance on this report to any persons or users other than Cancer Australia, or for any purpose other than that for which it was prepared.



**Stewart Brown**  
Chartered Accountants  
Level 2, Tower 1, 495 Victoria Avenue  
Chatswood NSW 2067



**Justin Weiner**  
Audit Partner  
Chartered Accountant (357529)  
ASIC Registered Company Auditor (540726)

3 August 2026

# Charitable fundraising

Cancer Australia is registered under the *Charitable Fundraising Act 1991* (NSW) to conduct fundraising activities.

## Fundraising appeals conducted during the financial period

Donations received to improve outcomes for Australians affected by cancer in 2025–26.

**Table C.1: Details of aggregated gross income and total expenses of fundraising appeals**

|                                            | 2026<br>\$  | 2025<br>\$    |
|--------------------------------------------|-------------|---------------|
| Donations                                  |             |               |
| Gross proceeds of fundraising appeal       | 319         | 56,358        |
| Total direct costs of fundraising appeal   | –           | –             |
| <b>Net surplus from fundraising appeal</b> | <b>319</b>  | <b>56,358</b> |
| <b>Net margin from fundraising appeals</b> | <b>100%</b> | <b>100%</b>   |

## Statement demonstrating how funds received were applied to charitable purposes

All funds received from fundraising appeals are used for activities that support Cancer Australia’s purpose of minimising the impact of cancer and improving outcomes for people affected by cancer in Australia.

**Table C.2: Comparison by monetary figures and percentages**

|                                       | 2026<br>\$ | 2025<br>\$ |
|---------------------------------------|------------|------------|
| Total cost of fundraising appeals     | –          | –          |
| Gross income from fundraising appeals | 319        | 56,358     |
| Percentage                            | 0%         | 0%         |
| Net surplus from fundraising appeals  | 319        | 56,358     |
| Gross income from fundraising appeals | 319        | 56,358     |
| Percentage                            | 100%       | 100%       |

# Appendix D: Mandatory reporting information

During 2025–26, Cancer Australia conducted the following advertising campaigns:

- › Prostate Cancer Awareness
- › Childhood Cancer Awareness
- › Gynaecological Cancer Awareness
- › Blood Cancer Awareness
- › Liver Cancer Awareness
- › Breast Cancer Awareness
- › Breast Cancer in Men Awareness
- › Lung Cancer Awareness
- › Pancreatic Cancer Awareness
- › Stomach Cancer Awareness
- › Skin Cancer Awareness and Sun Safety
- › Cervical Cancer Awareness
- › Ovarian Cancer Awareness
- › National Lung Cancer Screening Program: First Nations People Awareness
- › Melanoma Awareness
- › 2026 Jeannie Ferris Award: Call for Nominations
- › Oesophageal Cancer Awareness
- › Testicular Cancer Awareness
- › Brain Cancer Awareness
- › Bladder Cancer Awareness
- › Bowel Cancer Awareness
- › National Lung Cancer Screening Program: Primary Care Education.

Further information on those advertising campaigns is available at [www.canceraustralia.gov.au](http://www.canceraustralia.gov.au) and in the reports on Australian Government advertising prepared by the Department of Finance. Those reports are available on the Department of Finance's website.

The Campaign Advertising by Australian Government Departments and Agencies Report, prepared annually by the Department of Finance, provides details of campaigns for which expenditure was greater than \$250,000 (including GST).

**Table D.1: Advertising agencies used by Cancer Australia in 2025–26**

| Organisation     | Service provided                                                                                           | Amount paid (GST inc) |
|------------------|------------------------------------------------------------------------------------------------------------|-----------------------|
| Universal McCann | Event promotional campaign for 2025 ACCN Innovations Showcase                                              | \$21,770.03           |
| Universal McCann | Awareness campaign for prostate, gynaecological, blood, and childhood cancers                              | \$11,169.11           |
| Universal McCann | Awareness campaign for liver cancer, breast cancer, and breast cancer in men                               | \$14,143.57           |
| Universal McCann | Awareness campaign for lung, pancreatic, and stomach cancers                                               | \$8,910.63            |
| Universal McCann | Awareness campaign for skin cancer and sun safety                                                          | \$5,000.02            |
| Universal McCann | Awareness campaign for cervical cancer                                                                     | \$5,999.95            |
| Universal McCann | Awareness campaign for ovarian cancer                                                                      | \$5,499.95            |
| Universal McCann | Awareness campaign for National Lung Cancer Screening Program: First Nations People                        | \$9,885.94            |
| Universal McCann | Awareness campaign for Melanoma                                                                            | \$7,699.95            |
| Universal McCann | Awareness campaign for oesophageal and testicular cancers                                                  | \$9,899.95            |
| Universal McCann | Awareness campaign for brain and bladder cancers                                                           | \$8,593.77            |
| Universal McCann | Awareness campaign for bowel cancer                                                                        | \$7,081.03            |
| Universal McCann | Promotional campaign for the 2026 Jeannie Ferris Award call for nominations                                | \$5,499.95            |
| Universal McCann | Education campaign for primary health care providers supporting the National Lung Cancer Screening Program | \$172,634.95          |

**Table D.2: Market research undertaken by Cancer Australia in 2025–26**

| Organisation | Service provided | Amount paid (GST inc) |
|--------------|------------------|-----------------------|
| Nil          | Nil              | –                     |

## Grant programs

The following grant programs were administered by Cancer Australia during the period 1 July 2025 to 30 June 2026:

- › The Cancer Australia Research Initiative
- › Supporting People with Cancer
- › Priority-driven Collaborative Cancer Research Scheme
- › Support for Cancer Clinical Trials Program
- › Partnerships for Culturally Safe Cancer Care grant program
- › Partnerships for Cancer Research grant program
- › Networking for Cancer Equity Grant Program.

Information on grants awarded by Cancer Australia during the period 1 July 2025 to 30 June 2026 is available at [canceraustralia.gov.au](https://canceraustralia.gov.au).

## Disability reporting

Australia's Disability Strategy 2021–2031 (the Strategy) is the overarching framework for inclusive policies, programs and infrastructure that will support people with disability to participate in all areas of Australian life. The Strategy sets out where practical changes will be made to improve the lives of people with disability in Australia. It acts to ensure the principles underpinning the United Nations Convention on the Rights of Persons with Disabilities are incorporated into Australia's policies and programs that affect people with disability, their families and carers. All levels of government have committed to deliver more comprehensive and visible reporting under the Strategy. A range of reports on progress of the Strategy's actions and outcome areas will be published and available at [www.disabilitygateway.gov.au/ads](https://www.disabilitygateway.gov.au/ads).

Disability reporting is included in the Australian Public Service Commission's State of the Service reports and the APS Statistical Bulletin. These reports are available at [www.apsc.gov.au](https://www.apsc.gov.au).

## Freedom of information

Entities subject to the *Freedom of Information Act 1982* (FOI Act) are required to publish information to the public as part of the Information Publication Scheme (IPS). This requirement is in Part II of the FOI Act and has replaced the former requirement to publish a section 8 statement in an annual report. Each agency must display on its website a plan showing what information it publishes in accordance with the IPS requirements.

Cancer Australia displays an IPS Plan on its website listing the information it publishes and how it proposes to comply with IPS requirements. This is available at [www.canceraustralia.gov.au/about-us/freedom-information-act](https://www.canceraustralia.gov.au/about-us/freedom-information-act).

## Ecologically sustainable development and environmental performance

Section 516A of the *Environment Protection and Biodiversity Conservation Act 1999* requires Australian Government entities to detail their environmental performance and contribution to ecologically sustainable development in their annual reports.

In 2025–26, Cancer Australia maintained a range of measures which contributed to ecologically sustainable development, including:

- › adopting a ‘paper-light’ office, going digital wherever possible
- › using ecologically friendly printer paper, paper-based stationery items and cleaning products
- › recycling of paper, cardboard, printer cartridges and waste
- › setting printers to default to print on both sides of the paper and in black and white
- › ensuring equipment such as laptops, photocopiers, dishwashers, and printers incorporate energy-saving features.

The buildings in which Cancer Australia leases its office accommodation have a minimum National Australian Built Environment Rating System energy rating of 5.0 stars in Sydney and Canberra of 2 stars (this is due to limited occupancy, previously reported at 5.5 when at full occupancy).

Cancer Australia will continue to consider ecologically sustainable development as part of its business management approach.

## Climate Action in Government Operations APS Net Zero 2030 emissions reporting

As part of the reporting requirements under section 516A of the *Environment Protection and Biodiversity Conservation Act*, and in line with the Government’s Net Zero in Government Operations Strategy, all non-corporate Commonwealth entities are required to publicly report on the emissions from their operations.

The Greenhouse Gas Emissions Inventory presents greenhouse gas emissions over the 2025–26 period. Results are presented on the basis of carbon dioxide equivalent (CO<sub>2</sub>-e) emissions. Greenhouse gas emissions have been calculated in line with the Australian Public Service Emissions Reporting Framework, consistent with the whole-of-Australian Government approach as part of the APS Net Zero 2030 policy.

Not all data sources were available at the time of the report and amendments to data may be required in future reports.

Reporting on refrigerants is being phased in over time as emissions reporting matures.

**Table D.3: 2025–26 greenhouse gas emissions inventory – location-based method**

| Emission source                       | Scope 1<br>t CO <sub>2</sub> -e | Scope 2<br>t CO <sub>2</sub> -e | Scope 3<br>t CO <sub>2</sub> -e | Total<br>t CO <sub>2</sub> -e |
|---------------------------------------|---------------------------------|---------------------------------|---------------------------------|-------------------------------|
| Electricity (Location-Based Approach) | n/a                             | 44.63                           | 2.10                            | 46.73                         |
| Natural gas                           | 0.00                            | n/a                             | 0.00                            | 0.00                          |
| Solid waste                           | 0.00                            | n/a                             | 1.81                            | 1.81                          |
| Refrigerants                          | 0.00                            | n/a                             | n/a                             | 0.00                          |
| Fleet and other vehicles              | 0.00                            | n/a                             | 0.00                            | 0.00                          |
| Domestic commercial flights           | n/a                             | n/a                             | 71.42                           | 71.42                         |
| Domestic hire car                     | n/a                             | n/a                             | 0.22                            | 0.22                          |
| Domestic travel accommodation         | n/a                             | n/a                             | 21.17                           | 21.17                         |
| Other energy                          | 0.00                            | n/a                             | 0.00                            | 0.00                          |
| <b>Total t CO<sub>2</sub>-e</b>       | <b>0.00</b>                     | <b>44.63</b>                    | <b>96.72</b>                    | <b>141.35</b>                 |

**Note:**

1. Scope 1, Scope 2, Scope 3 and Total emissions are presented as tonnes carbon dioxide equivalent (t CO<sub>2</sub>-e).
2. Electricity emissions are calculated using the location-based method.
3. Refrigerants are being phased and are an optional source in 2025–26 emissions reporting.  
See the Emissions Reporting Framework for more details.
4. A portion of Cancer Australia's waste data was estimated based on customised waste generation benchmarks derived from other entities' operational data, due to landlord-managed waste services in multi-tenanted buildings limiting access to actual waste volumes. Benchmarks were applied using the lower of FTE or work point numbers for office tenancy, with all inputs sourced from the latest published AGPR.

**Table D.4: 2025–26 electricity greenhouse gas emissions**

|                                             | Scope 2<br>t CO <sub>2</sub> -e | Scope 3<br>t CO <sub>2</sub> -e | Total<br>t CO <sub>2</sub> -e | Electricity<br>kWh |
|---------------------------------------------|---------------------------------|---------------------------------|-------------------------------|--------------------|
| Location-based electricity emissions        | 44.63                           | 2.10                            | 46.72                         | 69,721.06          |
| Market-based electricity emissions          | 32.28                           | 4.39                            | 36.67                         | 39,851.63          |
| <b>Total renewable electricity consumed</b> | <b>n/a</b>                      | <b>n/a</b>                      | <b>n/a</b>                    | <b>29,869.44</b>   |
| Renewable Power Percentage                  | n/a                             | n/a                             | n/a                           | 12,054.78          |
| Jurisdictional Renewable Power Percentage   | n/a                             | n/a                             | n/a                           | 17,814.66          |
| GreenPower                                  | n/a                             | n/a                             | n/a                           | 0.00               |
| Large-scale generation certificates         | n/a                             | n/a                             | n/a                           | 0.00               |

**Note:**

1. The table above presents emissions related to electricity usage using both the location-based and the market-based accounting methods.
2. Scope 2, Scope 3 and Total emissions are presented as tonnes carbon dioxide equivalent (t CO<sub>2</sub>-e). Electricity data is reported in kilowatt hours (kWh).
3. Total renewable electricity excludes behind-the-meter solar other than generation used to create large-scale generation certificates (LGCs).
4. The renewable power percentage (RPP) accounts for the portion of electricity used, from the grid, that falls within the Renewable Energy Target (RET).
5. Jurisdictional Renewable Power refers to the Jurisdictional Renewable Power Percentage (JRPP). Currently, the Australian Capital Territory is the only jurisdiction with a JRPP.

## Work health and safety

During 2025–26, the following initiatives were undertaken in relation to work health and safety (WHS):

- › Influenza vaccinations were offered to all employees.
- › Workstation assessments were carried out for employees.
- › An Employee Assistance Program continued to be offered for employees and their immediate family members.
- › The agency's WHS Committee met periodically to review the safety management plan and workplace practices.
- › Comcare conducted a proactive inspection of Cancer Australia's Consultation, Coordination and Cooperation system and found the system to be compliant.

# Appendix E: Cancer Australia advisory groups

Cancer Australia's advisory group structure supports the agency's purpose and its leadership role in national cancer control. Advisory group members represent a broad range of expertise, experience and sectors, including consumer representation.

Cancer Australia values the advice and support extended to the organisation by the following strategic and project-specific advisory groups.

## **Intercollegiate Advisory Group**

The Intercollegiate Advisory Group provides expert advice to Cancer Australia to inform national approaches to reduce variations in cancer outcomes; promotes the use of best available evidence to achieve effective cancer care; identifies collaborative approaches across the system to address cancer control challenges across the cancer care continuum from prevention to treatment; and provides advice on emerging issues nationally and internationally to inform Cancer Australia's work.

The group was chaired by Professor Sandra O'Toole until March 2026 and is currently chaired by Associate Professor Dion Forstner.

## **Leadership Group on Aboriginal and Torres Strait Islander Cancer Control**

The Leadership Group on Aboriginal and Torres Strait Islander Cancer Control provides strategic advice and guidance to assist Cancer Australia and the Australian Government in Aboriginal and Torres Strait Islander cancer control. The group champions cross-sector collaboration in addressing and monitoring the progress of priorities in the Australian Cancer Plan and the National Aboriginal and Torres Strait Islander Cancer Framework; identifies and leverages opportunities to improve cancer outcomes at system, service and community levels; identifies emerging issues of national importance in Aboriginal and Torres Strait Islander cancer control and options to address these across multiple sectors; and provides input and advice in areas of specialised expertise.

The group is chaired by Associate Professor Lisa Whop.

## **Research and Data Advisory Group**

The Research and Data Advisory Group provides strategic advice to Cancer Australia on priority areas in cancer research and data. This includes expert guidance on Cancer Australia's research, clinical trials and data initiatives; strategies to enhance current programs, addressing emerging issues in national and international cancer research; setting research and data priorities; and fostering key national and international partnerships and collaborations that support Cancer Australia's leadership in these areas.

The group is chaired by Professor Raymond Chan.

## **National Cancer Expert Group**

The National Cancer Expert Group provides advice, guidance and expertise on cancer control matters of national interest to Cancer Australia. The group provides strategic input on emerging jurisdictional trends and issues of national significance to cancer control in Australia and advice on priorities for cancer control in Australia from a national perspective. The group supports implementation of the Australian Cancer Plan and, on request, assists the Cancer and Population Screening Committee through Cancer Australia's Chief Executive Officer.

The group is chaired by Professor Dorothy Keefe, PSM, MD.

## **Prostate Cancer Expert Advisory Group**

The Prostate Cancer Expert Advisory Group provides advice to the Minister for Health and Ageing, via Cancer Australia, on issues relating to prostate cancer. The group provides strategic advice on opportunities to improve prostate cancer experiences and outcomes across the continuum of care, from prevention and early detection to survivorship care. The group also informs the implementation of the Clinical Guidelines for the Early Detection of Prostate Cancer, including approaches to promotion and education, and provides strategic advice on approaches to nationally coordinated research investment and data collection in prostate cancer.

The group is co-chaired by Mr Dan Repacholi MP, Special Envoy for Men's Health, and Associate Professor Chris Milross.

## **Australian Cancer Plan 2-year Evaluation Expert Advisory Group**

The Australian Cancer Plan 2-year Evaluation Expert Advisory Group provided advice, guidance and sector expertise to support the evaluation of the Australian Cancer Plan (the Plan). The group advised on the evaluation methodology, interpretation of findings and evaluation outputs; and provided input on sector-wide activities aligned with the Plan's goals. The group was established in November 2025 and concluded following completion of the evaluation in mid-2026.

The group was chaired by Cancer Australia Deputy Chief Executive Officer Claire Howlett.

## **Childhood, Adolescent and Young Adult Cancer Roadmap Expert Advisory Group**

The Childhood, Adolescent and Young Adult Cancer Roadmap Expert Reference Group was established to guide the development of the Childhood, Adolescent and Young Adult Cancer Roadmap. The functions of the group included providing high-level strategic and expert advice to Cancer Australia to help guide the development of the roadmap, including supporting engagement with the sector and providing input and advice in areas of specialised expertise. The group was active in 2025–26 during the development of the roadmap and held its last meeting in April 2026.

The group was chaired by Cancer Australia CEO Professor Dorothy Keefe, PSM, MD.

# Appendix F: List of requirements

| PGPA Rule Reference | Part of Report                         | Description                                                                                                                                                                                                                                                                                                | Requirement                       |
|---------------------|----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|
| <b>17AD(g)</b>      | <b>Letter of transmittal</b>           |                                                                                                                                                                                                                                                                                                            |                                   |
| 17AI                | 1                                      | A copy of the letter of transmittal signed and dated by accountable authority on date final text approved, with statement that the report has been prepared in accordance with section 46 of the Act and any enabling legislation that specifies additional requirements in relation to the annual report. | Mandatory                         |
| <b>17AD(h)</b>      | <b>Aids to access</b>                  |                                                                                                                                                                                                                                                                                                            |                                   |
| 17AJ(a)             | 2–3                                    | Table of contents (print only).                                                                                                                                                                                                                                                                            | Mandatory                         |
| 17AJ(b)             | 133–140                                | Alphabetical index (print only).                                                                                                                                                                                                                                                                           | Mandatory                         |
| 17AJ(c)             | 127–132                                | Glossary of abbreviations and acronyms.                                                                                                                                                                                                                                                                    | Mandatory                         |
| 17AJ(d)             | 121–126                                | List of requirements.                                                                                                                                                                                                                                                                                      | Mandatory                         |
| 17AJ(e)             | IFC                                    | Details of contact officer.                                                                                                                                                                                                                                                                                | Mandatory                         |
| 17AJ(f)             | IFC                                    | Entity's website address.                                                                                                                                                                                                                                                                                  | Mandatory                         |
| 17AJ(g)             | IFC                                    | Electronic address of report.                                                                                                                                                                                                                                                                              | Mandatory                         |
| <b>17AD(a)</b>      | <b>Review by accountable authority</b> |                                                                                                                                                                                                                                                                                                            |                                   |
| 17AD(a)             | 5–10                                   | A review by the accountable authority of the entity.                                                                                                                                                                                                                                                       | Mandatory                         |
| <b>17AD(b)</b>      | <b>Overview of the entity</b>          |                                                                                                                                                                                                                                                                                                            |                                   |
| 17AE(1)(a)(i)       | 20                                     | A description of the role and functions of the entity.                                                                                                                                                                                                                                                     | Mandatory                         |
| 17AE(1)(a)(ii)      | 21                                     | A description of the organisational structure of the entity.                                                                                                                                                                                                                                               | Mandatory                         |
| 17AE(1)(a)(iii)     | 21                                     | A description of the outcomes and programmes administered by the entity.                                                                                                                                                                                                                                   | Mandatory                         |
| 17AE(1)(a)(iv)      | 19                                     | A description of the purposes of the entity as included in corporate plan.                                                                                                                                                                                                                                 | Mandatory                         |
| 17AE(1)(aa)(i)      | 66                                     | Name of the accountable authority or each member of the accountable authority                                                                                                                                                                                                                              | Mandatory                         |
| 17AE(1)(aa)(ii)     | 66                                     | Position title of the accountable authority or each member of the accountable authority                                                                                                                                                                                                                    | Mandatory                         |
| 17AE(1)(aa)(iii)    | 66                                     | Period as the accountable authority or member of the accountable authority within the reporting period                                                                                                                                                                                                     | Mandatory                         |
| 17AE(1)(b)          | N/A                                    | An outline of the structure of the portfolio of the entity.                                                                                                                                                                                                                                                | Portfolio departments – mandatory |

| PGPA Rule Reference | Part of Report                                 | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Requirement               |
|---------------------|------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|
| 17AE(2)             | N/A                                            | Where the outcomes and programs administered by the entity differ from any Portfolio Budget Statement, Portfolio Additional Estimates Statement or other portfolio estimates statement that was prepared for the entity for the period, include details of variation and reasons for change.                                                                                                                                                                                      | If applicable, Mandatory  |
| <b>17AD(c)</b>      | <b>Report on the Performance of the entity</b> |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                           |
|                     | <i>Annual performance Statements</i>           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                           |
| 17AD(c)(i); 16F     | 26–38                                          | Annual performance statement in accordance with paragraph 39(1)(b) of the Act and section 16F of the Rule.                                                                                                                                                                                                                                                                                                                                                                        | Mandatory                 |
| <b>17AD(c)(ii)</b>  | <b>Report on Financial Performance</b>         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                           |
| 17AF(1)(a)          | 39                                             | A discussion and analysis of the entity's financial performance.                                                                                                                                                                                                                                                                                                                                                                                                                  | Mandatory                 |
| 17AF(1)(b)          | 72–73                                          | A table summarising the total resources and total payments of the entity.                                                                                                                                                                                                                                                                                                                                                                                                         | Mandatory                 |
| 17AF(2)             | N/A                                            | If there may be significant changes in the financial results during or after the previous or current reporting period, information on those changes, including: the cause of any operating loss of the entity; how the entity has responded to the loss and the actions that have been taken in relation to the loss; and any matter or circumstances that it can reasonably be anticipated will have a significant impact on the entity's future operation or financial results. | If applicable, Mandatory. |
| <b>17AD(d)</b>      | <b>Management and Accountability</b>           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                           |
|                     | <i>Corporate Governance</i>                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                           |
| 17AG(2)(a)          | 1, 43                                          | Information on compliance with section 10 (fraud systems)                                                                                                                                                                                                                                                                                                                                                                                                                         | Mandatory                 |
| 17AG(2)(b)(i)       | 1                                              | A certification by accountable authority that fraud risk assessments and fraud control plans have been prepared.                                                                                                                                                                                                                                                                                                                                                                  | Mandatory                 |
| 17AG(2)(b)(ii)      | 1                                              | A certification by accountable authority that appropriate mechanisms for preventing, detecting incidents of, investigating or otherwise dealing with, and recording or reporting fraud that meet the specific needs of the entity are in place.                                                                                                                                                                                                                                   | Mandatory                 |
| 17AG(2)(b)(iii)     | 1                                              | A certification by accountable authority that all reasonable measures have been taken to deal appropriately with fraud relating to the entity.                                                                                                                                                                                                                                                                                                                                    | Mandatory                 |
| 17AG(2)(c)          | 43–48                                          | An outline of structures and processes in place for the entity to implement principles and objectives of corporate governance.                                                                                                                                                                                                                                                                                                                                                    | Mandatory                 |
| 17AG(2)(d) – (e)    | N/A                                            | A statement of significant issues reported to Minister under paragraph 19(1)(e) of the Act that relates to non-compliance with Finance law and action taken to remedy non-compliance.                                                                                                                                                                                                                                                                                             | If applicable, Mandatory  |

| PGPA Rule Reference                  | Part of Report | Description                                                                                                                                                                                                                                                                                                                                                     | Requirement              |
|--------------------------------------|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| <b>Audit Committee</b>               |                |                                                                                                                                                                                                                                                                                                                                                                 |                          |
| 17AG(2A)(a)                          | 44             | A direct electronic address of the charter determining the functions of the entity's audit committee.                                                                                                                                                                                                                                                           | Mandatory                |
| 17AG(2A)(b)                          | 45             | The name of each member of the entity's audit committee.                                                                                                                                                                                                                                                                                                        | Mandatory                |
| 17AG(2A)(c)                          | 45             | The qualifications, knowledge, skills or experience of each member of the entity's audit committee.                                                                                                                                                                                                                                                             | Mandatory                |
| 17AG(2A)(d)                          | 45             | Information about the attendance of each member of the entity's audit committee at committee meetings.                                                                                                                                                                                                                                                          | Mandatory                |
| 17AG(2A)(e)                          | 45             | The remuneration of each member of the entity's audit committee.                                                                                                                                                                                                                                                                                                | Mandatory                |
| <b>External Scrutiny</b>             |                |                                                                                                                                                                                                                                                                                                                                                                 |                          |
| 17AG(3)                              | 44             | Information on the most significant developments in external scrutiny and the entity's response to the scrutiny.                                                                                                                                                                                                                                                | Mandatory                |
| 17AG(3)(a)                           | 44             | Information on judicial decisions and decisions of administrative tribunals and by the Australian Information Commissioner that may have a significant effect on the operations of the entity.                                                                                                                                                                  | If applicable, Mandatory |
| 17AG(3)(b)                           | 44             | Information on any reports on operations of the entity by the Auditor-General (other than report under section 43 of the Act), a Parliamentary Committee, or the Commonwealth Ombudsman.                                                                                                                                                                        | If applicable, Mandatory |
| 17AG(3)(c)                           | N/A            | Information on any capability reviews on the entity that were released during the period.                                                                                                                                                                                                                                                                       | If applicable, Mandatory |
| <b>Management of Human Resources</b> |                |                                                                                                                                                                                                                                                                                                                                                                 |                          |
| 17AG(4)(a)                           | 49             | An assessment of the entity's effectiveness in managing and developing employees to achieve entity objectives.                                                                                                                                                                                                                                                  | Mandatory                |
| 17AG(4)(aa)                          | 50–55          | Statistics on the entity's employees on an ongoing and non-ongoing basis, including the following:<br>(a) statistics on full-time employees;<br>(b) statistics on part-time employees;<br>(c) statistics on gender;<br>(d) statistics on staff location.                                                                                                        | Mandatory                |
| 17AG(4)(b)                           | 52–57          | Statistics on the entity's APS employees on an ongoing and non-ongoing basis; including the following:<br>› Statistics on staffing classification level;<br>› Statistics on full-time employees;<br>› Statistics on part-time employees;<br>› Statistics on gender;<br>› Statistics on staff location;<br>› Statistics on employees who identify as Indigenous. | Mandatory                |

| PGPA Rule Reference                     | Part of Report | Description                                                                                                                                                                                                                                                                                                                                                                                                       | Requirement              |
|-----------------------------------------|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| 17AG(4)(c)                              | 49, 56         | Information on any enterprise agreements, individual flexibility arrangements, Australian workplace agreements, common law contracts and determinations under subsection 24(1) of the Public Service Act 1999.                                                                                                                                                                                                    | Mandatory                |
| 17AG(4)(c)(i)                           | 49, 56         | Information on the number of SES and non-SES employees covered by agreements etc identified in paragraph 17AG(4)(c).                                                                                                                                                                                                                                                                                              | Mandatory                |
| 17AG(4)(c)(ii)                          | 56             | The salary ranges available for APS employees by classification level.                                                                                                                                                                                                                                                                                                                                            | Mandatory                |
| 17AG(4)(c)(iii)                         | 49             | A description of non-salary benefits provided to employees.                                                                                                                                                                                                                                                                                                                                                       | Mandatory                |
| 17AG(4)(d)(i)                           | 57             | Information on the number of employees at each classification level who received performance pay.                                                                                                                                                                                                                                                                                                                 | If applicable, Mandatory |
| 17AG(4)(d)(ii)                          | 57             | Information on aggregate amounts of performance pay at each classification level.                                                                                                                                                                                                                                                                                                                                 | If applicable, Mandatory |
| 17AG(4)(d)(iii)                         | 57             | Information on the average amount of performance payment, and range of such payments, at each classification level.                                                                                                                                                                                                                                                                                               | If applicable, Mandatory |
| 17AG(4)(d)(iv)                          | 57             | Information on aggregate amount of performance payments.                                                                                                                                                                                                                                                                                                                                                          | If applicable, Mandatory |
| <b>Assets Management</b>                |                |                                                                                                                                                                                                                                                                                                                                                                                                                   |                          |
| 17AG(5)                                 | N/A            | An assessment of effectiveness of assets management where asset management is a significant part of the entity's activities                                                                                                                                                                                                                                                                                       | If applicable, mandatory |
| <b>Purchasing</b>                       |                |                                                                                                                                                                                                                                                                                                                                                                                                                   |                          |
| 17AG(6)                                 | 48             | An assessment of entity performance against the Commonwealth Procurement Rules.                                                                                                                                                                                                                                                                                                                                   | Mandatory                |
| <b>Reportable consultancy contracts</b> |                |                                                                                                                                                                                                                                                                                                                                                                                                                   |                          |
| 17AG(7)(a)                              | 46             | A summary statement detailing the number of new reportable consultancy contracts entered into during the period; the total actual expenditure on all such contracts (inclusive of GST); the number of ongoing reportable consultancy contracts that were entered into during a previous reporting period; and the total actual expenditure in the reporting period on those ongoing contracts (inclusive of GST). | Mandatory                |
| 17AG(7)(b)                              | 46             | A statement that “During [reporting period], [specified number] new reportable consultancy contracts were entered into involving total actual expenditure of \$[specified million]. In addition, [specified number] ongoing reportable consultancy contracts were active during the period, involving total actual expenditure of \$[specified million]”.                                                         | Mandatory                |
| 17AG(7)(c)                              | 46             | A summary of the policies and procedures for selecting and engaging consultants and the main categories of purposes for which consultants were selected and engaged.                                                                                                                                                                                                                                              | Mandatory                |

| PGPA Rule Reference                                    | Part of Report                                                                                                                                     | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Requirement              |
|--------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| 17AG(7)(d)                                             | 46                                                                                                                                                 | A statement that <i>“Annual reports contain information about actual expenditure on reportable consultancy contracts. Information on the value of reportable consultancy contracts is available on the AusTender website.”</i>                                                                                                                                                                                                                                     | Mandatory                |
| <b>Reportable non-consultancy contracts</b>            |                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                          |
| 17AG(7A)(a)                                            | 46                                                                                                                                                 | A summary statement detailing the number of new reportable non-consultancy contracts entered into during the period; the total actual expenditure on such contracts (inclusive of GST); the number of ongoing reportable non-consultancy contracts that were entered into during a previous reporting period; and the total actual expenditure in the reporting period on those ongoing contracts (inclusive of GST).                                              | Mandatory                |
| 17AG(7A)(b)                                            | 46                                                                                                                                                 | A statement that <i>“Annual reports contain information about actual expenditure on reportable non-consultancy contracts. Information on the value of reportable non-consultancy contracts is available on the AusTender website.”</i>                                                                                                                                                                                                                             | Mandatory                |
| <b>17AD(daa)</b>                                       | <b>Additional information about organisations receiving amounts under reportable consultancy contracts or reportable non-consultancy contracts</b> |                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                          |
| 17AGA                                                  | 46–47                                                                                                                                              | Additional information, in accordance with section 17AGA, about organisations receiving amounts under reportable consultancy contracts or reportable non-consultancy contracts.                                                                                                                                                                                                                                                                                    | Mandatory                |
| <b>Australian National Audit Office Access Clauses</b> |                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                          |
| 17AG(8)                                                | N/A                                                                                                                                                | If an entity entered into a contract with a value of more than \$100 000 (inclusive of GST) and the contract did not provide the Auditor-General with access to the contractor’s premises, the report must include the name of the contractor, purpose and value of the contract, and the reason why a clause allowing access was not included in the contract.                                                                                                    | If applicable, Mandatory |
| <b>Exempt contracts</b>                                |                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                          |
| 17AG(9)                                                | 48                                                                                                                                                 | If an entity entered into a contract or there is a standing offer with a value greater than \$10 000 (inclusive of GST) which has been exempted from being published in AusTender because it would disclose exempt matters under the FOI Act, the annual report must include a statement that the contract or standing offer has been exempted, and the value of the contract or standing offer, to the extent that doing so does not disclose the exempt matters. | If applicable, Mandatory |
| <b>Small business</b>                                  |                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                          |
| 17AG(10)(a)                                            | 48                                                                                                                                                 | A statement that <i>“[Name of entity] supports small business participation in the Commonwealth Government procurement market. Small and Medium Enterprises (SME) and Small Enterprise participation statistics are available on the Department of Finance’s website.”</i>                                                                                                                                                                                         | Mandatory                |
| 17AG(10)(b)                                            | 48                                                                                                                                                 | An outline of the ways in which the procurement practices of the entity support small and medium enterprises.                                                                                                                                                                                                                                                                                                                                                      | Mandatory                |

| PGPA Rule Reference                        | Part of Report                                                                            | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Requirement              |
|--------------------------------------------|-------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| 17AG(10)(c)                                | N/A                                                                                       | If the entity is considered by the Department administered by the Finance Minister as material in nature—a statement that <i>"[Name of entity] recognises the importance of ensuring that small businesses are paid on time. The results of the Survey of Australian Government Payments to Small Business are available on the Treasury's website."</i>                                                                                                                                | If applicable, Mandatory |
| <b>Financial Statements</b>                |                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                          |
| 17AD(e)                                    | 74–112                                                                                    | Inclusion of the annual financial statements in accordance with subsection 43(4) of the Act.                                                                                                                                                                                                                                                                                                                                                                                            | Mandatory                |
| <b>Executive Remuneration</b>              |                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                          |
| 17AD(da)                                   | 66–69                                                                                     | Information about executive remuneration in accordance with Subdivision C of Division 3A of Part 2–3 of the Rule.                                                                                                                                                                                                                                                                                                                                                                       | Mandatory                |
| <b>17AD(f) Other Mandatory Information</b> |                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                          |
| 17AH(1)(a)(i)                              | 113                                                                                       | If the entity conducted advertising campaigns, a statement that <i>"During [reporting period], the [name of entity] conducted the following advertising campaigns: [name of advertising campaigns undertaken]. Further information on those advertising campaigns is available at [address of entity's website] and in the reports on Australian Government advertising prepared by the Department of Finance. Those reports are available on the Department of Finance's website."</i> | If applicable, Mandatory |
| 17AH(1)(a)(iii)                            | N/A                                                                                       | If the entity did not conduct advertising campaigns, a statement to that effect.                                                                                                                                                                                                                                                                                                                                                                                                        | If applicable, Mandatory |
| 17AH(1)(b)                                 | 115                                                                                       | A statement that <i>"Information on grants awarded by [name of entity] during [reporting period] is available at [address of entity's website]."</i>                                                                                                                                                                                                                                                                                                                                    | If applicable, Mandatory |
| 17AH(1)(c)                                 | 115                                                                                       | Outline of mechanisms of disability reporting, including reference to website for further information.                                                                                                                                                                                                                                                                                                                                                                                  | Mandatory                |
| 17AH(1)(d)                                 | 115                                                                                       | Website reference to where the entity's Information Publication Scheme statement pursuant to Part II of FOI Act can be found.                                                                                                                                                                                                                                                                                                                                                           | Mandatory                |
| 17AH(1)(e)                                 | N/A                                                                                       | Correction of material errors in previous annual report                                                                                                                                                                                                                                                                                                                                                                                                                                 | If applicable, mandatory |
| 17AH(2)                                    | 12–13<br>Advisory Council Chair review as per Section 37 of the Cancer Australia Act 2006 | Information required by other legislation                                                                                                                                                                                                                                                                                                                                                                                                                                               | Mandatory                |

# Glossary

| Term                         | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>cancer care continuum</b> | The cancer care continuum concerns a person's cancer experience and interactions with the health system, including prevention and early detection, initial presentation, diagnosis, treatment, survivorship, and/or end-of-life care.                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>cancer control</b>        | <p>Cancer control aims to reduce the incidence, morbidity, and mortality of cancer and to improve the quality of life of cancer patients in a defined population, through the systematic implementation of evidence-based interventions for prevention, early detection, diagnosis, treatment, and palliative care.</p> <p>Comprehensive cancer control addresses the whole population, while seeking to respond to the needs of the different subgroups at risk.</p>                                                                                                                                                                                              |
| <b>care pathway</b>          | A care pathway is the management and sequence of care for a well-defined group of patients during a well-defined period of time, to provide efficient and effective care for patients with similar conditions.                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>clinical guidelines</b>   | Clinical guidelines are a graded set of recommendations to help clinical decision-making or service planning based on best available research. Ideally all clinical guidelines are developed according to international quality criteria. Some clinical guidelines may be based on systematic review of relevant research.                                                                                                                                                                                                                                                                                                                                         |
| <b>clinical trial</b>        | A clinical trial is research conducted with the patient's permission, which usually involves a comparison of 2 or more treatments or diagnostic methods. The aim is to gain better understanding of the underlying disease process and/or methods to treat it. A clinical trial is conducted with rigorous scientific method for determining the effectiveness of a proposed treatment.                                                                                                                                                                                                                                                                            |
| <b>co-design</b>             | <p>Co-design brings professionals and end-users together to design new services, resources, and policies. Applied to policy, this means enabling or empowering people affected by a policy issue to contribute to its solution.</p> <p>Co-design with Aboriginal and Torres Strait Islander people is fundamental to achieving change across the health system and to achieve better outcomes. <a href="#">Key Principles and Best Practices for co-design in health with First Nations Australians</a> include First Nations leadership, Culturally grounded approach, Respect, Benefit to community, Inclusive partnerships and Transparency and evaluation.</p> |
| <b>consumer</b>              | Consumer is used to refer to a person affected by cancer as a patient, survivor, carer, or family member; or a consumer organisation representing the views of consumers. See also people affected by cancer.                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>diagnosis</b>             | A diagnosis is the identification and naming of a person's disease.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

| Term                                                          | Description                                                                                                                                                                                                                                                                                                                           |
|---------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>epidemiology</b>                                           | Epidemiology is the study of the patterns and causes of health and disease in populations and the application of this research to improve health.                                                                                                                                                                                     |
| <b>genomics</b>                                               | Genomics is the study of genes and other genetic information, their functions, how they interact with each other and with the environment, and how certain diseases, such as cancer, form. This may lead to new ways to prevent, diagnose, and treat cancer.                                                                          |
| <b>governance</b>                                             | Governance refers to the set of responsibilities and practices, policies and procedures applied by the project or program steering committee. These provide strategic direction, ensure objectives are achieved, manage risks and use resources responsibly and with accountability.                                                  |
| <b>health outcome(s)</b>                                      | A health outcome is a health-related change due to a preventive or clinical intervention or service. The intervention may be single or multiple; and the outcome may relate to a person, group or population or be partly or wholly due to the intervention.                                                                          |
| <b>industry-independent cancer clinical trials</b>            | Industry-independent cancer clinical trials are clinical trials not funded by industry e.g. pharmaceutical companies. Industry-independent clinical trials may be funded by government, non-government agencies, the not-for-profit sector or philanthropic organisations.                                                            |
| <b>Multi-site Collaborative Cancer Clinical Trials Groups</b> | Multi-site Collaborative Cancer Clinical Trials Groups are a network of independently governed, cooperative clinical trials organisations that develop and conduct investigator-initiated, industry-independent cancer clinical trials across multiple sites in Australia and New Zealand.                                            |
| <b>oncology</b>                                               | Oncology is a branch of medicine that is focused on the prevention, diagnosis and treatment of cancer.                                                                                                                                                                                                                                |
| <b>palliative care</b>                                        | Palliative care is care that improves the quality of life of patients and their families facing problems associated with a life-threatening illness. Prevention and relief of suffering is provided through early identification and treatment of pain and other problems such as physical, psychosocial and spiritual.               |
| <b>patient-centred</b>                                        | A patient-centred approach considers patients' cultural traditions, their personal preferences and values, their family situations, and their lifestyles. A patient-centred approach makes patients and their families an integral part of the care team who collaborate with health care professionals in making clinical decisions. |
| <b>prevention</b>                                             | <p>Prevention is action to reduce or eliminate the onset, causes, complications or recurrence of disease or ill health, including through health promotion activities.</p> <p>Prevention is the ability to modify certain cancer-causing risk factors to reduce the likelihood of developing cancer.</p>                              |

| Term                       | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>primary care</b>        | <p>Primary care is a sub-component of the broader primary health care system. Primary health care is usually the first contact an individual with a health concern has with the health system. Primary health care covers health care that is not related to a hospital visit, including health promotion, prevention, early intervention, treatment of acute conditions and chronic condition management.</p> <p>Primary health care services are delivered in settings such as general practices, community health centres, allied health practices, Aboriginal Community Controlled Health Services and via technologies such as telehealth and video consultations. Primary health care professionals include general practitioners, nurses, nurse practitioners, allied health professionals, midwives, pharmacists, dentists, and Aboriginal and/or Torres Strait Islander Health Workers and Health Practitioners.</p> |
| <b>protocol</b>            | A protocol is detailed written instructions about how to complete a specific task. It describes how, when, where and who should be involved in the task. Protocols may refer to a clinical care process or the working relationship between agencies.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>proton beam therapy</b> | Proton beam therapy is a therapy where a beam of protons is used to irradiate cancerous tissue. It is a precise type of radiotherapy that results in less damage to healthy tissue.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>psychosocial</b>        | Psychosocial treatment is concerned with mental, emotional, social, and spiritual wellbeing or issues relating to these states. Psychosocial treatment is intended to address psychological, social and some spiritual needs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>quality of life</b>     | Quality of life refers to an individual's overall appraisal of their situation and subjective sense of wellbeing. Quality of life encompasses symptoms of disease and side effects of treatment, functional capacity, social interactions and relationships, and occupational functioning. Key psychological aspects include subjective distress, satisfaction with treatment, existential issues, and the impact of illness and treatment on sexuality and body image.                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>radiation oncology</b>  | Radiation oncology involves the use of radiation, usually x-rays or gamma rays, to kill tumour cells or injure them so they cannot grow or multiply.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>risk factor</b>         | A risk factor is a substance or condition that increases an individual's chances of getting a particular type of cancer.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>sarcoma</b>             | A sarcoma is a malignant tumour that starts in connective tissue.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>screening</b>           | Screening refers to an organised program (using tests, examinations or other procedures) to identify diseases such as cancer, or changes which may later develop into disease such as cancer, before symptoms appear.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>stage</b>               | Stage refers to the extent of a cancer and whether the disease has spread from an original site to other parts of the body.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

| Term                       | Description                                                                                                                                                                                                                                                                                                                                                                                                                |
|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>supportive care</b>     | <p>Supportive care in cancer is the prevention and management of the adverse effects of cancer and its treatment. This includes management of physical and psychological symptoms and side effects across the continuum of the cancer journey from diagnosis through treatment to post-treatment care.</p> <p>Supportive care includes rehabilitation, secondary cancer prevention, survivorship and end-of-life care.</p> |
| <b>translation science</b> | <p>Translation science is the process of turning observations in the laboratory, clinic and community into interventions that improve the health of individuals and populations.</p>                                                                                                                                                                                                                                       |

# Abbreviations

| Term     | Description                                                                   |
|----------|-------------------------------------------------------------------------------|
| ABN      | Australian Business Number                                                    |
| ACCN     | Australian Comprehensive Cancer Network                                       |
| ACT      | Australian Capital Territory                                                  |
| AIHW     | Australian Institute of Health and Welfare                                    |
| APS      | Australian Public Service                                                     |
| CARI     | Cancer Australia Research Initiative                                          |
| CCQ      | Cancer Council Queensland                                                     |
| CEO      | Chief Executive Officer                                                       |
| CFO      | Chief Financial Officer                                                       |
| COO      | Chief Operating Officer                                                       |
| CTGs     | Clinical Trials Groups                                                        |
| FOI      | Freedom of information                                                        |
| FOI Act  | <i>Freedom of Information Act 1982</i> (Cth)                                  |
| FRACMA   | Fellow of the Royal Australasian College of Medical Administrators            |
| FRANZCR  | Fellow of the Royal Australian and New Zealand College of Radiologists        |
| GP       | General practitioner                                                          |
| GST      | Goods and services tax                                                        |
| IARC     | International Agency for Research on Cancer                                   |
| IPS      | Information Publication Scheme                                                |
| LGBTQIA+ | Lesbian, gay, bisexual, transgender, queer/questioning, intersex, and asexual |
| MP       | Member of Parliament                                                          |
| MRFF     | Medical Research Future Fund                                                  |
| NACCHO   | National Aboriginal Community Controlled Health Organisation                  |
| NCCI     | National Cancer Control Indicators                                            |
| NCD      | Non-communicable disease                                                      |
| NHMRC    | National Health and Medical Research Council                                  |
| NLCSP    | National Lung Cancer Screening Program                                        |
| OCP      | Optimal Care Pathway                                                          |

| Term     | Description                                                             |
|----------|-------------------------------------------------------------------------|
| PBS      | Portfolio Budget Statements                                             |
| PGPA Act | <i>Public Governance, Performance and Accountability Act 2013 (Cth)</i> |
| PREMs    | Patient-reported experience measures                                    |
| PROMs    | Patient-reported outcome measures                                       |
| PSM      | Public Service Medal                                                    |
| SCCT     | Support for Cancer Clinical Trials                                      |
| SES      | Senior Executive Service                                                |
| SME      | Small and medium enterprises                                            |
| WHS      | Work health and safety                                                  |

# Index

## A

- abbreviations 131–2
- Aboriginal and Torres Strait Islander Cancer Framework 119
- Aboriginal and Torres Strait Islander Cancer Plan 29
- Aboriginal and Torres Strait Islander people
  - clinical trials, participation in 36
  - co-designed cancer care 18, 25, 29
  - First Nations Cancer Scholarships 25, 29, 30
  - First Nations Oncology Experience Program 30
  - improving health outcomes 6, 8, 9, 10, 25, 29, 34, 37
  - NCCI specific indicators 37
  - organisations, funding for 34
  - partnerships with 8, 10, 13, 29
  - postgraduate scholarship program 25, 30
  - research grants 29
  - staff 55
- Aboriginal Community Controlled Health Organisations 8, 10, 29, 31
- access to care, equity in 7
- ACCN Innovations Showcase 34
- accountability *see* management and accountability
- accountable authority 26, 66
  - Statement 77
- address and contact details *inside front cover*
- administrative tribunal decisions 44
- advertising 113, 114
- Advisory Council 10, 13, 15, 21
  - Chair review 12–13
  - establishment 14
  - function 14
  - meetings 14
  - membership 13, 14, 15, 21
- advisory groups 12, 21, 119–20
- AI CoLab 28
- Aitken, Professor Joanne 15
- analysis of performance objectives 38
- annual performance statements 26–38, 43
  - analysis 38
  - highlights 24
- APS *see* Australian Public Service (APS)
- Audit and Risk Committee 21, 43, 44–5
  - Charter 44
  - meetings 44
  - membership 21, 45
- Auditor-General 44, 47
- Auditor-General Act 1997* 20
- audits
  - financial statements 72–112
  - fundraising activities 109–12
  - internal arrangements 43
- Aurora Education Foundation 25, 29, 30
- AusTender 46, 48
- Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine 32
- Australian Alliance for Indigenous Genomics (ALIGN) 27
- Australian Brain Cancer Mission 28
- Australian Cancer Data Alliance 37
- Australian Cancer Database 29
- Australian Cancer Plan 6, 8, 12, 24, 119
  - 2-year Evaluation Expert Advisory Group 6, 12, 27, 120
  - implementation 6, 9, 10, 13
  - Monitoring and Evaluation Framework 27
- Australian Cancer Research Program 28
- Australian Capital Territory Health 28
- Australian Comprehensive Cancer Network (ACCN) 7, 9, 34
  - expansion 24, 33
  - Innovations Showcase 34
  - membership 34

- Australian Digital Health Agency 32
- Australian Government funding 28, 72, 73, 92
- Australian Indigenous Doctors Association 30
- Australian Institute of Health and Welfare (AIHW) 29, 36, 37
- Australian National Audit Office (ANAO) 47
- Australian National University 30
- Australian Public Service (APS) 20
  - Emissions Reporting Framework 116
  - Induction Program 43, 44
  - Net Zero 2030 policy 116
  - Values and Code of Conduct 44
- Australian Public Service Commission 44

## B

- best practice cancer care 26, 33–4
- brain cancer research 8, 28
  - funding partners 28
- Brown, Professor Alex 15
- burden of disease 18
- business performance *see* financial performance
- Business Plan 2025–26 43
- business planning 43
- Butler, Hon Mark, MP 10, 21, 32

## C

- Campaign Advertising by Australian Government Departments and Agencies Report 113
- Canberra Health Services 28
- cancer
  - deaths expected 2025 18
  - diagnoses 2025 18
  - disease burden, percentage of 18
- Cancer and Population Screening Committee 120
- Cancer Australia 37, 119
  - about 18
  - convening role 6
  - functions and role 18, 20
  - purpose 18, 19, 26
  - 2026–2029 focus 9

- Cancer Australia Act 2006* 14, 20
- Cancer Australia Advisory Council *see* Advisory Council
- Cancer Australia Enterprise Agreement 49, 56
- Cancer Australia Research Initiative (CARI) 8, 12, 25, 29, 35, 115
- cancer care
  - best practice 26, 33–4, 38
  - evidence-based models of 26, 32–3
- Cancer Council Australia 36
- Cancer Council Queensland 36
- cancer data *see* data capacity
- Cancer Elimination Collaboration 33
- Cancer Genomics Clinical Trials Fund 9, 27, 36
- Cancer Genomics Framework 27, 28
- cancer screening programs 9, 29, 30, 31, 37
  - lung cancer *see* National Lung Cancer Screening Program (NLCSP)
  - melanoma 9
  - prostate cancer 34
- Carrie's Beanies 4 Brain Cancer 28
- cervical cancer 31
- Chan, Professor Raymond 119
- charitable fundraising 112
- Charitable Fundraising Act 1991* (NSW) 112
- Chief Executive Officer 20, 21, 66 *see also* Keefe, Dorothy
  - annual review 6–10
  - letter of transmittal 1
  - remuneration 66
- Chief Financial Officer 21, 66, 77
- Childhood, Adolescent and Young Adult Cancer Roadmap 12, 24, 33
  - Expert Advisory Group 120
- childhood cancer 36
- Children's Cancer CoLab 32
- Children's Hospital Foundation Queensland 28
- chimeric antigen receptor T-cell (CAR-T) 9
- Chris O'Brien Lifehouse 8
- classification levels of staff 56
- climate action 116
- Clinical Oncology Society of Australia 32
- Clinical Policy Advice Branch 21

- clinical trials 25, 35
  - genomics-enabled 9, 36
  - multi-site delivery 35
- Closing the Gap Priority Reforms 8, 31
- Cockburn, Christine 13, 15
- code of conduct 44
- Collaborative Cancer Clinical Trials Groups 8, 35–6
- College of Aboriginal and Torres Strait Islander Nurses and Midwives 30
- Comcare 118
- Commonwealth Contracting Suite 48
- Commonwealth Fraud and Corruption Control Framework 2024 43
- Commonwealth Ombudsman 44
- Commonwealth Procurement Rules 46, 48
- community engagement 34
- community organisations 8, 27, 30, 34
- compliance reporting 43
- Comprehensive Cancer Centres 9
- consultancy contracts 46, 47
- consumer(s)
  - information and resources 26, 37, 38
  - consumer representation 119
- contact details *inside front cover*
- contracts
  - consultancy 46, 47
  - exempt 48
  - non-consultancy 46, 47
- corporate governance 43–8
- Corporate Operations Branch 21, 42
- Corporate Plan 2025–26 26, 43
- Council *see* Advisory Council
- Cox, Raylene 67
- Cure Brain Cancer Foundation 28

## D

- data capacity 36–7, 38
- Deakin University 32
- Department of Health, Disability and Ageing 10, 18, 28, 29, 32
  - information to, provision of 44
  - Portfolio Budget Statements 2025–26 21, 26, 43
- diagnosis, symptom-based guide 33
- disability, people with
  - cancer, with 32
- disability reporting 115
- Dolan, Professor Shelley 15

## E

- early-onset cancers 9, 12, 33, 35
  - review of the evidence and implications 33
- ecologically sustainable development 116
- electricity greenhouse gas emissions 117
- emerging cancer issues and priorities 9, 12, 18
- Employee Assistance Program 118
- employees *see* staff
- end-of-life care 34
- Enterprise Agreement 49, 56
- Entity Resource Statement 72
- Environment Protection and Biodiversity Conservation Act 1999* 116
- environmental performance 116
- equitable access 7, 8
- Equitable Cancer Outcomes across Rural and Remote Australia Research Group 32
- equity in outcomes 8, 34
- ethical standards 44
- Evidence, Priority Initiatives and Communications Branch 21
- evidence-based cancer information 26, 32–3
  - best practice cancer care 26, 33–4
  - provision of 37, 38
- exempt contracts 48
- expenses
  - administered 39
  - departmental 39
- external scrutiny 44

## F

Financial Markets Foundation for Children 28  
financial overview 39  
financial performance 72–3  
financial statements 72–112  
First Nations Cancer Outcomes 29  
First Nations Cancer Scholarships 25, 29, 30  
First Nations Oncology Experience Program 30  
five-year survival rates 18  
flexible work arrangements 49  
Fong, Professor Kwun 15  
Forstner, Associate Professor Dion 15, 119  
fraud and corruption control 1, 43  
freedom of information 115  
*Freedom of Information Act 1982* 115  
full-time staff 50, 51, 52, 53, 54  
functions 20  
funding partners 28  
fundraising report 109–12

## G

G7 Cancer initiative 31  
    Working Group 3 31  
Garma Festival 13  
Genomics Australia 28  
Ginnane, Gayle 21, 45  
glossary 127–30  
governance 9  
Grant Collaborative Community 25, 30  
grant programs 115  
    Cancer Australia Research Initiative 25, 29, 35, 115  
    guidelines 29  
    Networking for Cancer Equity grant 34, 115  
    Partnerships for Cancer Research program 30, 115  
    Partnerships for Culturally Safe Cancer Care (PCSCC) 25, 29, 30, 115  
    Priority-driven Collaborative Cancer Clinical Trials Groups 8, 35–6, 115

Support for Cancer Clinical Trials (SCCT) program 8, 25, 35, 115

Supporting People with Cancer 31, 34, 115  
Greenhouse Gas Emissions Inventory 116, 117  
electricity 117

## H

head office 21, 116  
health professionals, information for 37, 38  
Henderson, Deborah 15  
highlights 24–5  
Honeyball, Dr Florian 15  
Howlett, Claire 21, 67, 120  
human resources *see* staff

## I

independent auditors' reports 74–5, 110–11  
Indigenous health *see* Aboriginal and Torres Strait Islander people  
Indigenous Procurement Policy 48  
individual flexibility arrangements 49  
induction program 43, 44  
information and resources 26, 37, 38  
Information Publication Scheme (IPS) 115  
Intercollegiate Advisory Group 119  
internal audit arrangements 43  
International Agency for Research on Cancer (IARC) 31  
    Governing Council (GC) 31  
    Handbook on Lung Cancer Screening 31  
international participation 9, 31

## J

Jackson, Roslyn 21, 45  
judicial decisions 44

## K

Keefe, Dorothy 1, 13, 21, 26, 66, 67, 120  
 annual review 6–10  
 letter of transmittal 1  
 Kennedy, Associate Professor Glen 15  
 key management personnel 66  
 key performance indicators *see* annual  
 performance statements  
 Kid's Cancer Project 28  
 Kulay Kalingka Study 30, 37

## L

Lambert, Adam 21, 67  
*The Lancet Oncology* 31  
 leadership *see* national leadership in cancer  
 control  
 Leadership Group on Aboriginal and Torres Strait  
 Islander Cancer Control 30, 119  
 letter of transmittal 1  
 LGBTQIA+ OCP 32, 34  
 list of requirements 121–7  
 list of tables 3  
 liver cancer 31, 34  
 looking ahead 9–10  
 lung cancer 9 *see also* National Lung Cancer  
 Screening Program (NLCSP)  
 IARC Handbook on Lung Cancer Screening 31  
 screening 9, 29, 31  
 Lung Cancer Screening Program *see* National  
 Lung Cancer Screening Program  
 Lung Nodule Management Protocol 29

## M

McEwan, Steven 21, 67  
 management and accountability 42  
 Mark Hughes Foundation 28  
 market research 114  
 Medical Director 21, 67  
 Medical Research Future Fund (MRFF) 28  
 melanoma 9  
 Meredyth, David 21, 67

Milch, Professor Vivienne 21, 67  
 Milross, Associate Professor Christopher 10, 15  
 review 12–13  
 Special Envoy for Men's Health co-chair 12, 24,  
 32, 120  
 Minderoo Foundation Collaboration Against  
 Cancer Initiative 28  
 Minister for Health and Ageing 10, 14, 20, 21, 24,  
 27, 36, 44, 66  
 ministerial and parliamentary coordination 42, 44  
 Monitoring and Evaluation Framework 27  
 Movember Foundation 36–7  
 Multi-Site Collaborative Cancer Clinical Trials  
 Groups (CTGs) 8, 9  
 My Health App 32  
 My Health Record 32

## N

National Aboriginal Community Controlled  
 Health Organisation (NACCHO) 8, 10, 29, 31  
 Cancer Plan 31  
 National Lung Cancer Screening Program  
 (NLCSP) 29  
 National Agreement on Closing the Gap Priority  
 Reforms 8, 31  
 National Cancer Control Indicators (NCCI) 36, 37  
 National Cancer Control Performance Reporting  
 Framework 37  
 National Cancer Data Framework 7, 9, 12, 27, 33, 37  
 publication 24, 36  
 National Cancer Expert Group 120  
 National Centre for Aboriginal and Torres Strait  
 Islander Wellbeing 30  
 National Framework for Genomics in Cancer  
 Control 7, 8, 33  
 implementation 9, 27  
 National Health and Medical Research Council  
 (NHMRC) 8, 25, 35  
 National Health Data Hub 29  
 national leadership in cancer control 26, 27–31, 38  
 National Lung Cancer Screening Program  
 (NLCSP) 12, 29  
 Nodule Management Protocol 29

National Optimal Care Pathways Framework 7, 9, 12, 28, 32, 33

national technical services 35

Net Zero in Government Operations Strategy 116

Networking for Cancer Equity grant 34, 115

Neurosurgical Research Foundation 28

non-consultancy contracts 46, 47

non-ongoing staff 49, 51, 53, 54

Nowak, Professor Anna 15

## O

objectives 26

- analysis 38
- consumer and health professional cancer information and resources 26, 37, 38
- evidence-based best practice cancer care 26, 32–4, 38
- national leadership in cancer control 26, 27–31, 38
- research and data capacity 26, 36–7, 38

occupational health and safety *see* work health and safety

ongoing staff 49, 50, 52, 53, 54

Optimal Care Pathways (OCPs) 28

- development of new 32
- digitisation 32

organisational structure 21

O'Toole, Professor Sandra 119

Our Mob and Cancer 37

Outcome 1: Health policy, access and support 26

outcome(s) 21, 26

- expenses for 73
- structure 21

## P

palliative care 34

Pancare Foundation 32

parliamentary committees 44

part-time staff 50, 51, 52, 54

partnerships 6, 27, 28

- Aboriginal and Torres Strait Islander organisations 8
- international 31

Partnerships and Cancer Equity Branch 21

Partnerships for Cancer Research program 30, 115

Partnerships for Culturally Safe Cancer Care (PCSCC) 25, 29

- grant program 25, 30, 115

patient reported experience measures (PREMs) 36–7

patient reported outcomes measures (PROMs) 36–7

pay *see* remuneration

performance *see* annual performance statements

performance pay 57

personnel *see* staff

Peter MacCallum Cancer Centre 34

population screening 9

Portfolio Budget Statements (PBS) 21, 26, 43

postgraduate scholarship program 25, 30

Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 35, 115

procurement 48

- Indigenous Procurement Policy 48
- small business 48

program objectives 2025–26 26, 38

program structure 21

prostate cancer 34, 120

- Clinical Guidelines for the Early Detection 33, 120
- screening 34

Prostate Cancer Expert Advisory Group 12, 32–3, 120

- establishment 24

Prostate Cancer Outcomes Registry Australia New Zealand 37

proton beam therapy (PBT) 9  
*Public Governance, Performance and Accountability Act 2013* 1, 20, 26, 46, 77  
Public Governance, Performance and Accountability Rule 2014 1  
*Public Service Act 1999* 1, 20, 44  
purchasing 48  
purpose 18, 19, 26

## Q

quality of life 35, 129

## R

Rare Cancers Australia 32  
Raye, Doctor Simone 15  
remuneration 56  
    highly paid staff 69  
    key management personnel 67  
    senior executives 66, 68  
*Remuneration Tribunal Act 1973* 66  
Repacholi, Hon Dan 12, 24, 32, 120  
research 8  
    building capability 18  
    data capacity 26, 36–7, 38  
    funding and programs 26, 28, 30, 35  
    priorities 9  
    supporting strategic 25  
Research and Data Advisory Group 35, 119  
Richard Scolyer Professorial Chair,  
    Brain Cancer Research 8  
Robert Connor Dawes Foundation 28  
role 20

## S

salaries *see* remuneration  
sarcoma 34  
Scolyer, Professor Richard 8  
screening programs *see* cancer screening programs

Senior Executive Service (SES)  
    remuneration 66  
    SES Handbook 66  
Senior Executive Team 21  
Small and Medium Enterprise (SME)  
    participation 48  
Small, Belinda 21, 45  
small business 48  
Smith, Carolyn 15  
Special Broadcasting Service (SBS) 44  
Special Envoy for Men's Health 12, 24, 32, 120  
staff 9, 10  
    classification level 56  
    diversity 49  
    employment arrangements 49, 56  
    Enterprise Agreement 49, 56  
    full-time 50, 51, 52, 53, 54  
    Indigenous 55  
    individual flexibility arrangements 49  
    location, by 55  
    management of 49  
    non-ongoing 49, 51, 53, 54  
    number 21, 49  
    ongoing 49, 50, 52, 53, 54  
    part-time 50, 51, 52, 54  
    performance pay 57  
    previous reporting period 58–65  
    remuneration 56, 66–9  
    salary ranges 56  
    training and development 43, 44, 49  
stakeholders 6, 27, 28, 31  
Statement of acknowledgement *inside front cover*  
strategic and business planning 43  
Strategic Commissioning Framework 47  
Support for Cancer Clinical Trials (SCCT) program  
    8, 25, 35, 115  
Supporting People with Cancer  
    grant program 31, 34, 115

## T

tendering and contracting 46  
therapies, developments in 9  
Thoracic Society of Australia and New Zealand 29  
training and development 34, 44, 49

## U

Underhill, Associate Professor Craig 15  
Union for International Cancer Control 31  
United Nations Political Declaration on  
Non-communicable Diseases 31  
University of Melbourne 33  
University of Sydney 33

## W

websites 37  
    address *inside front cover*  
    Audit and Risk Committee Charter 44  
    National Cancer Control Indicators (NCCI) 36  
    review and updating 37  
Whop, Associate Professor Lisa 119  
Wiegold, Elmer 21, 67  
work health and safety 118  
WHS Committee 118  
World Health Organization (WHO) 31  
World Indigenous Cancer Conference 13


## Y

Yardhura Walani 30, 37  
Yates, Professor Patsy 13, 15

## Z

Zalcborg, Professor John 13, 15





# Cancer Australia 20

[canceraustralia.gov.au](http://canceraustralia.gov.au)  
© Cancer Australia